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Abstract 
 
A resurgence of diphtheria (Corynebacterium diphtheriae) occurred in the 
former Soviet Union in the 1990s.  Concerted control measures brought about a 
decline in cases, however some endemic transmission has continued and 
increasingly C. ulcerans cases have been reported in some Western European 
countries.  Questions existed regarding risk factors for infection, availability of 
diphtheria antitoxin (DAT) treatment, circulation of potentially toxigenic 
Corynebacteria, and UK population immunity. 
Surveillance data from the World Health Organization European Region, 
Diphtheria Surveillance Network (DIPNET) and UK were analysed.  In addition, 
47 countries provided information regarding their DAT treatment supplies.  To 
examine circulation of Corynebacteria, throat swabs were screened across ten 
countries.  UK diphtheria immunity was assessed by serosurvey, and 
vaccination coverage data from nine London Primary Care Trusts (PCTs) were 
analysed by ethnicity.   
During 2000-2009 C. diphtheriae cases declined across the European Region.  
C. ulcerans cases (associated with domestic animals) outnumbered C. 
diphtheriae (associated with travel to endemic areas) in DIPNET countries 
outside the former Soviet Union.  There was a clear protective effect of 
vaccination.  The case fatality rate for respiratory diphtheria was lower in Latvia 
than in other DIPNET countries.  Global shortages of DAT were highlighted.  
Screening identified endemic transmission of toxigenic C. diphtheriae in Latvia 
and Lithuania, and circulation of non-toxigenic strains in several countries.  UK 
population immunity had increased since the last serosurvey in 1996; in 2009 
75% of the population had at least basic protection.  Low childhood vaccination 
coverage in London related partly to the size of ethnic groups within a PCT but 
also to completeness of data records.   
Surveillance and screening datasets likely missed some cases/isolates due to 
lost clinical and/or laboratory expertise.  These skills need to be retained and 
high vaccination coverage levels achieved, as well as records accurately 
maintained.  A DAT alternative is needed, with improved availability and access. 
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1. Introduction 
 
Pathogenesis and disease 
Diphtheria is caused by toxin-producing strains of Corynebacterium diphtheriae, 
and more rarely Corynebacterium ulcerans, or Corynebacterium 
pseudotuberculosis.  C. diphtheriae is spread from person to person via 
respiratory droplets, contaminated fomites, or direct contact with infected skin 
lesions.  The classic presentation is a sore throat with a swollen ‘bull neck’ 
appearance and a membrane, comprised of fibrin, epithelial cells, bacteria and 
polymorphs, which obstructs the airway and makes it difficult to breathe.  A 
cutaneous presentation, typically ‘rolled edge’ ulcers, is more common in 
tropical areas of the world.  Respiratory disease has a high (5-10%) case fatality 
rate (CFR) (Begg, 1994).   
C. diphtheriae is classified into biovars (mitis, gravis, intermedius, or belfanti), 
according to colony morphology, and ribotypes based on genetic fingerprinting 
of genes coding for (16s and 23s) ribosomal RNA. 
Epidemiology of diphtheria in the UK and World Health Organization 
(WHO) European region 
Diphtheria was a much feared disease of childhood until the advent of 
antibiotics, general improvements in living conditions, and crucially, the 
introduction of national diphtheria immunisation programmes in the European 
Region (Figure 1) in the 1940s and 50s, marked a steep decline in cases. 
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Figure 1.  World Health Organization European Region and DIPNET 
member countries (map produced using country borders from 
thematicmapping.org (2013) and the QGIS Application (QGIS Development 
Team, 2014)) 
 
In 1984 the WHO set a target for the elimination of indigenous diphtheria in the 
European Region for the year 2000 (Begg, 1994).  This target was almost within 
sight when a major resurgence occurred in the countries of the former Soviet 
Union, from where between 1990 and 1998 more than 157,000 cases and 
5,000 deaths were reported (Dittmann et al., 2000).  At its peak, in 1994 and 
1995, the epidemic accounted for more than 85% of diphtheria cases reported 
worldwide (Figure 2) (World Health Organization, 2013).   
  
3 
 
Figure 2.  Diphtheria cases reported to the World Health Organization 
1980-1999 (source: World Health Organization (2013)) 
 
A number of factors contributed to the epidemic (Dittmann et al., 2000, Vitek 
and Wharton, 1998); the break-up of the former Soviet Union led to health 
services being disrupted, including supplies of vaccine and diphtheria antitoxin 
(DAT) treatment.  In addition there were large scale population movements, 
including military personnel and refugees from neighbouring endemic countries, 
possibly resulting in the introduction of epidemic strains.  Furthermore, immunity 
in the adult population in the vaccine era had waned in the absence of exposure 
to disease, leading to a susceptible adult population (reflected in the age 
distribution of cases and deaths).  There was also an extensive list of (mostly 
inappropriate) contraindications to vaccination in the childhood immunisation 
advice at that time (Tatochenko and Mitjushin, 2000), and a lower dose vaccine 
had been used for some primary immunisations (Vitek and Wharton, 1998) 
which meant that there were children within the population who were 
insufficiently protected. 
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A plan for co-ordinated action to control the epidemic was developed by WHO 
and the United Nations Children’s Fund (UNICEF), in collaboration with several 
other organisations.  It involved initiating mass immunisation, as well as early 
detection and management of cases and contacts (Dittmann et al., 2000).  In 
addition, a microbiological network, the European Laboratory Working Group on 
Diphtheria (ELWGD) was formed in 1993 to assist with supplies of reagents and 
improve training and skills that had been lost (Efstratiou and Roure, 2000).  The 
epidemic was largely brought under control, with case numbers steadily 
declining from 1995 onwards.  However, endemic transmission continued in 
some countries within the region, raising questions about population residual 
susceptibility. 
Spread to countries outside the former Soviet Union during the epidemic was 
fortunately limited (Eskola et al., 1998), and case numbers in the rest of the 
European Region at this time remained low.  However, the epidemic resulted in 
heightened awareness and increased screening practices.  Partly as a 
consequence of this, around the same time sporadic cases of diphtheria caused 
by C. ulcerans were increasingly reported from Western European countries 
and the United States (Communicable Disease Surveillance Centre, 2000, 
Lartigue et al., 2005, Schuhegger et al., 2009, Tiwari et al., 2008).  C. ulcerans 
was first isolated from human throat lesions in 1926 by Gilbert and Stewart 
(Gilbert and Stewart, 1926).  It has historically been associated with contact with 
dairy animals and/or the consumption of raw milk or dairy products (Bostock et 
al., 1984, Hart, 1984).  However, some of the more recent cases have not had 
this exposure history, raising questions about reservoirs of infection and 
transmission of this organism.   
Diphtheria cases from the UK and other Western European countries are most 
commonly reported as individual case reports.  However, over recent decades a 
sizable enhanced surveillance database of UK cases has been developed.  
Furthermore, in 2007-2010 the Diphtheria Surveillance Network (DIPNET) a 
project involving 25 member countries (Figure 1) was funded by the European 
Commission (Neal and Efstratiou, 2007).  The development of this network 
enabled the amalgamation of ten years of case-based data from member 
countries, as well as cross-country collaboration on other projects.  The case-
based data included information about vaccination status, disease 
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presentations, outcomes and risk factors.  Diphtheria vaccination is known to be 
highly effective in preventing diphtheria symptoms.  However, information about 
vaccination status had not previously been formally analysed with respect to the 
varying severity of clinical presentations observed in recent diphtheria cases.   
Respiratory diphtheria requires treatment with DAT and antibiotics (Begg, 
1994).  DAT acts against the toxin and must be administered quickly, before the 
toxin has had a chance to bind to receptors, whilst antibiotics are needed to 
clear the infection.  DAT is a preparation of immunoglobulins or immunoglobulin 
F(ab’)2 fractions produced from the immunisation of horses, it has a shelf-life of 
approximately two years.  Problems with sourcing DAT from international 
suppliers had been anecdotally reported.  In addition there had been a number 
of informal requests for loan of DAT from one country to another when cases 
had arisen.  It was apparent that some countries lacked a supply themselves, 
but the full picture in terms of stocks of treatment, current producers and 
possible alternatives was unknown.  Even in the UK, where stocks of DAT are 
maintained in several centres across the country, not all cases receive this 
treatment, though the extent of use amongst cases had not been formally 
reviewed.  During the epidemic, the availability of DAT supplies was shown to 
dramatically influence CFRs (Dittmann et al., 2000).  In the post-epidemic era, 
where supplies of DAT are variable across the European Region, CFRs had not 
previously been calculated.  In addition, how CFRs currently compared in the 
UK to those of the pre-vaccine era was unknown. 
A barrier to maintaining a current stock of DAT within a country, given various 
other competing priorities, is the low perception of risk either of imported cases 
or endemic circulation.  Although surveillance data can give an indication of the 
circulation of disease-causing organisms in a population, it does not provide a 
complete picture.  As well as issues with case recognition and ascertainment, 
there may be asymptomatic carriage.  This may be particularly relevant in 
vaccinated populations because the diphtheria vaccine targets the toxin rather 
than the organism itself.  Non-toxigenic strains are unlikely to be detected in the 
absence of specific screening procedures.  There have been reports of non-
toxigenic strains causing severe disease (Romney et al., 2006), but in general, 
because the clinical presentations of diphtheria are toxin-mediated, they do not 
give rise to the same public health concerns.  Yet it is possible for a non-
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toxigenic strain to carry the toxin gene but not express it (non-toxigenic toxin-
bearing (NTTB) strains) (Groman, 1984).  In addition, in some circumstances 
the toxin gene can be transmitted via a bacteriophage to a non-toxigenic strain 
so that it becomes toxigenic (Uchida et al., 1971, Freeman, 1951).  Hence non-
toxigenic strains provide a reservoir from which toxigenic organisms can 
potentially arise (De Zoysa et al., 2005).  Some studies have previously 
attempted to assess carriage of toxigenic and non-toxigenic organisms in 
specific populations, but full methodology was often not available and carriage 
rates varied (Alexandrou-Athanasoulis et al., 2006, Von Hunolstein et al., 2003, 
Lucenko et al., 2006).  The carriage of these organisms in a population has 
important public health implications, particularly, given our knowledge of the 
outbreak in the former Soviet Union, if there are susceptible adult populations 
(as have been reported in studies from Europe and elsewhere (Edmunds et al., 
2000, Di Giovine et al., 2013) and areas of low childhood immunisation 
coverage. 
Diphtheria immunity and vaccination coverage in the UK 
Immunity to diphtheria is acquired either through vaccination or natural infection 
(though this does not always confer immunity).  In the UK, some older 
individuals have natural immunity but most immunity is now vaccine-acquired.  
The diphtheria vaccine is highly effective (estimated effectiveness for three or 
more doses 97% (95% confidence interval 94-98%) (Bisgard et al., 2000)).  In 
the UK, diphtheria vaccine is currently given as part of a 5-in-1 vaccine that also 
protects against tetanus, pertussis, polio and Haemophilus influenzae type b 
(DTaP/IPV/Hib), and is scheduled at 2, 3 and 4 months of age (primary course) 
(Public Health England, 2014a).  Following this a pre-school booster is 
scheduled between 3 years 4 months and five years of age (DTaP/IPV), and a 
school leaving (also known as ‘adolescent’) booster around 14 years of age 
(Td/IPV) (Public Health England, 2014a).   
Diphtheria immunity in England was assessed at the time of the epidemic in the 
former Soviet Union, using samples collected in 1991 (Miller et al., 1994).  
Overall 67% of the population at this time had full (>0.1 IU/mL) immunity which, 
in combination with good national childhood immunisation coverage, did not 
give cause for concern.  However, the susceptible population was expected to 
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increase with the gradual replacement of natural immunity (and natural 
boosting) by less long-lasting vaccine-induced immunity in older people.  A 
seroepidemiology study undertaken in England and Wales using sera from 
1996 found that at that time only 16% of the total population had full (≥0.1 
IU/mL) diphtheria immunity (Maple et al., 2000).  The diphtheria component was 
added to the school leaver booster in 1994 in order to boost immunity in 
adulthood.  In addition, since 1992, glycoconjugate vaccines, containing either 
tetanus toxoid or CRM197 (a non-toxigenic natural variant of diphtheria toxin), 
have been included in the UK schedule for infants in routine and catch-up 
programmes.  Immune responses to CRM197 have been shown in trials to 
significantly increase diphtheria antitoxin levels (Burrage et al., 2002).  An 
increase in population immunity from these changes was therefore expected but 
had not been previously assessed. 
Immunity and vaccination coverage are regularly monitored at a national level in 
the UK, and vaccination coverage is published quarterly and annually at 
Primary Care Trust (PCT) level (Public Health England, 2014b).  However, the 
vaccination coverage data received at the national centre are aggregated, and 
consequently do not enable further scrutiny.  Overall good coverage statistics 
can mask pockets of unimmunised children within a PCT if coverage varies 
across different populations within a PCT.  Maintaining high vaccination 
coverage can be challenging, particularly where populations are mobile, and/or 
language barriers exist.  Vaccination coverage by ethnicity for diphtheria-
containing vaccines was previously assessed for broad ethnic groups nationally 
(for children born 2000-2001) as part of the Millennium Cohort Study, which 
found that children of Black Caribbean mothers were more likely to be 
unimmunised than those of other ethnic groups (Samad et al., 2006).  In 
addition, a study in Manchester (of children born 2002-2007) found that white 
infants were least likely to be vaccinated with primary vaccines (Baker et al., 
2011).  London is an increasingly ethnically diverse city, encompassing both 
long-established and new migrant populations, including those arriving from 
diphtheria-endemic regions of the world.  Identification of low coverage within 
particular groups of children within London could enable appropriate targeting of 
immunisation resources.   
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This thesis aims: 
 To describe the epidemiology of diphtheria in the UK (1986-2008) and 
WHO European Region (2000-2009), including trends, risk factors for 
infection, and influences on disease severity and case fatality. 
 To explore the evidence base for the use of DAT in the UK, and issues 
relating to its supply internationally. 
 To gain an understanding of the circulation of both toxigenic and non-
toxigenic organisms, including C. ulcerans, in endemic and non-endemic 
countries within the WHO European Region. 
 To examine the susceptibility of the UK population in terms of both: 
o Diphtheria immunity levels, taking into account changes to the UK 
vaccination schedule  
o Childhood vaccination coverage within different ethnic groups in 
London. 
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3. Contribution to knowledge and scholarship 
 
Epidemiology of diphtheria in the UK and WHO European Region 
Trends 
Between 2000 and 2009 the number of diphtheria cases reported to the WHO 
European Regional Office continued to decline from a peak in 1995 (Figure 3).  
Diphtheria incidence in the European Region decreased by 95% from 
1.82/million population in 2000 to 0.07/million population in 2009.  Most (85%) 
cases reported from the European Region during 2000-2009 were from Russia 
and Ukraine.  However, Latvia (a country with a population of only two million) 
had the highest annual incidence in the European Region during 2000-2009.  In 
2009, although only six symptomatic cases were reported (compared to over 
250 in 2000 when an outbreak occurred in the military), Latvia remained the 
only country with an incidence rate greater than 1 per million population.   
 
Figure 3.  Diphtheria cases reported to the World Health Organization 
1980-2012 (source: World Health Organization (2013))  
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The DIPNET surveillance database included case-based data relating to 
infections (symptomatic and asymptomatic) with toxigenic strains of C. 
diphtheriae, C. ulcerans and C. pseudotuberculosis for its 25 member countries 
for 2000-2009.  The Baltic States (Estonia, Latvia and Lithuania) were included 
within DIPNET, but the other 22 countries within the network were from outside 
the former Soviet Union.  Estonia and Lithuania reported four and six 
symptomatic C. diphtheriae cases, respectively, at the beginning of the 
surveillance period (2000-2002), Lithuania also reported two further 
symptomatic cases in 2008.   
Fewer than sixteen symptomatic (ranging from mild symptoms to classic 
respiratory diphtheria) cases each year were reported overall from the 22 
DIPNET countries excluding the Baltic States during 2000-2009 (Figure 4).  
Twelve DIPNET countries reported zero cases during this time period. 
 
Figure 4.  Isolates from symptomatic cases reported by DIPNET member 
countries excluding the Baltic States, 2000-2009 (data from Publication 2, 
Table 1) 
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Symptomatic C. ulcerans cases outnumbered symptomatic C. diphtheriae 
cases for DIPNET countries excluding the Baltic States during 2000-2009.  The 
majority (87%, 46/53) of C. ulcerans reports were from France, Germany and 
the UK.  Cases of C. pseudotuberculosis remained very rare throughout the 
European Region. 
In the UK, between one and nine symptomatic cases of diphtheria were 
recorded each year between 1986 and 2008.  C. ulcerans cases were more 
common than C. diphtheriae cases in the UK between 2004 and 2008. 
The majority of C. diphtheriae isolates 2000-2009 from the epidemic region with 
a known biovar were biovar gravis.  In contrast, the majority of UK C. 
diphtheriae biovars (1986-2008) were biovar mitis. 
As well as the basic counts of cases described above, twelve countries from the 
epidemic region provided monthly reports to the WHO Regional Office for 
Europe with more detailed information such as patient age, sex, and outcome.  
These data were analysed for the period 2000-2009 (and 2002-2009 to exclude 
the military outbreak that occurred in Latvia in 2000).  Detailed case-based data 
for the same time period for DIPNET countries, including Latvia, were available 
from the DIPNET surveillance database.  UK enhanced surveillance data 
concerning cases from 2000-2009 were included within the DIPNET 
surveillance database, and also analysed separately for the period 1986-2008.  
Within the DIPNET and UK databases, information was recorded concerning 
risk factors/exposures, disease symptoms, vaccination histories and outcomes.  
These data enabled the study of common risk factors for infection, as well as 
disease severity and case fatality. 
Risk factors for infection 
In the epidemic region, toxigenic C. diphtheriae cases were reported across all 
age groups with most cases reported in teenagers and adults.  However, the 
severity of infection depended on immunity; the greatest risk of death was in 
those too young to be vaccinated and older adults (≥40 years) unvaccinated or 
with waning immunity.  More than 60% (123/196) of symptomatic cases in 
Latvia during 2002-2009 were in females, a similar bias was observed in the 
epidemic region as a whole for adult cases (≥20 years of age) during 2002-
14 
2009.  This could relate to the increased exposure of women to infection in their 
roles as caregivers in occupational and/or domestic settings, and/or the 
increased immunity in men because of vaccination during military service.  
Unemployment was identified as a risk factor amongst the Latvian cases, 
reflecting the association of diphtheria with low socio-economic conditions. 
In DIPNET countries outside of the epidemic region, C. diphtheriae cases were 
commonly associated with recent return from travelling abroad, contact with 
travellers, or recent migration from endemic areas.  The sex distribution was 
even in symptomatic C. diphtheriae cases for DIPNET countries excluding 
Latvia, and for the UK individually.  Similarly, in the UK, the main risk factor for 
C. diphtheriae infection was travel to an endemic country, and although there 
was a wide age range, the mean and median age of cases were both <25 
years.  Three cases of laboratory-acquired C. diphtheriae in the UK highlighted 
both the importance of maintaining immunisations for occupational exposure, 
and safe laboratory practice.   
C. ulcerans cases in those DIPNET countries that detected this organism most 
commonly occurred in older adults (59% (29/49) of cases were ≥45 years of 
age), predominantly females.  The cases reported during 2000-2009 had not 
travelled abroad, and did not have traditional risk factors such as consumption 
of raw milk or contact with dairy animals.  Ninety-four percent (32/34) of cases 
for which information was available had had contact with domestic animals.  All 
recent (between 2003 and 2008) cases of C. ulcerans in the UK had had 
contact with domestic cats or dogs, however, the organism was only isolated 
from one dog from which of one of these cases had been in contact (animals 
were only swabbed for five cases).  An identical strain was also isolated from a 
patient and dog with which the patient had been in contact in France (non-
toxigenic strain), and from a patient and their pig in Germany.   
Insufficient information was available to determine common risk factors for C. 
pseudotuberculosis infection from the four cases that arose in DIPNET 
countries during 2000-2009. 
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Disease severity and case fatality 
C. diphtheriae cases reported from former Soviet Union countries generally had 
respiratory presentations; apart from one cutaneous case these were the only 
presentations (excluding asymptomatic carriers) reported from Latvia during 
2000-2009.  In DIPNET European countries outside the former Soviet Union 
both cutaneous and respiratory presentations were reported for C. diphtheriae 
and C. ulcerans (as well as one C. diphtheriae case with bacterial endocarditis).  
For C. diphtheriae the cutaneous cases reflected acquisition in tropical areas of 
the world (cutaneous C. ulcerans cases did not have a history of travel abroad).  
Most (15/17, 88%) C. diphtheriae cutaneous cases in DIPNET countries 
excluding Latvia during 2000-2009 were biovar mitis whereas most (17/28, 
61%) respiratory cases with a known biovar were biovar gravis.  The majority 
(3/4) of C. pseudotuberculosis cases had cutaneous presentations. 
The classic respiratory presentation with pseudomembrane did not arise in any 
UK cases who were fully vaccinated (though cannot be ruled out in immunised 
individuals as did occur in fully vaccinated persons in other DIPNET countries).  
The most common presentation amongst UK cases was respiratory disease; 
typically a sore throat in a partially immunised individual, although occasionally 
such cases were fully immunised.  Vaccination showed a significant protective 
effect with respect to severity of infection across all DIPNET data; fully 
vaccinated cases in general had milder disease than unvaccinated cases.   
All five fatal cases in the UK during 1986-2008 were unimmunised.  In addition, 
most patients (74%) and infants (93%) who died within the epidemic region 
during 2000-2009 were unvaccinated.  Case fatality rates were highest for those 
with classic respiratory presentations, but were also high when those with any 
respiratory symptoms were included in the denominator (Figure 5).  The CFR 
was significantly higher for respiratory diphtheria in DIPNET countries excluding 
Latvia, compared to in Latvia.  DIPNET countries excluding Latvia are less 
familiar with identifying and treating the disease and in some cases did not have 
the resources/procedures in place to detect and respond to cases appropriately.  
The CFR in the UK for the period 1986-2008 was similar to that in the pre-
vaccine era in England and Wales, though smaller numbers meant there was 
less certainty around the recent estimate. 
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Figure 5.  Case fatality rates with 95% confidence intervals for UK, Latvia 
and DIPNET countries excluding Latvia (data from England and Wales 
notifications (Public Health England, 2014c), and Publications 1 and 2) 
 
Evidence base for the use of DAT in the UK, and issues relating to its 
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Information regarding receipt of DAT is requested on the UK enhanced 
surveillance form for diphtheria, which is completed in the event of a case.  
Information is requested regarding whether or not DAT was administered, as 
well as the dose and date of administration (although completion of the latter 
two fields is poor).  These data were available for the analysis of UK cases 
reported between 1986 and 2008. 
UK guidelines for the management and control of diphtheria recommend DAT 
for respiratory presentations, the dose depending on the site, the degree of 
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toxicity and the duration of illness (Bonnet and Begg, 1999).  However, although 
DAT is available in the UK, the majority of respiratory cases reported between 
1986 and 2008 did not receive this treatment (Figure 6).  Of the 60 UK cases 
with respiratory symptoms that did not receive DAT, most (57/60) recovered.  
Many of these cases were fully or partially immunised (23/60 (38%) were fully 
immunised, 10/60 partially immunised, 7/60 unknown immunisation status, and 
only 10/60 unimmunised).  Given that no fully vaccinated cases developed the 
severest disease presentation, even without DAT treatment, the benefits of 
administration of DAT, for mild, fully immunised, cases (when is it not clinically 
indicated) need to be weighed against potential side-effects.  DAT can cause 
hypersensitivity reactions which manifest either immediately as an anaphalactic 
reaction and/or a few days later as serum sickness (the symptoms of which can 
include generalised erythema, urticaria and itching) (Public Health England, 
2013). 
 
Figure 6.  Proportion of UK cases administered diphtheria antitoxin 1986-
2008, by clinical presentation (data from Publication 1, table 3) 
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DAT was administered to nine cases with classic respiratory symptoms (six 
unvaccinated, two partially vaccinated and one with unknown vaccination 
status), two of whom died.  There were three fatalities among the six patients 
with these symptoms (five unvaccinated, one partially vaccinated) who did not 
receive DAT.  Timely administration of DAT is dependent on prompt recognition 
and diagnosis, and often, because of unfamiliarity with the disease, correct 
diagnosis was delayed; even when DAT was administered it was often at a late 
stage (DAT has been shown to be ineffective if administered after the second 
day of diphtheritic symptoms (Logina and Donaghy, 1999)).   
The global availability of DAT was assessed by means of an international 
survey, sent to 57 countries in total.  Of 47 countries where the status of DAT 
stocks was known for 2007-2008, only 27 (57%) held a current stock of DAT 
(including the four countries that produce and supply internationally), the 
remainder had no stock, or an expired stock.  Various arrangements were in 
place for the holding of stocks, from national level through to district/hospital 
supplies.  Most stocks were obtained internationally, though three countries 
(Turkey, Bulgaria and Japan) had their own internal suppliers.  The four 
international producers of DAT identified at the time of the survey were based in 
Brazil, Croatia, India and Russia.  However, at the time of writing, DAT was not 
available from the Croatian or Brazilian producers, further reducing the 
international availability of this treatment.  As yet there are no internationally 
available alternatives to the liquid preparation, which requires refrigeration, and 
expires after 2-3 years (although a freeze-dried version is used in Japan).  
Several countries which had reported cases in the eight years prior to the 
survey did not hold current stocks, or had stocks which were close to expiry.  A 
central European or other international stock might be a possible approach but 
this option has not been fully explored and, even if possible, may not enable 
timely enough access to treatment.  Ideally a non-animal based alternative 
(without the side-effects of horse serum and easier to produce) would be 
developed. 
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Circulation of both toxigenic and non-toxigenic organisms in endemic and 
non-endemic countries within the WHO European Region  
In order to gain an understanding of the circulation of potentially toxigenic 
strains, ten countries (Bulgaria, Estonia, Finland, Greece, Italy, Ireland, Latvia, 
Lithuania, Turkey, and England (representing the UK)) participated in a 
screening study.  During the study period (between December 2007 and June 
2008) routinely submitted throat swabs were screened for potentially toxigenic 
Corynebacteria.  The only one of these countries with known endemic 
transmission of toxigenic strains was Latvia.   
During the screening period two toxigenic strains were identified in Latvia which, 
when added to the seven non-toxigenic strains also identified, gave a combined 
carriage rate for Latvia of 2.5 per 1,000 (lower than the carriage rate of 3.7 per 
1,000 population from a Latvian study conducted during 2002-2006 (Lucenko et 
al., 2006)).  Toxigenic strains (two cases and two carriers) were also detected in 
Lithuania in persons with no history of travel or contact with travellers, 
suggesting the presence of endemic transmission in this country also.  The last 
reported case of diphtheria in Lithuania had been in 2002.  The two cases 
identified in Lithuania during the screening study were unlinked and had classic 
respiratory presentations.  At least one of these cases would not have been 
detected in the absence of the study, highlighting the impact of this laboratory 
screening exercise on case ascertainment.  The toxigenic strains isolated in 
Latvia and Lithuania were ribotype Sankt-Petersburg, one of the major epidemic 
clones.  Furthermore, two of four non-toxigenic strains isolated in Lithuania 
during the study period were non-toxigenic toxin gene bearing strains, indicating 
additional circulation of the toxin gene beyond the toxigenic strains detected. 
Carriage rates of non-toxigenic strains amongst swabs screened (from patients 
with sore throats) ranged from 0-4.0 per 1,000 swabs screened (Figure 7).  
However, ascertainment appeared to be related to laboratory training as strains 
were more frequently detected in laboratories that had had recent training in 
diphtheria diagnostics (Estonia, Latvia, Turkey, UK). 
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Figure 7.  Carriage rates of toxigenic (tox) and non-toxigenic (non-tox) 
strains for patients with sore throats in participating countries (data from 
publication 4, table 2) 
 
Although the study was limited by the sample sizes achieved in each country, 
the study indicated overall that circulation of non-toxigenic strains appears 
largely limited to C. diphtheriae; only one non-toxigenic C. ulcerans and one 
non-toxigenic C. pseudotuberculosis were detected in total during the study 
compared to 26 non-toxigenic C. diphtheriae strains.  In countries with endemic 
circulation of toxigenic strains, circulation of non-toxigenic strains is also 
occurring.  However, non-toxigenic strains are also circulating to a greater 
(Turkey) or lesser (Estonia, UK) extent in non-endemic countries.  Endemic 
transmission of toxigenic strains and non-toxigenic toxin gene bearing strains 
continues in two of the former Soviet Union countries included within DIPNET.   
Susceptibility of the UK population 
Residual sera from routine diagnostic testing, representing the entire ranges of 
age and most geographical regions of the population of England, were assayed 
using multiplexed fluorescent bead assay to quantify IgG antibodies to 
diphtheria toxoid.  The proportions susceptible (antitoxin level <0.01 IU/mL), 
with basic protection (0.01-0.099 IU/mL) and with full protection (≥0.1 IU/mL) 
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were calculated.  The proportions protected were then standardised by age and 
sex to the UK population.   
Population-level diphtheria immunity in 2009 was observed in accordance with 
the UK vaccination schedule.  The highest proportions fully protected occurred 
in the early years of life, during and in the years directly following administration 
of the primary course and pre-school booster, as well as in the (approximately 
ten) years subsequent to administration of the school leaver booster.  Overall, 
after adjusting for age group, the anti-diphtheria IgG geometric mean 
concentration for males was 26% higher than for females (95% confidence 
interval 9-46%, p=0.001), a finding that could not be fully explained. 
Geometric mean concentrations of diphtheria IgG antibodies were significantly 
higher in 2009 compared to 1996 for ages 1-3 years, due, in part, to a boosting 
effect of the pneumococcal conjugate vaccine (PCV) (containing CRM197) which 
has been included in the UK schedule since September 2006, when there was 
also a catch-up to two years of age.  Meningococcal conjugate vaccines also 
utilising CRM197 were introduced into the UK infant immunisation schedule from 
1999 with a catch-up to 18 years of age. 
Lowest immunity levels were observed in the youngest age group (which 
included those too young to have received primary immunisations), in children 
aged 10-11 years (prior to administration of the school leaver booster) and also 
in adults (>35 years).  These older adults are not scheduled to receive any 
further routine diphtheria vaccines (though may receive diphtheria as part of the 
tetanus booster in the event of a tetanus-prone injury if they are not already fully 
immunised).  This may be more of a concern for C. ulcerans infection which has 
an older case distribution than C. diphtheriae in the UK.  However, the numbers 
of C. ulcerans cases are small, and immunity would be expected to improve in 
adults as increasingly those moving in to the older age groups will have 
received diphtheria vaccine as a school leaver booster. 
Overall, 75% of the UK population had at least basic protection against 
diphtheria (≥0.01 IU/mL) in 2009, an increase when compared to 60% in 1996 
(p<0.001).  The proportion fully protected (≥0.1 IU/mL) was 41% in 2009 
(compared to 16% in 1996, p<0.001).  This increase related to both the addition 
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of CRM197 containing glycoconjugate vaccines to the UK schedule, and the 
inclusion of diphtheria vaccine in the school leaver booster. 
The serosurvey results, whereby increases in immunity correspond to UK 
immunisation programme changes, reflect good national immunisation 
coverage.  However, coverage in London is lower than nationally.  In order to 
examine London coverage in more detail, data for children born April 2001 to 
March 2010 were extracted from the Child Health Information Systems (CHISs) 
of nine London Primary Care Trusts.  Vaccination coverage of diphtheria-
containing vaccines was assessed at first and second birthdays (primary 
vaccinations) as well as fifth birthday (primary vaccinations and pre-school 
booster). 
Limited data fields were available from the CHIS.  Of those available in the 
system, not all were well completed, for example nationality was available for 
less than 2.5% of extracted records.  However, ethnicity was better recorded, 
and enabled further analysis.   
Overall, across the nine London PCTs included in the study, consistently good 
coverage of the primary course (>88% at first birthday, >89% at second 
birthday) was achieved across the five largest ethnic groups.  Coverage of the 
preschool booster at fifth birthday was >65% across the five largest ethnic 
groups.  Although some of the smallest ethnic groups had good coverage, the 
lowest coverage in each cohort was among the smaller ethnic groups and those 
with unknown ethnicity.  Adjusting for gender, deprivation, PCT and year of birth 
did not substantially change the ethnicity patterns in coverage.  No particular 
ethnic groups were found to have consistently poor coverage across all PCTs.  
An interaction was found between PCT and ethnicity for all three age cohorts 
(p<0.001).  This was most pronounced for the white-Polish ethnic group, and 
related to population size.  Where white-Polish populations were larger within a 
PCT, coverage was closer to the average for the PCT, but two PCTs with 
smaller populations had lower than average coverage for this ethnic group 
(Figure 8, first birthday as example).   
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Figure 8.  Difference in coverage at first birthday between the average for 
each PCT* (excluding those with unknown ethnicity) and coverage within 
the white-Polish ethnic group in each PCT (error bars indicate 95% 
confidence intervals) 
*Note: All nine participating PCTs are included in figure 8, but data are 
displayed only for those with ≥50 children in the white-Polish group 
 
Deprivation scores were assigned based on geographic coding of area of 
residence.  Deprivation was not found to be a strong indicator of coverage 
overall and for most ethnic groups there was no relationship between 
deprivation and coverage.  However, interactions between ethnicity and 
deprivation were significant for each cohort.  A trend of reducing coverage by 
increasing deprivation was observed across each age cohort for the White-
British (Figure 9, first birthday as example) and not known ethnic groups only.   
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Figure 9.  Vaccination coverage at first birthday by deprivation quintile 
(1=least deprived, 5=most deprived) for the white-British ethnic group 
(error bars indicate 95% confidence intervals) 
 
The opposite trend was seen for Indian (Figure 10, first birthday as example) 
and white-Other/mixed/unspecified at first and second birthdays only.  Trends 
were not seen for other ethnicities. 
 
Figure 10.  Vaccination coverage at first birthday by deprivation quintile 
(1=least deprived, 5=most deprived) for the Asian or Asian British - Indian 
ethnic group (error bars indicate 95% confidence intervals) 
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For all age cohorts, children who were not assigned to a GP in the CHIS had 
lower vaccination coverage than children with a GP practice code recorded.  
This was not a surprising finding, as not registering in general practice is 
generally considered to be problematic in terms of access to healthcare, but this 
had not previously been demonstrated with available data (a search of Pubmed 
(21/09/2013) with the following terms did not find any studies that had reported 
childhood vaccination status with respect to unregistered children: ((registration 
AND ("general practice" OR GP OR "child health")) OR (unregistered AND 
children)) AND (vaccination OR immunisation OR immunization OR vaccine). 
Recorded vaccination coverage appeared to be strongly associated with the 
general level of record keeping for a child, in so far as those children with 
records complete in other areas (for example with ethnicity completed, with their 
record linked to a maternal record, and assigned to a GP practice on the 
system), were more likely to have vaccinations recorded.  Incomplete records 
could simply have been out of date (e.g.  relating to children who have since 
moved out of the area), or they could relate to children still living within the PCT 
who are genuinely out of touch with the health system and consequently 
missing out on vaccinations and other areas of healthcare.  Either way, records 
should be checked and removed/children followed up if vaccination coverage is 
to be accurately monitored and improved.   
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4. Critical reflection of methodological issues and indication 
of the future direction of research 
 
Epidemiology of diphtheria in the UK and WHO European Region 
Trends 
Trends in diphtheria incidence in the WHO European Region were assessed 
from surveillance data submitted to the WHO European Regional Office by its 
member states.  Annual reporting of aggregate case numbers is a requirement 
of all 53 member states.  The WHO case definition for diphtheria includes only 
classic respiratory diphtheria cases resulting from infection with toxigenic C. 
diphtheriae (Begg, 1994); these data therefore enabled monitoring of severe 
infections with the potential for epidemic spread. 
DIPNET member countries submitted case-based data to DIPNET for the 
period 2000-2009.  The DIPNET case definition includes infections caused by 
toxigenic C. ulcerans and C. pseudotuberculosis, as well as C. diphtheriae; 
enabling monitoring of the full range of diphtheria cases detected by its 25 
member countries. 
The WHO case definition includes a requirement for a confirmed case (as 
opposed to a ‘possible’ or ‘probable’ case) to have both a respiratory 
presentation with pseudomembrane and to be laboratory confirmed (Begg, 
1994), so the specificity is high.  Similarly, the DIPNET case definition requires 
that confirmed cases are either laboratory confirmed (with various clinical 
presentations possible), or have a classic respiratory presentation and an 
epidemiological link to a laboratory confirmed case.  Fifty-three Latvian cases 
not fitting the DIPNET case definition (without laboratory confirmation) were 
also included because they were in the national dataset; the inclusion of these 
cases was reliant on the experience of the Latvian clinicians involved in the 
diagnosis.  The inclusion of cases laboratory confirmed only by PCR detection 
of the tox gene (as opposed to demonstration of phenotypic toxigenicity using 
the Elek test) highlighted a discrepancy between some countries’ 
definitions/laboratory procedures for confirming diphtheria and the European 
(DIPNET and WHO) standards.  Given that these cases were symptomatic it is 
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likely that they were toxigenic strains, but the possibility of infection with NTTB 
strains cannot be excluded. 
Despite each DIPNET member country, excluding Latvia, submitting only small 
numbers of cases, there was often a lack of clarity in the data.  Numbers 
submitted to DIPNET often differed from those submitted to WHO or the 
European Centre for Disease Control for the corresponding years (after taking 
into account differences in case definitions (Begg, 1994, European 
Commission, 2012)).  Discrepancies were queried with individual countries and 
resolved, but suggested there were limitations with record keeping and/or 
communication within some countries.  This can sometimes be caused by poor 
communication between epidemiological and laboratory personnel (perhaps 
due to physical separation and sometimes institutional cultural barriers). 
The use of national surveillance data from each member country meant that 
WHO and DIPNET data were comprehensive in terms of their data collections, 
but did not rule out under-ascertainment (or record keeping errors) in individual 
country surveillance systems.  Zero annual case numbers, as reported by 
several DIPNET countries, can be an indicator of the success of control 
programmes, but can also result from under-ascertainment.  This is more 
relevant in countries where diphtheria cases are very rare, and laboratory skills 
are lost, and for C. ulcerans in particular because these cases often do not fulfil 
the standard laboratory screening criteria for diphtheria (such as travel to an 
endemic area).  In general the C. ulcerans cases reported to DIPNET were from 
countries with particular interests in the infection and/or those with highly 
developed laboratory and epidemiological surveillance systems.  Given the 
financial constraints and lack of routine screening for Corynebacteria in most 
European countries, as well as unfamiliarity with the clinical disease, the 
surveillance systems in some countries may not be sensitive for diphtheria.  
However, rather than meaning that large outbreaks were occurring undetected 
during the study periods (though there was some undetected endemic 
transmission in Lithuania), it is likely that occasional isolated cases were 
sometimes missed/not correctly diagnosed as diphtheria. 
In the UK not all laboratories routinely screen for diphtheria, and it is therefore 
possible that, although some cases with milder or atypical symptoms were 
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detected, others may have been missed.  Diphtheria is notifiable in the UK (to 
Local Authority and ultimately national level) under the Health Protection 
(Notification) Regulations 2010 (Public Health England, 2014c).  However, case 
finding through medical literature proved useful in the detection of two additional 
C. ulcerans cases in the UK that had not been reported to the national centre 
through standard channels.  Literature searching may also be useful in the 
surveillance of other rare infections, where unfamiliarity with organisms and 
procedures can lead to cases not being reported appropriately.  The use of 
several data sources (notifications, death registrations, laboratory reports, case 
follow-up forms, literature searching) ensured that the UK data presented were 
as comprehensive as possible. 
It might be beneficial to develop a set of standards against which a country’s 
surveillance system for diphtheria could be measured so that these can be 
taken into account when viewing reported case numbers.  Surveillance 
indicators developed for the surveillance of other vaccine preventable diseases 
that might be appropriate include; the proportion of confirmed cases with 
complete surveillance information, the number of cases of suspected disease 
that are reported, investigated and ruled out as cases, and the interval between 
date of symptom onset and public health notification (Roush, 2011). 
For diphtheria surveillance an approach relating to a country’s laboratory 
screening policies might be a relatively straightforward measure (e.g.  if all 
throat swabs nationally are screened for diphtheria a system would be 
considered very sensitive, if screening is carried out by a few sentinel 
laboratories it would be moderate and if screening is only carried out at the 
specific request of a clinician it would be least sensitive). 
C. ulcerans detection might also provide a means of assessing sensitivity.  It 
seems reasonable to assume that this organism is present to a similar extent in 
domestic animals in most countries; hence a similar incidence of cases would 
be expected.  Those countries that regularly detect cases could therefore be 
considered to have sensitive surveillance systems relative to those that have 
not detected C. ulcerans.   
For endemic C. diphtheriae countries it might be possible to calculate some 
indicators to give a guide to surveillance system sensitivity.  If we assume that, 
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in populations with similar vaccination coverage, for each severe case of 
diphtheria that is identified, there will also likely be a certain number of milder 
cases and asymptomatic carriers.  In Latvia during 2000-2009 overall, 
approximately five milder respiratory cases/asymptomatic carriers were 
detected for every two classic respiratory diphtheria cases.  In contrast in 
Lithuania for the same period four milder respiratory cases/asymptomatic 
carriers were reported with seven classic respiratory diphtheria cases.  If the 
Latvian ratio of 5:2 is applied to the Lithuanian data we would have expected 
approximately 17 milder respiratory cases/asymptomatic carriers to have been 
reported in the Lithuanian dataset rather than four, suggesting the surveillance 
system in Lithuania missed several cases.  This approach is based on the 
theory that countries who only detect the severest cases of diphtheria have 
relatively insensitive surveillance systems.  It is complicated however by 
assumptions that population immunity and conditions for disease transmission 
are similar in both countries.   
New and/or re-emerging threats from C. diphtheriae can potentially be better 
understood through the application of the latest molecular genomic 
technologies.  Ribotyping was the typing method used in the 1990s epidemic to 
characterise C. diphtheriae strains (Popovic et al., 2000), and remains the most 
affordable method in use, particularly within developing countries.  Multilocus 
Sequence Typing (MLST) is now being increasingly used, along with other 
methods, but there is currently no generally accepted standard method for 
strain characterisation (ribotyping therefore, still remains the gold standard).   
Whole genome sequencing however, has the potential to provide greater clarity, 
both in terms of our understanding of circulating strains, their origins, and 
spread, and the pathogenicity mechanisms that could enable particular strains 
to become epidemic strains.   
The genomes of a range of C. diphtheriae strains have been sequenced. The 
toxin gene itself (in particular the active A subunit) is very stable (the B subunit 
is more variable (Nakao et al., 1996)), hence the long-term success of vaccine 
and antitoxin treatment. However, it is possible for more than one copy to be 
inserted into a bacterial chromosome resulting in increased toxin production 
(Rappuoli et al., 1983a, Rappuoli et al., 1983b).  Pathogenicity islands that can 
be transferred horizontally have also been identified, the majority of which 
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encode subunits of adhesive pili, used for bacterial adhesion to host tissues 
(Mokrousov, 2009, Trost et al., 2012). To date little antimicrobial resistance in 
C. diphtheriae has been reported (apart from reports of macrolide resistance in 
South East Asia (Kneen et al., 1998), rifampicin resistance in Russia (Maple et 
al., 1994), and some multi-drug resistance in strains isolated in Brazil (Pereira 
et al., 2008) and Canada (Mina et al., 2011)), but it is feasible that genes 
encoding antimicrobial resistance mechanisms could be transferred horizontally 
(indeed an integron containing drug resistance gene cassettes framed by 
insertion sequences has already been identified within a C. diphtheriae biovar 
mitis genome (Barraud et al., 2011)), possibly from other species, providing 
further challenges for the treatment of this disease.   
Risk factors for infection 
For analyses beyond counts of case numbers, additional data fields were 
available from detailed monthly reporting to the WHO Regional Office for 
Europe, DIPNET enhanced surveillance, and UK enhanced surveillance. 
Although four of the 16 countries asked to participate in WHO monthly 
surveillance did not do so, data were still available on a sizable number of 
cases.  In addition the data collection undertaken as part of the DIPNET 
surveillance project created a database of European cases with common data 
fields, providing an opportunity to analyse larger numbers of cases than is 
usually possible in the post-vaccine era.  Even so, for non-endemic countries 
these numbers were still relatively small (and for two cases the data were 
limited further by country-specific confidentiality restrictions preventing release 
of case details).  Only limited case details were available for more than 200 of 
the Latvian cases provided to DIPNET.  More than half of these cases with 
missing information were from the military outbreak and therefore represented a 
different case-profile (in terms of age and gender) from the rest of the Latvian 
dataset, but the remainder could have informed the profiling of cases that arose 
in the general population. 
Completion of fields such as ‘risk group’ and ‘veterinary contact’ depended to a 
certain extent on a country’s interpretation/investigations around a case as well 
as their recording of this information for past cases.  The vaccination status field 
would have had different methods of completion (e.g.  patient recall vs 
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documented records) for different cases, and in some instances was assumed 
based on a patient’s age and country of birth.  In addition different vaccination 
schedules in different countries meant that the classification of partially/fully 
vaccinated may have differed with respect to the number of doses received in 
some instances.  In the UK completeness of surveillance forms, and vaccination 
histories, was variable.  A standardised questionnaire was only in use since 
1995, and questions on companion animals (for C. ulcerans) were only included 
from 2003 onwards.  Since the quality of any analysis is dependent on the 
accuracy of the data on which it is based, variations in data collection 
methodology and missing data were potentially serious limitations.  However, 
these data provided the only means of studying this rare disease in current 
European populations, and were sufficiently complete to enable several 
common themes to be observed.  The availability of comprehensive DIPNET 
and UK surveillance forms should improve data recording for future cases.  In 
addition in the UK an electronic information management system (HPZone) is 
now utilised by Public Health England to record information on cases and 
incidents.  HPZone is used in both local health protection units and the national 
surveillance centre enabling viewing of data between local and national teams.  
It records all possible cases at local level and documents the risk assessment 
and laboratory and epidemiological investigations, improving data quality in the 
last five years. 
Cases of diphtheria due to C. ulcerans were shown to have a range of 
presentations, including classic respiratory diphtheria, and the majority of C. 
ulcerans cases reported by DIPNET countries had had contact with domestic 
animals.  However, there remain some unanswered questions relating to the 
spread of this organism.  It has been demonstrated to have a wide host range 
(Seto et al., 2008) which includes companion animals, and identical organisms 
have been isolated from human cases and the domestic pets with which they 
have been in contact (Hogg et al., 2009, Berger et al., 2011).  In addition, a 
study in Japan found that carriage of C. ulcerans in healthy domestic dogs was 
7.5% (44/583; 42 toxigenic and three non-toxigenic strains were identified in 44 
dogs (from one dog both toxigenic and non-toxigenic organisms were isolated)) 
(Katsukawa et al., 2012).  Another carriage study in which swabs from the 
oropharynx of healthy cats and dogs in rescue centres were screened for 
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Corynebacteria is also underway in North West England (only preliminary 
results published to date (National Consortium for Zoonosis Research, no 
date)).  But the direction of transmission (animal to human and/or human to 
animal) and whether the organism can be passed from human to human are 
aspects around which there is still uncertainty.  These two questions may only 
be further understood should specific case scenarios arise.  Even then, the 
testing of animals in the event of a case in the UK continues to be problematic, 
not least because some cases have been exposed to many animals.  There is 
currently no guidance relating to the testing or treatment of animals associated 
with human toxigenic C. ulcerans cases.  Questions exist regarding for 
example, who should cover the costs of screening animals, as well as the 
course of action should a toxigenic strain be identified in a companion animal 
(whether or not the animal should be treated to eliminate carriage, and if so 
which treatment to use as the antibiotics used in human treatment are not 
suitable for animals).  Swabbing of companion animals is therefore not always 
conducted.   
Disease severity and case fatality 
Classification of cases caused by toxigenic strains into categories relating to 
their disease severity (classic respiratory, mild diphtheria/severe pharyngitis, 
asymptomatic) and vaccination status (vaccinated, partially vaccinated, 
unvaccinated) enabled a test for trend to be applied, which gave an overview of 
the relationship between vaccination status and disease severity across the 
DIPNET dataset.  In the UK dataset, the relationship between vaccination status 
and disease severity was analysed as a simple comparison of the proportions of 
cases vaccinated vs partially/unvaccinated presenting with classic respiratory 
diphtheria which also demonstrated a clear effect. 
The classification of disease severity into different groupings also enabled the 
calculation of case fatality rates for classic respiratory symptoms as well as any 
respiratory symptoms.  Cases with classic respiratory diphtheria are difficult to 
treat, even if DAT is readily available, as it may be too late for the DAT 
treatment to be effective.  This may explain the similarities in the case fatality 
rates for classic respiratory diphtheria in the UK, Latvia and DIPNET countries 
excluding Latvia.   
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Case fatality rates for any respiratory symptoms can vary across different 
populations for a number of reasons.  For cases to be included in the 
surveillance dataset requires that they are recognised and correctly diagnosed 
as diphtheria.  Lack of diagnosis of mild cases could raise the apparent case 
fatality rate if only the severest disease is recognised as diphtheria.  Only 
countries that have staff competent in the laboratory diagnosis of diphtheria, the 
resources available to perform the testing, and the policies in place to initiate 
screening will reliably detect milder cases of disease.   
A high case fatality rate, as well as demonstrating the seriousness of an 
infection, indicates that a large proportion of cases have low immunity levels 
and for whatever reason are not prevented from progressing to severe disease 
by medical treatment.  Appropriate medical treatment may not be administered 
if the disease is not correctly diagnosed in time, or if DAT is not available.  As 
observed during the epidemic in the former Soviet Union, the availability of DAT 
can have a dramatic impact on CFRs.  In Russia, where DAT was always 
available, the CFR was approximately 3%, compared to >20% at the start of the 
epidemic in the Newly Independent States (excluding the Russian Federation) 
where supplies of DAT and antibiotics were limited (Dittmann et al., 2000).  In 
recent years prompt treatment of cases has been problematic for countries that 
do not maintain a supply of DAT. 
Evidence base for the use of DAT in the UK, and issues relating to its 
supply internationally 
Fields relating to DAT administration for UK cases were poorly completed, in 
particular those relating to the timing of administration and dose of DAT.  
Because the impact of DAT treatment is heavily dependent on timing, it was 
therefore difficult to draw strong conclusions from the data regarding the 
effectiveness of DAT treatment.  However, the fact that <50% of severe cases 
(respiratory symptoms with membrane or exudate) received DAT does indicate 
that even in the UK, where DAT is readily available, there were difficulties 
surrounding the treatment of diphtheria cases.  These include timely diagnosis, 
as well as the acceptability of DAT.  Data concerning the treatment of cases 
were not collected across DIPNET countries but would have been of value to 
contribute to this analysis. 
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As well as improving completion of fields relating to DAT administration on 
surveillance forms for UK cases, it may be possible to link records for requests 
for DAT from issuing centres to provide confirmation of timings in relation to 
onset of symptoms.  These data are also now better recorded through HPZone 
(the electronic patient management system now in use in the UK, described 
above) so recent data should allow improved analyses to be undertaken.   
The DAT survey allowed assessment of the extent of DAT supplies and 
shortages.  Invitation to complete the survey, beyond DIPNET members, was 
primarily dependent on contact details being available for an appropriate person 
within a particular country.  Expanding the survey, through the assistance of the 
WHO to Russian-speaking countries enabled wider participation.  However, 
there were still many countries not reached by the survey, and it would have 
been particularly interesting to understand the situation in diphtheria-endemic 
countries outside of the European Region.  Even without wider participation, the 
results demonstrated the challenges in the supply of this product.  The review 
has already been of value to those advocating for a supply of DAT in their 
country, as well as those needing information about current suppliers.   
Further development is needed to explore alternatives to equine DAT.  
Promisingly, a human monoclonal antibody was recently identified which binds 
to the receptor-binding domain of the diphtheria toxin and completely protected 
guinea pigs from intoxication in an in vivo model (Sevigny et al., 2013).  
Additional testing is planned to explore its safety and efficacy for development 
as a human treatment. 
As well as being used for diphtheria therapy, DAT is also a component of the 
Elek test used for the laboratory confirmation of diphtheria.  A review has 
recently been undertaken to explore access to DAT for both therapeutic and 
diagnostic purposes; it further emphasises the need for alternatives and/or a 
central stockpile (Both et al., 2014).   
Circulation of both toxigenic and non-toxigenic organisms, including C. 
ulcerans, in endemic and non-endemic countries within the WHO 
European Region 
Carriage of potentially toxigenic organisms in ten DIPNET countries was 
assessed by screening routinely submitted (throat) swabs from people with sore 
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throats.  Given that a sore throat is a symptom of respiratory diphtheria, this had 
the advantage of focussing study resources on populations from which these 
organisms were most likely to be isolated, but the carriage rates did not then 
apply to the populations as a whole. 
The sample size calculated for the study (for the number of swabs each country 
was required to screen) was based on the prevalence of 3.7 per 1,000 
population from a previous screening study in Latvia.  Latvia has the highest 
incidence of diphtheria in the European region, so the sample size may have 
been too small to detect organisms in other countries.  Even so, more than half 
of the participating countries (Bulgaria, Finland, Greece, Italy, Ireland and 
Latvia) screened fewer than 2,700 samples; there was therefore insufficient 
power in these studies, hence the wide confidence intervals on the zero 
estimates.   
The ten countries that participated in the study ranged from countries within 
Europe that routinely report cases (Latvia, UK), to countries that had not 
reported any cases in the seven years immediately preceding the study 
(Bulgaria, Greece, Ireland).  Central Europe was not represented, but there was 
no evidence to suggest that carriage would be different in Central Europe 
compared to in other countries included in the study.  Within countries, the 
study relied on voluntary participation of laboratories; as such the areas served 
did not always represent the general population of that country (for example, no 
London laboratories participated from the UK).  The age of the populations 
sampled in each country also varied, with some countries including a large 
number of swabs from children’s hospitals (these were the only swabs included 
for Greece).  Given that immunity levels vary with age, and that children often 
have higher immunity than adults, this may have influenced the low/zero 
carriage rates for these countries.  The higher number of females compared to 
males in the study as a whole may simply have related to higher consultation 
rates amongst females in general practice. 
The study relied on the national policies and procedures in place in individual 
countries for the submission of throat swabs.  Clinicians in different countries, 
and possibly also within countries, have different criteria for submitting a throat 
swab for laboratory investigation.  This depends on the policies within different 
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countries (in some countries additional costs are incurred for transporting 
samples), as well as a clinician’s criteria/knowledge for clinical suspicion.   
All countries participating in the study processed throat swabs for potentially 
toxigenic Corynebacteria according to their standard protocols and WHO 
guidelines.  Ideally a standard study laboratory protocol would have been used.  
However, most countries base their laboratory protocol on WHO guidelines, so 
protocols across countries should have been similar.  Furthermore, all 
organisms reported in the study were confirmed at the Health Protection 
Agency’s Respiratory and Systemic Infections Department, UK.   
A DIPNET international external quality assurance study was conducted just 
after the study period had ended, in which all ten countries from the carriage 
study participated (Neal and Efstratiou, 2009).  It found that only 6/34 centres 
produced acceptable results for all six specimens, and many centres could not 
isolate the target organism.  Training workshops had been conducted in Turkey 
and Estonia just prior to the start of the study; both of these countries identified 
non-toxigenic strains, suggesting laboratory competence in some of the other 
participating countries (that did not identify any isolates) was an issue.   
Although surveillance forms were completed for patients identified as infected 
with toxigenic strains, those carrying non-toxigenic strains were not followed up.  
Since no public health action is taken around detection of non-toxigenic strains, 
follow-up may have caused undue concern in these patients.  However, it would 
have been interesting to know the vaccination status of those carrying non-
toxigenic strains, if they had any other symptoms (beyond a sore throat), and if 
they had a recent history of travel abroad. 
As described above, this study was limited by several factors which should be 
taken into account when viewing the results.  Ideally the study would have 
included laboratory training prior to the screening period, a common laboratory 
screening protocol, funding for personnel as well as laboratory media, wider 
participation and greater sample sizes from participating countries.  However, it 
was limited by the resources available.  Despite these limitations the 
demonstration of endemic transmission in Lithuania was an important finding 
with direct public health implications.  In addition, although carriage estimates 
within several countries were uncertain (given the wide confidence intervals), 
37 
pooling the results gives a carriage rate across the ten participating DIPNET 
member countries, for both toxigenic and non-toxigenic strains combined, of 1.1 
per 1,000 swabs screened (95% confidence interval 0.8-1.6).  The study also 
serves as a baseline from which the methodology can be developed for future 
assessments of carriage.   
Following the screening study, Lithuania increased its laboratory screening 
practices.  It would be interesting to know the impact of this change in relation to 
detection of strains (both toxigenic and non-toxigenic).  Since the screening 
study was undertaken in 2007, Lithuania has reported only one further toxigenic 
C. diphtheriae case to WHO (in 2011) (World Health Organization, 2013).  
Unfortunately austerity measures resulting from the financial crisis across 
Europe will have adversely affected screening practices/surveillance and thus 
any increases in screening immediately following the study may not have been 
long in duration.   
The UK has a large migrant population which includes increasingly populations 
from eastern European countries (Latvia and Lithuania joined the EU in 2004).  
Detection of strains as part of screening undertaken in the UK, either in specific 
migrant populations, or routinely if country of birth data are collected, could 
potentially indicate continuing/increased transmission in countries with more 
limited laboratory resources.   
Susceptibility of the UK population 
Diphtheria immunity levels, taking into account changes to the UK 
vaccination schedule  
National vaccination coverage is documented over time, and the low numbers 
of diphtheria cases reported nationally, along with high recorded vaccination 
coverage suggest that population immunity is high, and consequently the 
diphtheria vaccine in use in the UK is effective.  However, a serosurvey allows 
direct measurement of the population immunity afforded by the vaccination 
programme. 
The sera used in the serosurvey represented most geographical regions of 
England, as well as a range of ages.  The results were standardised to the UK 
population as a whole to give a measure of overall immunity for the UK.  This 
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seemed reasonable given that the vaccination schedule applies to the whole of 
the UK.  Vaccination coverage is generally higher in Scotland than England 
though, so UK immunity may have been very slightly underestimated in this 
study.   
Unfortunately individual vaccination histories of the patients whose sera were 
included in the survey were not available (in contrast to collections e.g. at the 
National Institute for Public Health and the Environment, RIVM in the 
Netherlands) so to what extent they matched the UK vaccination schedule, and 
represented national vaccination coverage could not be determined. 
The residual sera used in the study were collected typically from patients 
presenting with symptoms requiring diagnostic testing.  However, sera from 
patients known to be immunocompromised were excluded from the archive 
collection; previous studies using this sampling base have shown it to be 
representative of the wider population (Osborne et al., 2000).   
The international standard correlates of protection for diphtheria (whereby 
antitoxin levels <0.01 IU/mL denote susceptibility, antitoxin levels 0.01-0.099 
IU/mL provide basic protection, and antitoxin levels ≥0.1 IU/mL are fully 
protective) were derived from studies of patients with diphtheria and relate to 
protection from severe disease (World Health Organization, 2009) (in contrast 
to those for tetanus, which lacks established criteria).   
The multiplexed fluorescent bead assay was used to measure antitoxin levels in 
2009, a different method to that used in 1996.  The multiplex assay enabled a 
large number of samples to be run rapidly against multiple antigens (in this case 
Haemophilus influenzae type b, diphtheria, and tetanus).  This method was 
more cost effective, and also used less serum volume than the methods used in 
1996 (indirect enzyme linked immunosorbent assay (ELISA) and dissociation 
enhanced lanthanide fluorescence immunoassay (DELFIA)).  Standardisation of 
a panel of samples from 1996 enabled the results from 1996 and 2009 to be 
compared despite the use of different laboratory methods at the two time points.   
The UK does not schedule any diphtheria booster immunisations for adults 
(several European countries offer ten yearly boosters although compliance is 
not known as reliable coverage data is not available).  Immunity in older age 
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groups could be further explored, particularly in relation to countries that offer 
additional boosting to understand not only the differences in adult immunity 
levels (for smaller age groups than studied here), but also how widely these 
boosters are taken up by adults in countries where they are offered. 
Given that there are variations in vaccination coverage across the country, it 
may also be of interest to explore regional variations in immunity, which it was 
not possible to do within this serosurvey data.   
Childhood vaccination coverage within different ethnic groups in London 
Childhood vaccination coverage data were extracted from CHISs in nine 
London PCTs, using a common script and analysed by ethnicity.   
The study took place during 2011/2012, around the time of a major re-
organisation of the NHS including the abolishment of PCTs (childhood 
vaccination coverage is now assessed by Local Authority (as well as by PCT to 
allow for continuity with historical data)).  Participation in the study was 
voluntary and relied on interest within each PCT; completion was challenging 
given the absence of specific funding, and the organisational changes occurring 
in PCTs at that time.  However, the nine PCTs that participated represented 
several geographical locations across London.  A comparison of Greater 
London Authority projections overall for the same time period (children aged 0-4 
years in 2009, and equivalent calendar years for children born 2005-2009 from 
the study dataset) found that the proportion of Black and Minority Ethnic groups 
in the study dataset was 51%, whilst the proportion of Black and Minority Ethnic 
groups for the same time period for Greater London was similarly 53%.  In 
terms of vaccination coverage, the study PCTs came from all four quartiles of 
2010/2011 London PCT COVER data for diphtheria-containing vaccines at first, 
second and fifth birthdays.  Therefore, although not specifically selected for the 
study, the participating PCTs did appear representative of Greater London 
PCTs as a whole. 
Participation of a greater number of London PCTs would have improved the 
sample sizes, which could have been beneficial for observing coverage in 
smaller ethnic groups.  Participation beyond London could also have expanded 
the range of ethnic groups to include those not concentrated in London.  
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However, even with only nine London PCTs participating, the dataset was large 
(over 300,000 records), and included a range of ethnicities, including those 
most common in the UK as a whole (White British, Indian, Pakistani).   
The study was limited to London PCTs using the RiO CHIS because the 
extraction script was written for this system by one of the study authors.  
Participation by PCTs using other systems would have been possible but would 
have depended on the interest and skills of particular data managers familiar 
with those systems.  Some PCTs expressed interest in participating but did not 
feel able to extract the data, highlighting a drawback of CHISs that have a 
limited range of options available for extractions and are difficult to query.  RiO 
is now being used more widely beyond London in the south of England 
(Evenstad, 2014, Todd, 2014) so a future study could have wider participation. 
An advantage of using RiO data was that these data were routinely collected on 
a large scale over several years.  The RiO system contains documented 
immunisation data for each child, which should be more accurate than data 
based on maternal recall of vaccinations (as used by the Millennium Cohort 
study of childhood vaccination coverage (Samad et al., 2006)). 
Diphtheria-containing vaccines (as opposed to other vaccines) were chosen as 
the measure of vaccination coverage because they have been routine for many 
years, and are generally well accepted.  For this reason they can also to a 
certain extent provide a proxy for the level of contact a child has had with the 
UK health system.  The vaccination status of each child was calculated by 
taking into account all diphtheria-containing vaccines recorded for that child.  
This allowed vaccines not routinely administered in the UK but containing 
equivalent dosage to be included.  The method of assigning vaccination status 
was more rigorous than some COVER extractions in so far as every dose was 
required to be recorded, rather than only the final dose.   
Although the exact date of vaccination was available, only month and year of 
birth were extracted for confidentiality reasons.  It was therefore not possible to 
calculate if the vaccination was received ‘by first birthday’ exactly.  However, the 
calculation was generous, counting those vaccines received up to 13 months 
rather than exactly 12 months.  Given that the primary course is scheduled 
between 2 and 4 months of age, the numbers fully vaccinated at 13 months 
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would not have been expected to differ greatly from the number fully vaccinated 
at 12 months. 
Partially immunised and completely unimmunised were included in the same 
grouping (termed ‘not fully immunised’).  Although partial immunisation would 
provide some protection, the goal of the immunisation programme is full 
vaccination.  The COVER programme monitors completion of the primary 
course, hence that was the measure used for this study (the number/proportion 
of children fully vaccinated is also the requirement for annual country reports to 
the WHO).  However, it might be of interest to further explore the data and 
determine the proportions partially immunised for each ethnic group to improve 
understanding of the breakdown of vaccination status, in particular of children in 
ethnic groups with low overall coverage. 
The study was limited to the data fields available for extraction in the RiO CHIS.  
Consequently there may have been variables missing from the model that might 
affect vaccination coverage.  However, the variables that were included 
(gender, deprivation, PCT and fiscal year of birth) did not show much evidence 
of confounding the ethnicity effect.  Although other variables may explain the 
differences, it could be argued that these are part of the profile of ethnicity so 
the unadjusted coverage is still important.  In other published analyses 
additional factors were studied such as family size, maternal smoking, maternal 
education and lone parenthood (Samad et al., 2006, Baker et al., 2011).  But 
although the study based in Manchester included some of these other 
measures, their principle finding related to deprivation (Baker et al., 2011), 
which was a measure included in this study. 
Despite the number of fields available being limited, the data in the fields 
included in the model was near complete; gender (>99.9% complete), 
deprivation (98% complete), PCT (100% complete) and fiscal year of birth 
(100% complete).  In the ethnicity data a category was included for ‘not known’ 
to display the characteristics of records with missing information in this regard.   
There were insufficient data fields available for extraction to assess the 
individual deprivation score of each child; deprivation was therefore assessed 
according to the geographical area of residence, Lower Super Output Area 
(LSOA).  Given that there were on average 1,600 people resident in each LSOA 
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in 2010 (Office for National Statistics, 2011) and that deprivation can vary in 
close proximity in London areas, there would have been some inaccuracies in 
this method.  However, LSOA was the smallest geographical area available for 
use in the study given that postcodes needed to be removed (for confidentiality 
reasons) before the data left the PCT.  The Income Deprivation Affecting 
Children Index was chosen (as opposed to other geographical measures of 
deprivation) because it relates to children, the subject of this study.  It is a 
ranking based on the percentage of children aged 0-15 years in each LSOA 
living in families that are income-deprived (Local Government Association, 
2014).   
Multivariable logistic regression enabled the effect of other variables (gender, 
deprivation, PCT and year of birth) on coverage to be taken into account.  
Interactions were examined based on a priori reasoning.  An interaction 
between PCT and ethnicity was examined because different PCTs may take 
different approaches to targeting coverage in particular ethnic groups.  In 
addition, an interaction between ethnicity and deprivation was examined 
because the Manchester study had identified that for white infants, lower 
coverage was significantly associated with living in a deprived area, but for 
black infants or black British infants and Pakistanis, there was no significant 
association between deprivation and immunisation (Baker et al., 2011). 
No record of immunisation indicates that either the child did not receive the 
immunisations, or any immunisations received were not recorded.  Populations 
moving in to a PCT may not have had their immunisation records transferred 
across.  This process is largely done manually as these data cannot always be 
automatically transferred between systems.  This could give a falsely low 
coverage result.  If demographic data are also missing from the record, and the 
record is not linked to a maternal record this suggests missing data could be the 
main issue (rather than lack of receipt of vaccines).  Children without 
immunisations recorded may also be children who have moved out of the 
system but have not had their record deleted.  Without clarifying these data 
issues at the PCT-level, the true vaccination coverage cannot be determined.  
Information about country of birth and date of arrival in the UK (where relevant) 
would be useful to further understand some of these issues. 
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It may be possible to link child health system records with birth registrations 
data to see what proportion of records match to UK birth details for the same 
period.  This may help to further understanding of populations with low 
immunisation coverage/without GP practice codes recorded on the system if 
children are shown either to have been born outside their current area of 
residence or if their birth was not registered in the UK. 
Another option is to improve country of birth recording at the GP practice level.  
Some GP systems have the facility for the country of birth field to be specifically 
added in to their standard data-capture screen.  Encouraging collection of this 
information within GP practices could improve the data on CHISs, as well as 
enabling GPs to take country of birth related health issues into account when 
considering patient care (Public Health England, no date). 
A national reconciliation exercise of CHIS and GP systems is currently being 
undertaken to assess the potential for children to be registered with GPs but not 
known to CHIS systems.  It is thought this will particularly highlight children who 
have moved in from abroad.  It also includes an analysis of the systems in place 
for the transfer of data between GP/CHIS and CHIS/CHIS. 
Whilst combining data across the nine participating PCTs enabled the analysis 
of overall coverage for different ethnic groups across London, the study also 
provided a means for each individual PCT to explore their coverage data.  
Individual analyses were fed back to each participating PCT providing 
breakdowns of coverage by ethnicity, and numbers of unregistered children, so 
that these data could be used for further investigations at a local level. 
In conclusion, the studies described here, although limited to varying extents by 
issues relating to ascertainment and/or record keeping, have provided a 
valuable update on the current epidemiology of diphtheria in the UK and 
European Region.  Importantly, they have also highlighted the need to maintain 
laboratory and clinical expertise in this area, and to continue striving for good 
population immunity throughout the European Region.   
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SUMMARY
Diphtheria is an uncommon disease in the UK due to an eﬀective immunization programme;
consequently when cases do arise, there can be delays in diagnosis and case-fatality rates remain
high. We reviewed 102 patients with infections caused by toxigenic corynebacteria (an average of
four per year) reported in the UK between 1986 and 2008: 42 Corynebacterium diphtheriae,
59 C. ulcerans and one C. pseudotuberculosis, as well as 23 asymptomatic carriers. Five fatalities
were reported, all in unvaccinated patients. The major risk factor for C. diphtheriae infection
continued to be travel to an endemic country. C. ulcerans infections became more common than
C. diphtheriae infections in the UK; they were associated with contact with companion animals.
The occurrence of indigenous severe C. ulcerans infections and imported C. diphtheriae cases
highlights the need to maintain UK routine vaccination coverage at the 95% level in the UK,
as recommended by the World Health Organization.
Key words : Corynebacterium, diphtheria, epidemiology, immunization, vaccine-preventable
diseases.
INTRODUCTION
Diphtheria, historically one of the most feared dis-
eases of childhood, is now uncommon in the UK due
to national immunization since the 1940s (Fig. 1).
Since 1990, UK diphtheria vaccination coverage at
age 2 years has exceeded 90%, rising to 94% from the
beginning of the 21st century, close to the World
Health Organization (WHO) 95% target. Diphtheria
vaccine is made from inactivated diphtheria toxin
and protects individuals from the eﬀects of toxin-
producing corynebacteria. Three Corynebacterium
spp. can potentially produce diphtheria toxin;
C. diphtheriae (associated with epidemic diphtheria
and spread from person-to-person via respiratory
droplets and close contact), C. ulcerans and C. pseudo-
tuberculosis (both less common globally and tradi-
tionally associated with farm animal contact and
dairy products). The classic and most severe presen-
tation of diphtheria is a respiratory disease with a
swollen ‘bull neck’ and strongly adherent pseudo-
membrane, which obstructs the airways. Patients with
less severe respiratory disease can present with a sore
* Author for correspondence: Ms. J. M. White, Immunisation,
Hepatitis and Blood Safety Department, Health Protection Agency
Centre for Infections, London, NW9 5EQ, UK.
(Email : joanne.white@hpa.org.uk)
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throat. Diphtheria can also cause cutaneous infection,
characterized by ‘rolled edge’ ulcers, which are more
common in tropical areas of the world.
Diphtheria vaccine is currently scheduled in the
UK as shown in Table 1. An accelerated schedule (2, 3,
4 months) for infant immunization replaced an ex-
tended schedule [2] (3, 412–5, 8
1
2–11 months) in the
early 1990s [3], and the low-dose diphtheria compo-
nent was added to the school-leaver dose of tetanus
toxoid (Td) in 1994 (Td/IPV since 2004) [4]. A total of
ﬁve doses of a diphtheria-containing vaccine at ap-
propriate intervals are considered to give satisfactory
long-term protection in most circumstances.
UK guidelines for the control of diphtheria,
and laboratory diagnosis of infections caused by
Corynebacterium diphtheriae and C. ulcerans were
published in 1999 [5]. A clinical case of respiratory
diphtheria requires rapid administration of diphtheria
antitoxin (a concentrated immunoglobulin prepara-
tion prepared from horse serum, that neutralizes
circulating toxin), as well as antibiotics to clear the
bacterial infection. Antibiotics of choice are eryth-
romycin, azithromycin, clarithromycin, or penicillin,
all of which are active in vitro against C. diphtheriae
and C. ulcerans. Administration of diphtheria vaccine
is recommended during convalescence because diph-
theria infection does not always confer immunity.
This paper summarizes all cases of diphtheria
and other related infections caused by toxigenic
corynebacteria that have been reported in the UK
Table 1. UK vaccination schedule for diphtheria-containing vaccines
Age Vaccine
2, 3, 4 months DTaP/IPV/Hib (diphtheria, tetanus, acellular pertussis, polio, Haemophilus inﬂuenzae
group b antigens)
3 years and 4 months to 5 years dTaP/IPV or DTaP/IPV (diphtheria, tetanus, acellular pertussis and polio)
13–18 years Td/IPV (tetanus, diphtheria and polio)
’ All travellers to epidemic or endemic areas should ensure that they are fully immunized according to the UK schedule.
Additional doses of vaccines may be required according to the destination and the nature of travel intended. Where
tetanus, diphtheria or polio protection is required and the ﬁnal dose of the relevant antigen was more than 10 years
ago, Td/IPV should be given.
’ Individuals who may be exposed to diphtheria in microbiology laboratories and clinical infectious disease units should
be tested and, if necessary, given a booster dose of a diphtheria-containing vaccine. An antibody test should be
performed at least 3 months after immunization to conﬁrm protective immunity and the individual should ideally be
given a booster dose at 10-year intervals thereafter.
’ Diphtheria vaccine may also be given as part of the combined Td/IPV vaccine given to individuals presenting with a
tetanus-prone injury.
Source : Green Book 2006 [1].
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Fig. 1. Diphtheria notiﬁcations and deaths in England and Wales 1914–2008 (notiﬁcations up to 1985, laboratory-conﬁrmed
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during the last 23 years, highlighting key trends and
characteristics of the disease, as well as its changing
epidemiology.
METHODS
Information concerning diphtheria cases in the years
1986–2008 was obtained from the following routine
sources :
’ Statutory notiﬁcations to the Oﬃce for National
Statistics up to 1996, which then transferred to the
Communicable Disease Surveillance Centre, now
the Health Protection Agency (HPA) Centre for
Infections (CfI).
’ Death registrations to the Oﬃce for National
Statistics.
’ Laboratory reports from the WHO Collaborating
Centre for Diphtheria and Streptococcal Infec-
tions, Respiratory and Systemic Infections De-
partment.
’ Case follow-up information from the HPA CfI
Immunization, Hepatitis and Blood Safety De-
partment.
In addition a literature search was carried out across
Medline, EMBASE and Scopus databases during
July–September 2008 in order to identify any addi-
tional cases not reported through routine surveillance.
The search strategies covered titles and abstracts of
English-language publications from 1985 to 2008 and
comprised key-word combinations of ‘diphtheria’,
‘Corynebacterium AND diphtheriae ’, ‘Corynebacter-
ium AND ulcerans’, ‘Corynebacterium AND pseudo-
tuberculosis ’.
In the UK, toxigenicity testing of suspect isolates
from local laboratories is carried out by the WHO
Collaborating Centre for Diphtheria and Strepto-
coccal Infections, Respiratory and Systemic Infec-
tions Department (RSID) at the HPA in London.
Historically, the Elek test has been used since 1940 to
assess toxin production; prior to 1991, toxigenicity
was also assessed by an in vivo subcutaneous test, and
since 1993 PCR has been used to detect the presence
of the toxin gene. However, the gold standard
phenotypic test is the Elek test [6]. Case follow-up is
prompted by either a report of a toxigenic Coryne-
bacterium isolate from the RSID, a direct communi-
cation with a consultant in communicable disease
control or a clinician involved in the management of a
suspected case, or notiﬁcation of a suspected case of
diphtheria to the local authority. Follow-up of all
toxigenic isolates (cases and carriers) of Coryne-
bacterium spp. has been standardized since 1995 using
a questionnaire to ascertain the patient’s clinical
and immunization history, travel history and contact
with travellers, exposure to raw dairy produce and
domestic animals (C. ulcerans only) and management
of the case and contacts. Information about contact
with companion animals (cats/dogs) for C. ulcerans
cases has been included on follow-up forms since
2003.
Here, a conﬁrmed case is deﬁned according to the
Diphtheria Surveillance Network (DIPNET, www.
dipnet.org) case deﬁnition (see Appendix) whereby
a toxigenic isolate of C. diphtheriae, C. ulcerans or
C. pseudotuberculosis has been isolated from the
patient with an appropriate clinical presentation. An
asymptomatic carrier is deﬁned as having a toxigenic
isolate with no symptoms. In this paper cases are
further grouped according to the severity of their
disease, the most severe presentation being classic
respiratory diphtheria with pseudomembrane.
Statistical analyses involved x2 tests using Stata
statistical software, release 8.0 (StataCorp, USA).
Patients were assigned to four groups according to
their vaccination status :
’ Fully immunized for age [have received all sched-
uled vaccinations appropriate for their age (and
vaccination schedule of their time), if they have a
history of recent travel to an endemic area or work
in a laboratory handling diphtheria this includes
receipt of appropriate booster immunizations].
’ Partially immunized (have received some scheduled
vaccinations but not all appropriate for their age,
or have not received appropriate booster vacci-
nations for travel/occupation).
’ Vaccination history not known or not reported.
’ Unimmunized (if no history was available, patients
born prior to 1940 were assumed to be unim-
munized).
RESULTS
During the 23-year period 1986–2008, there were
125 toxigenic Corynebacterium isolates ; C. diphtheriae
(62), C. ulcerans (62) and C. pseudotuberculosis (1).
The data for C. diphtheriae and C. ulcerans, clinical
presentation and immunization status are summar-
ized in Table 2 (data for C. pseudotuberculosis are
described later). The analysis includes two cases of
toxigenic C. ulcerans which had not been routinely
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Table 2. Toxigenic C. diphtheriae and C. ulcerans isolates by clinical presentation and immunization status
Immunization
status at the time
of infection/clinical
presentation
C. diphtheriae C. ulcerans
Grand total
C. diphtheriae
and C. ulcerans
(%)
Fully
immunized
for age
Partially
immunized
Vaccination
history not
known or
not reported Unimmunized
Total
(%)
Fully
immunized
for age
Partially
immunized
Vaccination
history not
known or
not reported Unimmunized
Total
(%)
Classic respiratory
presentation with
adherent
pseudomembrane
observed in
tonsils, pharynx,
or larynx
1* 4* (includes
2 fatal cases)
5 (8%) 2 1 7 (includes
3 fatal
cases)
10 (16%) 15 (12%)
Respiratory
presentation with
exudate#
2 1 3 (5%) 3 1 4 (6%) 7 (6%)
Respiratory
presentation (sore
throat) with no
pseudomembrane
or exudate
5 4 4 1 14 (23%) 16 1 16 4 37 (60%) 51 (41%)
Respiratory and
cutaneous
lesions$
1 3 4 (6%) — 4 (3%)
Cutaneous lesions 4 4 2 5 15 (24%) 6 2 8 (13%) 23 (19%)
Other (bacterial
endocarditis)
1 1 (2%) — 1 (1%)
Asymptomatic· 8 11 1 20 (32%) 2 1 3 (5%) 23 (19%)
Total 18 11 18 15 62 21 3 24 14 62 124
* One patient from each of these groups also had cutaneous lesions but has been assigned to this group since this is the most serious presentation.
# Observation of tonsillar exudate, although not a solid membrane, could indicate the early stages of membrane formation.
$ Toxigenic organism isolated from both sites.
· May have been swabbed due to another illness or may be a contact (with no symptoms) of a conﬁrmed case.
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reported but were detected through the literature
search [7, 8].
Fifteen cases of classic respiratory diphtheria with
pseudomembrane were reported between 1986 and
2008, none of whom were fully vaccinated (Table 2).
The most frequent presentation among UK cases
is respiratory disease ; typically a sore throat in a
fully or partially immunized individual. Twenty-nine
patients presented with cutaneous lesions, six of
whom also had respiratory symptoms (including two
with a pseudomembrane). One patient with toxigenic
C. diphtheriae infection presented with bacterial
endocarditis. Vaccination history was frequently un-
available in the follow-up notes for C. ulcerans cases
(particularly earlier cases), and for asymptomatic
carriers of C. diphtheriae. However, based on all cases
with available data, the protective eﬀect of vacci-
nation could be demonstrated since none of the 39
fully vaccinated cases were recorded as presenting with
classic respiratory diphtheria with pseudomembrane,
whereas 14 of the 43 unvaccinated/incompletely
vaccinated cases presented with these symptoms
(P<0.001).
The following analysis excludes the asymptomatic
patients listed in Table 2, these patients are described
separately later. Between one and nine symptomatic
cases of diphtheria were recorded each year in the UK
between 1986 and 2008 (Fig. 2) ; an average of four
cases per year. The yearly incidence rates ranged from
0.0141 (in 1986) to 0.0017 (in 2004) cases per 100 000
population. In the last 10 years C. ulcerans, rather
than C. diphtheriae, has been the predominant cause
of diphtheria in the UK. Forty per cent of the
C. diphtheriae cases were reported from the London
region, whereas the C. ulcerans cases were distributed
more evenly across the country. The predominant
toxigenic C. diphtheriae biotype in the UK during
1986–2008 was var. mitis (81% of cases), followed by
var. gravis (17%) and var. intermedius (one case only).
The majority of C. ulcerans cases (76%) were
female whereas the sex distribution was even for
C. diphtheriae (Fig. 3). In addition C. ulcerans cases
were generally older than C. diphtheriae cases with
mean and median age for C. ulcerans cases of 38 years
compared to 15 years (mean) and 21.5 years (median)
for C. diphtheriae cases.
C. diphtheriae risk factors
The main risk factor for acquisition of toxigenic
C. diphtheriae was travel to the Indian sub-continent,
Africa or South East Asia (Table 3). Only eight cases
had no history of travel or contact with a traveller
recorded, three of which were laboratory-acquired
infections. All three cases of laboratory-acquired
diphtheria were due to toxigenic C. diphtheriae and
occurred in separate incidents. The ﬁrst in 1987 con-
cerned a senior registrar in medical microbiology who
had handled a non-toxigenic isolate of C. diphtheriae
and a toxigenic control strain. The patient was known
to have received childhood immunizations and pres-
ented with a severe sore throat with white exudate
on both tonsillar beds. The second case in 1997 con-
cerned an experienced medical laboratory scientiﬁc
oﬃcer (MLSO) who became infected with a toxigenic
strain of C. diphtheriae while handling a sample dis-
tributed by the National External Quality Assessment
Scheme for microbiology in a non-containment
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Fig. 2. Toxigenic cases of diphtheria and outcome in the UK, 1986–2008.
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facility [20]. The MLSO was known to have received
childhood immunizations and developed severe
tonsillitis. The third case in 2003 also occurred in a
laboratory worker handling liquid samples of a
toxigenic strain on an open bench in a microbiology
laboratory.
C. ulcerans risk factors
Only eight C. ulcerans cases had a history of travel
abroad within the 3 months prior to the onset of their
infection. Seven of 59 (12%) C. ulcerans cases were
recorded as having consumed raw milk or dairy pro-
ducts, one of these also had contact with cattle. One
further case, who had previous contact with a range of
animals, was also recorded as having had contact with
cattle. All 13 cases reported between 2003 and 2008
had made contact with domestic pets (cats and dogs)
[24–27]. In recent years domestic cats and dogs in
contact with ﬁve UK cases were swabbed but in only
one case was C. ulcerans isolated, that case was from
dogs that the patient had been in contact with; the
strain was identical to that found in the patient [28].
Case management
Six of 15 classic respiratory presentations with
pseudomembrane did not receive diphtheria antitoxin
(Table 4). Antitoxin was not administered to three of
these cases because the disease was not recognized
in time [7, 8, 23], for the other three an explanation
was not available. Most cases (77% of those with
treatment known) were prescribed appropriate anti-
biotics (erythromycin, azithromycin, clarithromycin,
or penicillin) although the precise timing of adminis-
tration was not available. In total, only 18/96 cases
that recovered (8%) are recorded as receiving diph-
theria vaccine during convalescence.
Deaths
There were ﬁve fatal cases (two C. diphtheriae, three
C. ulcerans) between 1986 and 2008, a case-fatality
rate in patients with respiratory symptoms of 6%.
The deaths all occurred in unvaccinated patients.
Clinical presentations and treatments are detailed in
Table 4; in each of the fatal cases the disease was not
immediately recognized as diphtheria and there were
consequent delays in administration of appropriate
treatment. The fatality rate in patients with classic
respiratory diphtheria (including all fatal cases) was
33%. The death of a school-aged child in 2008, due to
C. diphtheriae infection, was only diagnosed at post-
mortem [23]. The presentation was consistent with
laryngeal diphtheria, not recognized at the time of
treatment. The other C. diphtheriae fatality occurred
in 1994; a 14-year-old male patient, recently returned
from Pakistan, who presented with pharyngitis, a
unilateral pharyngeal swelling, bull neck and respir-
atory distress [14]. A pseudomembrane was visible
during attempts to drain what was initially considered
to be quinsy. In view of the patient’s respiratory
Incidence of UK C. diphtheriae cases by age and sex
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distress he was intubated and ventilated but subse-
quently developed complete heart block and renal
failure. Antitoxin and high-dose intravenous penicil-
lin were administered, but this was delayed due to late
diagnosis. The three deaths from C. ulcerans were all
in elderly (>70 years) females. The ﬁrst (in 1988)
presented with sore throat, painful cough and diﬃ-
culty breathing, and died the same day without re-
ceiving antitoxin [7]. She had stridor, and yellowish
mucus covering the fauces and palate. At autopsy the
entire respiratory tree from the upper part of the
larynx to the small bronchi was found to be covered
by a thick yellowish membrane. The second fatal case
(in 2000) was admitted to hospital with a pharyngeal
membrane and died of pneumonia 10 days after
admission (no antitoxin was administered) [29]. The
most recent fatality from C. ulcerans (in 2006) was
hospitalized with a 2-day history of malaise, sore
throat and a change in the sound of her voice. On the
day of admission she had diﬃculty breathing and said
that she felt her throat was closing. A preliminary
diagnosis of angio-oedema was made, related to her
recent treatment with an angiotensin-II receptor
antagonist, and the patient was treated accordingly.
However, her condition deteriorated and a diagnosis
of diphtheria was made when a greyish-white
membrane was observed across the pharynx during
a tracheostomy. She received diphtheria antitoxin
(4 days after onset of ﬁrst symptoms) and antibiotics
but died from her infection [27].
Transmission and carriage
Only one cluster of symptomatic cases, comprising
four unimmunized family members, was identiﬁed
during the study period. This cluster of cases caused
by C. diphtheriae var. mitis occurred in 1986, in a
family of recent immigrants from Bangladesh. The
14-month-old index case and 6-year-old sibling had
both classic respiratory and cutaneous diphtheria.
Another 3-year-old sibling had classic respiratory
diphtheria, and a 9-year-old sibling had respiratory
diphtheria. Their 47-year-old father was found to
be an asymptomatic carrier. Extensive investigation
of almost 250 contacts identiﬁed no further cases.
A total of 20 asymptomatic carriers of toxigenic
C. diphtheriae were recorded between 1986 and 2008;
eight were fully immunized, one was unimmunized,
and for the remaining 11 the immunization histories
were unknown. The carriers fell into three main
groups:
’ Contacts of an index case, thought to have ac-
quired infection through contact with an index case
in the UK (three index cases, eight carriers).
’ Fellow travellers of a case or carrier ; may have
acquired the infection abroad from the same source
as the index case or carrier, or through contact with
the index case (three index cases, four fellow
traveller carriers).
’ Patients that had recently returned from travel
abroad and were seeking medical attention for
an unrelated condition (n=7, four of whom were
siblings from the same family).
In addition, an asymptomatic carrier of toxigenic
C. diphtheriae was identiﬁed when screened as a
contact of a patient infected with a non-toxigenic
C. diphtheriae strain; contact-tracing would not
usually be carried out in response to non-toxigenic
infections.
Of the 16 unrelated cutaneous cases four (25%)
had infected contacts, while two (10%) of the 20 un-
related isolations of C. diphtheriae from the throat
had infected contacts (patients with both respiratory
and cutaneous diphtheria excluded), the diﬀerence in
these percentages was not signiﬁcant (P=0.37).
Two unrelated C. ulcerans cases each had an
infected asymptomatic contact. In 1996 toxigenic
C. ulcerans was isolated from a 20-year-old male who
Table 3. Origin of infection for toxigenic cases
C. diphtheriae 1986–2008 in the UK
Origin of infection No. of cases
History of travel 32
Bangladesh [9, 10] 10
South East Asia [11] (one also Nepal) 6
Africa [9, 12, 13] 6
Pakistan [9, 14, 15] 5
India [16] 3
Other [17–19] 2
Contact with traveller (Greece and Pakistan) 2
Laboratory acquired [20] 3
No history of travel* [21–23] 5
Total# 42
* One case report describes contact with a family member
who had travelled to Africa, returning approximately
1 month before the child became ill [23]. This contact was
swabbed and tested negative for C. diphtheriae, although
this does not exclude the possibility of earlier carriage of the
organism.
# This total excludes the 20 asymptomatic infections which
are described later.
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presented with a sore throat, and also from his
asymptomatic 18-year-old sibling. They both lived in
a rural area but had no contact with cattle or raw
dairy produce, no data regarding domestic pets were
recorded. In 1998 toxigenic C. ulcerans was isolated
from a 35-year-old male who presented with res-
piratory diphtheria with a pseudomembrane. The
organism was also isolated from his asymptomatic
11-year-old son. Five household dogs were swabbed
but C. ulcerans was not isolated. Details concerning
the third asymptomatic C. ulcerans case in Table 2 are
not available. The absence of any apparent source of
infection for the ﬁrst two incidents raised the possi-
bility of person-to-person transmission.
Management of contacts was generally undertaken
with advice from the Centre for Infections and, from
1999, with reference to UK published guidance [5]
and hence was consistent with respect to swabbing of
contacts, oﬀering diphtheria vaccine, and prescribing
prophylactic antibiotics (macrolides) where necessary.
C. pseudotuberculosis
In addition to the C. diphtheriae and C. ulcerans cases
described above, one case of toxigenic C. pseudo-
tuberculosis was reported in 2008. This was the only
reported isolation of toxigenic C. pseudotuberculosis
from a human in the UK during the study period. The
organism was isolated from the aortic root vegetation
of an injecting drug user with endocarditis. C. pseudo-
tuberculosis is typically associated with contact with
cattle, sheep and goats [30] ; however, this patient had
no history of animal contact and no possible source of
infection was identiﬁed.
DISCUSSION
Diphtheria vaccine is highly eﬀective, and good im-
munization coverage in the UK has resulted in very
few cases of diphtheria being reported over the last
23 years. Although infection has been reported in
vaccinated or partially vaccinated individuals, severe
or fatal cases have been limited to the unvaccinated,
and this analysis demonstrates the protective eﬀect of
vaccination. The main risk factor for C. diphtheriae
infection remains travel, or contact with someone
who has recently travelled, to an endemic area;
asymptomatic carriers of C. diphtheriae can pose a
threat to unimmunized individuals [31]. Individuals
intending to travel abroad (particularly to the Indian
sub-continent, South East Asia or Africa) should
ensure they have received all childhood immuniza-
tions as well as booster vaccinations appropriate for
their destination [1, 32]. These data also highlight the
importance of ensuring those with potential occu-
pational exposure to toxigenic organisms follow UK
recommendations and are fully protected by vacci-
nation [1], and strongly emphasize the importance of
Table 4. Treatment prescribed to toxigenic C. diphtheriae and C. ulcerans cases by presentation (fatal cases
indicated in parentheses)
Presentation
Antitoxin
administered
Appropriate
antibiotic
Late-appropriate
antibiotic
Not
known
Inappropriate/
not prescribed Total
Classic respiratory
(with pseudomembrane)
Yes 4 4 (2) 1 9
No 2 1 (1) 3 (2) 6
Respiratory with exudate Yes 2 1 3
No 4 4
Respiratory (sore throat) with no
pseudomembrane or exudate
Yes 2 1 3
No 29 1 16 2 48
Respiratory and cutaneous lesions Yes 2 2
No 1 1 2
Cutaneous lesions Yes 1 1
No 9 4 7 2 22
Bacterial endocarditis Yes 0
No 1 1
Asymptomatic Yes 1 1
No 22 22
Total Yes 11 5 (2) 3 0 19
No 46 6 46 (1) 7 (2) 105
Total 57 11 49 7 124
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microbiology laboratory workers undertaking proce-
dures in containment facilities [33].
The epidemiology of diphtheria in the UK appears
to be changing with the majority of toxigenic isolates
in recent years associated more often with C. ulcerans
than C. diphtheriae. Travel does not appear to be a
major risk factor for C. ulcerans.
C. ulcerans is a veterinary pathogen and infection in
humans was traditionally associated with the con-
sumption of raw milk or dairy products (cow and
goat) [34–36]. The last outbreak of milk-borne diph-
theria reported in the UK was in 1943 (prior to
the introduction of the national immunization pro-
gramme) [34]. However, many cases reported in this
paper had no association with raw milk products
or farming communities suggesting another source.
Although there is no direct evidence of person-
to-person transmission for C. ulcerans, this route of
transmission was considered following events in the
USA and UK in the mid 1990s. In 1997 the US Center
for Disease Control and Prevention reported a
case of membranous pharyngitis caused by toxigenic
C. ulcerans in which it recommended people exposed
to the index case should be treated along similar lines
to cases exposed to toxigenic C. diphtheriae, because it
was considered there was inadequate information
about human-to-human transmission [37]. The 1999
UK guidelines for the control of diphtheria were
also changed to include the recommendation that
anyone who has been in close contact with a case
of diphtheria caused by toxigenic C. diphtheriae or
C. ulcerans (whatever the clinical presentation) in the
previous 7 days should be considered as potentially at
risk [5]. This was based on the US recommendation
and the report of two asymptomatic C. ulcerans con-
tacts in the UK in 1996 and 1998. However, domestic
cats and dogs have recently been proposed as poten-
tial sources of human infection [38, 39]. Identical
strains were reported from a UK patient and dogs
that the patient had been in contact with [28] ; further
studies in this area would be of beneﬁt in order to
elucidate the transmission route. The reason for the
bias in C. ulcerans cases towards females is unclear
although it may be related to the greater tendency for
females to consult a general practitioner [40], or could
be related to pet ownership habits if domestic animals
are indeed a reservoir of C. ulcerans. However, it is
thought that about half of households in the UK own
pets [41]. It is important to note that these analyses
are based on small numbers of cases so this discussion
is only speculative.
Maintaining high immunization coverage across
the UK is essential given the occurrence of sporadic,
and apparently indigenous, C. ulcerans cases ; clin-
icians could use routine consultations as opportu-
nities to check the immunization status of elderly
patients who may not have received diphtheria im-
munizations during childhood, and of adult patients
born before 1980 who would not have been oﬀered a
routine booster dose of diphtheria at school-leaving
age (introduced in 1995).
Despite being clinically indicated, several of the
cases reported in this paper did not receive antitoxin
treatment. In some this was due to the delay in diag-
nosis ; antitoxin has been shown to be ineﬀective if
administered after the second day of diphtheritic
symptoms [42]. In the UK, antitoxin can only be ob-
tained from one of nine issuing centres, coordinated
by the HPA, CfI [1]. Antitoxin is given on clinical
diagnosis but, as it is an animal blood product, treat-
ment can have severe side-eﬀects so the beneﬁts and
risks need careful consideration. Most patients were
prescribed appropriate antibiotics although the in-
formation available was not always detailed so only
limited conclusions can be drawn. The low percentage
of patients recorded as receiving a diphtheria vaccine
booster during convalescence may be due to this
section of the follow-up questionnaire being under-
completed if vaccine is generally given after the ques-
tionnaire has been returned, or it might highlight a
gap in convalescent care.
Cutaneous infection has previously been reported
to be more contagious than respiratory diphtheria
[43–45] ; although the data reported in this paper
appear to support this, the numbers are too small to
adequately test this hypothesis. As well as infection of
contacts of cutaneous diphtheria cases, toxigenic or-
ganisms were isolated from the throats of six patients
with cutaneous infection, suggesting autoinfection.
The presentation of bacterial endocarditis due
to toxigenic C. diphtheriae is unusual, and is more
commonly reported as due to non-toxigenic [46–48]
rather than toxigenic strains [49, 50]. As the fatal
cases demonstrated, even severe diphtheria can be
unrecognized, or the diagnosis delayed, as most
clinicians are unfamiliar with the disease. Case ascer-
tainment may be particularly high in the UK due to
the expertise and interest of the London-based WHO
Collaborating Centre for Diphtheria & Streptococcal
Infections. In addition, some UK laboratories rou-
tinely screen all throat swabs for corynebacteria, and
hence detect mild and atypical infections.
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In the UK, although diphtheria is a statutory
notiﬁable disease, where reporting is supposed to be
on clinical suspicion, the majority of notiﬁcations
relate to non-toxigenic strains [51]. The Centre for
Infections can oﬀer advice regarding case manage-
ment and the reference laboratory provides full
species conﬁrmation and toxigenicity testing (full de-
tails are provided on the HPA website [52]). The toxin
test is the most important component of micro-
biological diagnosis and it is of concern that in one
paper reporting a fatal C. ulcerans case the toxin re-
sult was not described and it was not reported to the
HPA (although the strain was assumed to be toxigenic
because of the pathology described) [7]. For those
cases reported to the HPA CfI, the quality of follow-
up data was variable and comprised a combination
of notes, microbiology reports, and fully/partially
completed follow-up forms. Data for recent years was
generally more complete due to the use of a standar-
dized follow-up form. It is important to continue to
improve the quality and completeness of the surveil-
lance data, particularly for a rare disease such as
diphtheria where analyses are based on small numbers
of cases. We also recommend the use of literature-
searching for unreported cases as good practice in
investigations for other rare diseases which may not
always be routinely reported. Vaccination histories,
particularly for immigrants and elderly patients are
often diﬃcult to obtain and hence were sometimes
based on assumptions relating to the country of origin
and the age of the patient. Despite these limitations
the data available has allowed analysis of recent
trends and presentations which should be of interest
to vaccine policy makers, public health specialists and
clinicians encountering a case in the future.
APPENDIX
EU Case Deﬁnition for National Diphtheria
Surveillance
Community Decision of 19 March 2002 (under 2119/
98/EC).
Modiﬁed version (by A. Efstratiou, N. Crowcroft,
J. White, on behalf of DIPNET, November 2002).
Clinical description
Clinical picture compatible with diphtheria, i.e. an
upper respiratory tract illness characterized by sore
throat, low grade fever, and an adherent membrane
of the tonsils, pharynx or nose or non-respiratory
diphtheria ; cutaneous, conjunctival, otic and genital
lesions.
Laboratory criteria for diagnosis
Isolation of diphtheria toxin-producing coryne-
bacteria from a clinical specimen.
Case classiﬁcation
Possible : Not applicable.
Probable case : A clinically compatible case that is
not laboratory conﬁrmed and does not have an
epidemiological link to a laboratory-conﬁrmed case.
Conﬁrmed case : A clinically compatible case that is
laboratory conﬁrmed with the isolation of a toxigenic
strain of C. diphtheriae, C. ulcerans, or C. pseudo-
tuberculosis or has an epidemiological link to a
laboratory-conﬁrmed case.
Conﬁrmed case (other) : Non-respiratory/cutaneous
diphtheria cases with isolation of toxigenic strains, or
cases not meeting the speciﬁed clinical criteria but
with isolation of toxigenic strains (e.g. mild respirat-
ory diphtheria, or respiratory diphtheria with absence
of membrane).
Asymptomatic carriers : Asymptomatic carriers (any
anatomical site) with toxigenic strains.
Cases with non-toxigenic C. diphtheriae, C. ulcerans
or C. pseudotuberculosis should not be reported.
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Diphtheria incidence has decreased in Europe since 
its resurgence in the 1990s, but circulation continues in 
some countries in eastern Europe, and sporadic cases 
have been reported elsewhere. Surveillance data from 
Diphtheria Surveillance Network countries and the World 
Health Organization European Region for 2000–2009 were 
analyzed. Latvia reported the highest annual incidence in 
Europe each year, but the Russian Federation and Ukraine 
accounted for 83% of all cases. Over the past 10 years, 
diphtheria incidence has decreased by >95% across the 
region. Although most deaths occurred in disease-endemic 
countries, case-fatality rates were highest in countries to 
which diphtheria is not endemic, where unfamiliarity can lead 
to delays in diagnosis and treatment. In western Europe, 
toxigenic Corynebacterium ulcerans has increasingly been 
identifi ed as the etiologic agent. Reduction in diphtheria 
incidence over the past 10 years is encouraging, but 
maintaining high vaccination coverage is essential to 
prevent indigenous C. ulcerans infections and reemergence 
of C. diphtheriae.
In 1994, following success of widespread vaccination programs earlier in the century, diphtheria was 
proposed as a candidate for elimination in the World 
Health Organization (WHO) European Region; the goal 
was for elimination of indigenous diphtheria by 2000 (1). 
However, during the 1990s, when this goal seemed within 
sight, several factors caused a resurgence of diphtheria to 
epidemic proportions in the newly independent states of 
the former Soviet Union. There were a large number of 
unnecessary contraindications to vaccination in guidance 
for these countries at that time, which led to reductions in 
adequate vaccination coverage in children. This problem 
was exacerbated by mistrust in vaccinations among health 
professionals and the public and by use of low-dose 
formulation vaccine for primary vaccinations. Waning 
immunity in the adult population, large-scale population 
movements caused by breakup of the former Soviet Union, 
disruptions in health services, and lack of adequate supplies 
of vaccine and antitoxin for prevention and treatment in 
most affected countries provided conditions under which 
diphtheria could spread (2,3). At the peak of the epidemic 
in 1995, there were >50,000 cases reported in the WHO 
European Region (2). Intensive vaccination strategies 
brought the disease under control in most countries, but 
some endemic transmission still continues.
Clinical diphtheria is caused by toxin-producing 
corynebacteria. Three species (Corynebacterium 
diphtheriae, C. ulcerans, and C. pseudotuberculosis) 
can potentially produce diphtheria toxin. C. diphtheriae 
is the most common of potentially toxigenic species and 
is associated with epidemic diphtheria and person-to-
person spread. The organism has 4 biovars (gravis, mitis, 
intermedius, and belfanti). C. ulcerans is historically 
associated with cattle or raw dairy products, and, although 
it is rarely reported, its incidence has increased slightly in 
some countries in western Europe and in the United States 
in recent years (4–6). C. pseudotuberculosis rarely infects 
humans and is typically associated with farm animals (7). 
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Currently, no direct evidence has been found of person-to-
person spread of C. ulcerans or C. pseudotuberculosis.
Classical respiratory diphtheria is characterized by 
formation of a gray-white pseudomembrane in the throat 
that is fi rmly adherent (8). A swollen, bull-neck appearance 
caused by infl ammation and edema of soft tissues 
surrounding lymph nodes is associated with severe illness 
and higher death rates (8). In progressive disease, the toxin 
can bind to cardiac and nerve receptors and cause systemic 
complications. Milder respiratory disease may manifest as 
a sore throat, most commonly seen in patients who are fully 
or partially vaccinated. In some tropical areas, cutaneous 
symptoms, characterized by rolled-edge ulcers, are more 
common. Patients may have both cutaneous and respiratory 
disease. The purpose of this study was to analyze diphtheria 
data for Europe during 2000–2009.
Methods
Case-based diphtheria surveillance data from each of 
25 Diphtheria Surveillance Network (DIPNET) member 
countries (Austria, Belgium, Bulgaria, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Ireland, Italy, Latvia, Lithuania, the Netherlands, 
Norway, Poland, Portugal, Romania, Slovenia, Spain, 
Sweden, Turkey, and the United Kingdom) for 2000–2007 
were submitted retrospectively to the coordinating center 
in the United Kingdom during 2008. Data for 2008 and 
2009 were obtained in August 2009 and September 2010 
from the DIPNET online database, which was launched in 
September 2007.
We analyzed cases meeting the DIPNET case defi nition 
(isolation of a toxigenic strain or clinically compatible 
case with an epidemiologic link to a laboratory-confi rmed 
case) (online Technical Appendix 2, wwwnc.cdc.gov/
EID/pdfs/11-0987-Techapp2.pdf). In addition, 48 cases 
without laboratory confi rmation and pseudomembrane 
(mild diphtheria/severe pharyngitis) and 5 cases with 
unknown manifestations were included for Latvia because 
these cases had been recorded in the national dataset. For 
most cases, toxigenicity was confi rmed by using the Elek 
phenotypic test (9). However, in some cases, toxigenicity 
was evaluated only by detection of the toxin gene with PCR. 
We assumed that all cases in this dataset were toxigenic 
(toxin producing) because the number of cases without Elek 
confi rmation was small and referred to symptomatic cases. 
Data fi elds collected included year; organism; biovar; and 
patient age, sex, clinical manifestations, vaccination status, 
veterinary contact, risk group, and outcome. Further strain 
characterization (ribotyping) was available for a limited 
number of isolates as part of a screening study in 10 
DIPNET countries (10).
Cases were assigned to 5 clinical manifestation groups. 
These groups were classic respiratory diphtheria with 
pseudomembrane (the most serious form of the disease); 
mild diphtheria/severe pharyngitis (respiratory symptoms 
without the pseudomembrane); cutaneous (toxigenic 
organism isolated from skin lesions); other (e.g., toxigenic 
organism isolated from blood); and asymptomatic (carriers 
of toxigenic organisms, usually contacts of a confi rmed 
case-patient).
Additional information concerning countries in the 
WHO European Region that are not DIPNET member 
countries was provided by the WHO Regional Offi ce for 
Europe. Twenty-fi ve of 53 member states of the WHO 
European Region are members of DIPNET. WHO European 
Region countries (including DIPNET members) report total 
cases annually to the WHO Regional Offi ce for Europe 
through the WHO/United Nations Children’s Fund Joint 
Reporting Form, which is the global annual data survey of 
WHO member states for vaccine-preventable diseases and 
immunization program indicators. In addition, 16 countries 
in 2003 (Figure 1) were asked to prospectively participate in 
monthly surveillance and provide more detailed information 
(e.g., pathogen biovar; patient age, sex, and outcome; 
and carriers among contacts). Twelve countries currently 
provide monthly reports to WHO Regional Offi ce for 
Europe through this system. The only major source of cases 
that has not participated in the monthly reporting system (but 
218 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 2, February 2012
Figure 1. Diphtheria Surveillance Network (DIPNET) and World 
Health Organization (WHO) European Region countries. 1, Albania; 
2, Andorra; 3, Armenia; 4, Austria; 5, Azerbaijan; 6, Belarus; 7, 
Belgium; 8, Bosnia and Herzegovina; 9, Bulgaria; 10, Croatia; 11, 
Cyprus; 12, Czech Republic; 13, Denmark; 14, Estonia; 15, Finland; 
16, France; 17, Georgia; 18, Germany; 19, Greece; 20, Hungary; 21, 
Iceland; 22, Ireland; 23, Israel (neighboring countries not shown); 
24, Italy, 25; Kazakhstan; 26, Kyrgyzstan; 27, Latvia; 28, Lithuania; 
29, Luxembourg; 30, Malta; 31, Monaco; 32, Montenegro; 33, the 
Netherlands; 34, Norway; 35, Poland; 36, Portugal; 37, Republic of 
Moldova; 38, Romania; 39, Russian Federation; 40, San Marino; 
41, Serbia; 42, Slovakia; 43, Slovenia; 44, Spain; 45, Sweden; 
46, Switzerland; 47, Tajikistan; 48, Former Yugoslav Republic of 
Macedonia; 49, Turkey; 50, Turkmenistan; 51, Ukraine; 52, United 
Kingdom (Great Britain and Northern Ireland); 53, Uzbekistan. 
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does report annually) is the Russian Federation. Rates per 
1 million person-years were calculated by using population 
estimates derived from the Population Division of Economic 
and Social Affairs of the United Nations Secretariat (11).
Statistical Analyses
Proportions were compared by using χ2 or Fisher exact 
tests, as appropriate, in Stata statistical software version 7.0 
(StataCorp LP, College Station, TX, USA). For assessment 
of a trend for variables in ordered groups (vaccinated, 
partially vaccinated, unvaccinated) and severity of disease 
(classic respiratory, mild diphtheria/severe pharyngitis, 
asymptomatic), the Wilcoxon test for trend in Stata (12) 
was used. This test enabled nonparametric analysis across 
these groups.
Results
Overall, across the WHO European Region, the number 
of cases of diphtheria has substantially decreased since 
the epidemic in the 1990s (Figure 2). Data on clinically 
confi rmed cases and toxigenic isolates of C. diphtheriae 
and C. ulcerans reported to DIPNET during 2000–2009 are 
shown in Tables 1 and 2, respectively. Member countries 
that are not listed reported no isolates. Data are analyzed 
separately for Latvia, where diphtheria is endemic.
Diphtheria-Endemic Countries in 
WHO European Region
During 2000–2009, Latvia reported the highest annual 
incidence rate of diphtheria in the European Region each 
year and a 10-year incidence rate of 23.8 cases/1 million 
person-years. This rate was ≈7× higher than in countries 
with the next highest 10-year incidence: i.e., Georgia (3.5), 
Ukraine (3.3), and the Russian Federation (3.0). However, 
during this time, 4,304 (>61%) of 7,032 cases in the 
WHO European Region were reported from the Russian 
Federation, and 2 countries, the Russian Federation and 
Ukraine, accounted for 83% of all cases.
Over the past 10 years, diphtheria incidence decreased 
by >95% across the region (from 1.82/1 million population 
in 2000 to 0.07/million in 2009), including in Latvia (from 
111.22/million in 2000 to 2.67/million in 2009). In 2009, 
Latvia was the only country in the region that had not yet 
achieved the elimination benchmark of an incidence <1 
case/million population (Figure 2).
Most cases reported to WHO through the monthly 
surveillance system were in teenagers and adults. However, 
the major risk groups for death have been infants (too 
young for complete primary vaccination) and adults >40 
years of age (unvaccinated or with waning immunity). 
Although risk did not differ by sex in cases in children, 
during 2002–2009, ≈2× as many cases were reported in 
women >20 years of age than in men (510 [64%] vs. 292 
[36%], respectively). Most (75%) case-patients reported 
in the European Region were at least partially vaccinated, 
but most (74%) case-patients and (93%) infants who died 
were unvaccinated). C. diphtheriae biovar gravis was the 
predominant strain (60%–80%). Of isolates from Latvia 
(Table 1), 355 (99%) of 358 with a known biovar were 
gravis and 3 (1%) were mitis.
Clinical manifestations and vaccination status for 
cases from Latvia (all C. diphtheriae) reported to DIPNET 
are shown in Table 3. Most (340/341) case-patients with 
symptoms had respiratory manifestations, and 141 (41%) 
of 340 respiratory case-patients had classic diphtheria 
symptoms. Vaccination showed a signifi cant protective 
effect with respect to severity of infection (p<0.001 by test 
for trend).
For symptomatic cases for 2002–2009 (excluding the 
military outbreak in 2000 and cases from 2001 for which 
limited information was available) the highest overall 
incidences were in children 0–4 and 5–15 years of age 
and adults 45–64 years of age; lower incidence rates were 
observed in other age groups (Figure 3). Most (123/196, 
63%) symptomatic cases during those years were in female 
patients.
The second most common risk factor (after military 
service) identifi ed among symptomatic case-patients in 
Latvia was unemployment (60 case-patients). Information 
was not available regarding connections of case-patients to 
other countries of the former Soviet Union.
Non–Disease-Endemic Countries (DIPNET)
Clinical manifestations and immunization status for 
case-patients with toxigenic C. diphtheriae and C. ulcerans 
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F igure 2. Diphtheria cases per 1 million population in the World 
Health Organization (WHO) European Region and number of 
countries with a rate >1 cases/1 million population, 2000–2009.
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isolates and epidemiologically linked cases reported by 
24 DIPNET member countries, excluding Latvia, during 
2000–2009 are shown in Table 4. Vaccination had a 
signifi cant protective effect with respect to severity of 
infection (p = 0.001 by test for trend).
C. diphtheriae Isolates
Isolates of C. diphtheriae were sporadically reported 
in the 24 DIPNET member countries, excluding Latvia. 
Each year, 0–6 symptomatic cases of toxigenic C. 
diphtheriae infection were reported by each country (53 
cases during 2000–2009). For each case-patient, 0–4 
asymptomatic contacts were reported (14 in the 10-year 
period). Of 60 isolates with a biovar recorded during 
2000–2009, a total of 32 were gravis and 28 were mitis. 
Seventeen cutaneous cases, 35 respiratory (24 classic 
respiratory) cases, and 1 case with other manifestations 
were reported. Most (15/17, 88%) cutaneous cases were 
caused by biovar mitis, and most (17/28, 61%) respiratory 
cases with a known biovar were caused by biovar gravis. 
Sixteen of 17 patients with cutaneous disease had recently 
returned from traveling, had contact with travelers, or were 
recent immigrants from a disease-endemic area, as was 
the situation for 12 of 35 patients with respiratory disease. 
One case-patient with bacterial endocarditis had contact 
with a relative who had recently traveled to Pakistan. For 
case-patients with C. diphtheriae symptomatic infection, 
sex distribution was even. A higher incidence rate was 
observed in male patients 0–4 years of age (Figure 3), but 
this fi nding was infl uenced by 6 cases reported in Turkey 
during 2001–2003.
C. ulcerans Isolates
A total of 4–8 isolations of toxigenic C. ulcerans were 
reported by DIPNET member countries each year (53 [50 
symptomatic] during 2000–2009). Of these cases, 51% 
were reported by the United Kingdom, 19% by Germany, 
and 17% by France. Of the symptomatic cases for which 
patient sex/age group were known, 38 (78%) of 49 were 
in female patients and 29 (59%) of 49 were in patients >45 
years of age. Incidence rate was higher in female patients 
than in than male patients (0.014/1 million person-years vs. 
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Table 1. Toxigenic Cornyebacterium diphtheriae isolates and epidemiologically linked cases and deaths reported by DIPNET member 
countries, Europe, 2000–2009* 
Characteristic
Patient
description†
No. toxigenic isolates or clinical cases with epidemiologic link (no. deaths) 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Country            
 Estonia Symptomatic 2 2 0 0 0 0 0 0 0 0 
Asymptomatic 1 7 0 0 0 0 0 0 0 0 
Total 3 9 0 0 0 0 0 0 0 0 
 Finland Total 0 2 (1) 0 0 0 0 0 0 0 0 
 France Total 0 0 1 0 1 0 1 1 (1) 1 0 
 Germany Total 1 2 4 0 0 1 0 0 0 2 
 Latvia Symptomatic 145 0 45 26 20 20 32 18 29 6 
Asymptomatic 61 24 15 22 2 2 11 5 12 3 
Not known 119 91 0 0 0 0 0 0 0 0 
Total 325 (9) 115 (5) 60 (3) 48 (2) 22 (1) 22 (2) 43 (6) 23 (1) 41 (2) 9 (1) 
 Lithuania Symptomatic 2 0 4 0 0 0 0 0 2 0 
Asymptomatic 0 0 1 0 0 0 0 0 2 0 
Total 2 0 5 (1) 0 0 0 0 0 4 (1) 0 
 Norway Symptomatic 0 0 0 0 0 0 0 0 3 0 
Asymptomatic 0 0 0 0 0 0 0 0 1 0 
Total 0 0 0 0 0 0 0 0 4 0 
 Sweden Total 0 0 0 0 0 0 0 0 0 1 
 Turkey Symptomatic 1 3 1 0 0 0 0 0 0 0 
Asymptomatic 2 0 0 0 0 0 0 0 0 0 
Not known 1 4 1 1 0 0 0 0 0 0 
Total 4 (1) 7 (3) 2 (1) 1 0 0 0 0 0 0 
 United Kingdom Total 1 0 6 3 0 0 1 0 2 (1) 2 
Total known symptomatic 
patients
NA 152 9 61 29 21 21 34 19 37 11 
Total (all countries) NA 336 (10) 135 (9) 78 (5) 52 (2) 23 (1) 23 (2) 45 (6) 24 (2) 52 (4) 14 (1) 
Total known symptomatic 
patients, excluding Latvia 
NA 7 9 16 3 1 1 2 1 8 5 
Total, excluding Latvia NA 11 (1) 20 (4) 18 (2) 4 1 1 2 1 (1) 11 (2) 5 
*DIPNET, Diphtheria Surveillance Network; NA, not applicable. A total of 89 cases were clinically diagnosed without microbiological confirmation (76 in 
Latvia, 11 in Turkey, and 2 in Lithuania). 
†If only total is displayed for a country, all patients were symptomatic. 
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0.004/1 million person-years). Eleven cutaneous cases, 38 
respiratory (14 classic respiratory) cases, and 1 case with 
other manifestations were reported. Ninety-four percent 
of case-patients for which information was available had 
contact with domestic animals. Traditional risk factors such 
as consumption of raw milk products were not reported, 
and no patients had a recent history of travel. One of the 
2 case-patients infected with C. ulcerans who died in the 
United Kingdom had an identical strain of C. ulcerans to 
that isolated from a dog with which the patient had been 
in contact (14). A similar fi nding was observed in France 
for a nontoxigenic case reported in 2003 (5,15). In 2007, 
identical strains were isolated from a patient infected with 
C. ulcerans and her pig in Germany (16).
C. pseudotuberculosis Isolates
Four case-patients with diphtheria caused by toxigenic 
C. pseudotuberculosis were reported: 1 in France in 2005 
and 1 in 2008, 1 in Germany in 2004, and 1 in United 
Kingdom in 2008. Three of these patients had cutaneous 
manifestations (1 was unvaccinated, 2 had an unknown 
vaccination status) and 1 (partially vaccinated) had bacterial 
endocarditis. To our knowledge, none of these infected 
patients died. Animal contact (with a calf) was recorded for 
only 1 patient (1 had no history of animal contact and 2 had 
an unknown history of animal contact).
Deaths Caused by Diphtheria
During 2000–2009, a total of 32 deaths caused by 
diphtheria were reported in Latvia, and 13 deaths (10 
caused by C. diphtheriae and 3 caused by C. ulcerans) 
(Tables 1, 2) were reported by the remaining 24 DIPNET 
countries. Overall, patients with respiratory disease and a 
pseudomembrane had a signifi cantly higher case-fatality 
rate (CFR) than patients with respiratory disease without 
a pseudomembrane (14.6% vs. 1.3%; p<0.001). For case-
patients in Latvia, the CFR was 5% for patients with any 
respiratory symptom (including classic manifestations) and 
12% for patients with classic respiratory symptoms. Of 18 
case-patients in Latvia who died, 14 were >40 years of age 
and 4 were <7 years of age; all were unvaccinated.
Nine of 13 patients who died of diphtheria in DIPNET 
countries excluding Latvia had classic respiratory diphtheria 
symptoms, and 2 had severe pharyngitis (2 had unknown 
manifestations). All 3 deaths caused by C. ulcerans (2 in 
the United Kingdom and 1 in Germany) were in elderly 
(>75 years of age) patients (unvaccinated or vaccination 
status unknown). Two of the patients infected with C. 
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Table 2. Isolates of toxigenic Corynebacterium ulcerans and patient deaths reported by DIPNET member countries, Europe, 2000–
2009*
Characteristic
Patient
description†
No. toxigenic isolates (no. deaths) 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Country            
 France Total 0 1 0 1 3 0 2 1 0 1 
 Germany Total 1 1 (1) 0 0 1 2 1 2 0 2 
 Italy Total 0 0 1 0 0 0 0 0 0 0 
 The Netherlands Total 0 1 0 0 0 0 0 1 0 0 
 Romania Asymptomatic 0 0 1 0 0 0 0 0 0 0 
Total 0 0 1 0 0 0 0 0 0 0 
 Sweden Symptomatic 0 0 0 0 0 0 0 0 1 0 
Not known 0 0 0 0 1 0 1 0 0 0 
Total 0 0 0 0 1 0 1 0 1 0 
 United Kingdom Total 7 (1) 3 2 2 1 2 2 (1) 3 3 2 
No. symptomatic patients NA 8 6 3 3 5 4 5 7 4 5 
No. isolates NA 8 (1) 6 (1) 4 3 6 4 6 (1) 7 4 5 
*DIPNET, Diphtheria Surveillance Network; NA, not applicable 
†If only total is shown for a country, all patients were symptomatic. 
Table 3. Vaccination status of case-patients and clinical manifestations of toxigenic Corynebacterium diphtheriae infections and 
epidemiologically linked cases without laboratory confirmation, Latvia, Europe, 2000–2009* 
Vaccination status 
Classic diphtheria 
(with membrane) 
Mild diphtheria/ 
severe pharyngitis Cutaneous Asymptomatic Not known Total 
Full 64† 118 0 71 0 253 
Partial 1 3 0 5 0 9 
Unvaccinated 74 70 1 18 0 163 
Not known 2 8 0 63 210 283 
Total 141 199 1 157 210 708 
*p<0.001 by test for trend (vaccination status and disease severity). 
†Includes 52 fully vaccinated case-patients with classic respiratory diphtheria (with membrane) from an outbreak in the military in 2000. The outbreak 
comprised 145 symptomatic case-patients and 25 asymptomatic contacts. A total of 96% of these case-patients and contacts were 18–23 years of age at 
the time of diagnosis. Spread of disease was traced to use of a communal drinking cup (13).
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diphtheriae who died were unvaccinated infants (1 from 
Mayotte and 1 from Finland). The infant in Finland died at 
3 months of age in 2001 after recent contact with visitors 
from Russia (17). Six other children died: an unvaccinated 
school age child in the United Kingdom (18) and 5 children 
<7 years of age in Turkey (vaccination status unknown). 
Two adults in Lithuania (ages 45–64 years; vaccination 
status unknown) also died. The CFR for patients with any 
respiratory symptoms reported for patients infected with 
toxigenic C. diphtheriae or C. ulcerans in regions where 
diphtheria was not endemic was 15%; CFR was 24% 
among patients with classic respiratory diphtheria.
The difference between CFRs for respiratory diphtheria 
cases in Latvia and member countries excluding Latvia (5% 
and 15%, respectively) was signifi cant (p = 0.002). The 
difference between CFRs for classic respiratory diphtheria 
in Latvia and the member countries excluding Latvia (12% 
and 24%, respectively) showed borderline signifi cance (p 
= 0.06).
Any case-patients without symptoms recorded who 
died likely had respiratory diphtheria. However, because 
symptoms were also not available for several surviving 
case-patients for whom clinical manifestations were less 
certain, all case-patients for whom clinical manifestations 
were unavailable were excluded from analysis.
Discussion
Substantial progress has been made in controlling 
diphtheria across Europe since the epidemic in the 1990s, 
but diphtheria has not disappeared as a serious public 
health threat. After major disruption to a mass vaccination 
program, recovery time is lengthy, and pockets of 
unvaccinated persons can remain because recovery is not 
necessarily homogeneous.
The protective effect of vaccination in preventing 
progression to severe disease is clear. However, 64 patients 
in Latvia recorded as fully vaccinated had classic respiratory 
diphtheria symptoms. Most of these patients were infected 
during a military outbreak in 2000 and would have been 
scheduled for primary vaccinations during the 1980s, when 
changes in vaccines, vaccination policy, medical practice, 
and public acceptance led to less intensive vaccination of 
children in the former Soviet Union. Beginning in 1980, 
Soviet vaccination recommendations enabled use of an 
alternative primary vaccination schedule against diphtheria 
that recommended 3 doses of a lower-potency vaccine (19). 
The classifi cation of fully/partially vaccinated relies on 
specifi c interpretation of a country. Since the 2000 outbreak, 
greater attention has been given to checking vaccination 
records of new recruits into the Latvian military, and 
booster vaccinations are given where appropriate.
Lower CFRs for respiratory diphtheria in disease-
endemic areas compared with those in nonendemic areas 
highlight how lack of familiarity with a rare disease 
can affect diagnosis and treatment. As the incidence 
of diphtheria has decreased, so has the practice of 
routine laboratory screening (20). No DIPNET member 
country routinely screens all throat swab specimens for 
corynebacteria, although sentinel screening of all throat 
swab specimens is conducted in Denmark, Ireland, and 
the United Kingdom. All other DIPNET countries (and 
outside sentinel screening areas) perform screening 
only at the request of the clinician or if the laboratory 
identifi es particular criteria for screening from information 
accompanying a swab specimen (DIPNET, unpub. data). 
This practice has resulted in a loss of laboratory expertise 
and the opportunity for infections to go undetected because 
only clinically indicated swab specimens are tested; thus, 
milder cases or those with unusual manifestations may be 
missed.
A recent DIPNET external quality assurance 
evaluation of 6 simulated throat specimens found that only 
6 of 34 international centers produced acceptable results 
for all 6 specimens; many centers could not isolate the 
target organism (21). In some poor countries, screening 
can be limited by cost of laboratory reagents, and problems 
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Figure 3. Diphtheria incidence per 1 million person-years for Latvia 
(Corynebacterium diphtheriae, 2002–2009) and the remaining 
24 Diphtheria Surveillance Network (DIPNET) countries (C. 
diphtheriae and C. ulcerans, 2000–2009). Error bars indicate 95% 
CIs. The period 2002–2009 excludes the military outbreak in 2000 
and cases from 2001 for which limited information was available.
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have also occurred in obtaining Elek reagents and media 
(21). During a recent screening study across 10 countries 
in Europe, toxigenic organisms were isolated in Latvia 
and Lithuania (10). At least one of these cases in Lithuania 
would not have been correctly diagnosed in the absence 
of the screening study. In addition to the potential for 
missed or late diagnoses, in areas where diphtheria is 
not endemic, diphtheria antitoxin treatment is not always 
available, which can have serious consequences. A recent 
international survey highlighted global shortages of 
diphtheria antitoxin (22). Information about administration 
and timing of antitoxin treatment was not collected for this 
analysis, but studying such timing in relation to differing 
CFRs would be useful.
Higher incidence rates of C. diphtheriae among women 
in disease-endemic countries could be caused by several 
factors. Women more commonly work as caregivers in 
domestic and health care settings, consultation rates are 
usually higher among women, and men are more likely to 
have received diphtheria vaccine during military service.
Although the United Kingdom, France, and Germany 
regularly report isolations of toxigenic C. ulcerans, it 
is unlikely that this organism is present only in these 
countries. The ability to detect C. ulcerans could indicate 
the capability of a country to detect potentially toxigenic 
organisms and provide an indicator of good surveillance. 
Detection of mild diphtheria cases (any toxigenic organism) 
is another potential indicator of good surveillance. C. 
ulcerans appears to have a wide host range and has been 
isolated from many domestic and wild animals, including 
the killer whale and lion (nontoxigenic strain) (23). During 
2002 and 2003, toxigenic C. ulcerans strains isolated from 
domestic cats in the United Kingdom were found to have 
the predominant ribotypes observed among human clinical 
isolates, which suggests that cats could be a potential 
reservoir for human infection (24). Identical C. ulcerans 
strains have been isolated from diphtheria patients and 
dogs in France and the United Kingdom (14,15). The 
presence of this organism reinforces the need to maintain 
high vaccination levels in all countries. Higher incidence 
of infection among elderly women could be related to 
pet ownership habits, in combination with low or waning 
immunity.
Vaccination coverage for diphtheria is assessed 
annually in many countries in Europe by using a 
range of methods, including computerized vaccination 
registers, survey methods, administrative methods, or a 
combination (25). These methods will provide varying 
degrees of accuracy in coverage estimates, which makes 
countries diffi cult to compare. Coverage for vaccination 
with diphtheria-tetanus-pertussis 3 vaccine (third dose of 
diphtheria, tetanus, pertussis vaccine) in early childhood in 
2009 was >90% for most (85%) countries in the European 
Region, and 66% of countries (including Latvia, Lithuania, 
Turkmenistan, and the Russian Federation) reported 
coverage >95% (26). Coverage in Ukraine decreased from 
98% in 2006 and 2007 to 90% in 2008 and 2009. Austria, 
Denmark, Georgia, and Moldova recorded diphtheria-
tetanus-pertussis 3 vaccine coverage <90%. Azerbaijan and 
Malta had the lowest coverage (73% for both countries) in 
the European Region in 2009.
Following high-profi le vaccine-scare stories in 
some countries in eastern Europe, such as the Russian 
Federation and Ukraine, anti-vaccination groups have 
gained strength by using television, the Internet, and other 
media for publicity (27); this activity could seriously 
affect vaccination coverage. Adult diphtheria immunity 
can be increased through scheduled booster vaccinations 
every 10 years (e.g., as in Austria, Belgium, Bulgaria, 
Cyprus, Estonia, Finland, France, Germany, Greece, 
Latvia, Norway, Portugal, and Romania) or as part of 
a combined tetanus and low-dose diphtheria vaccine 
given for tetanus-prone injuries. In Latvia, annual adult 
vaccination coverage surveys are undertaken, but in most 
countries adult coverage is rarely assessed. Seroprevalence 
studies have indicated that many adults in some countries 
have immunity levels below the protective threshold (28). 
Gaps in immunity in the adult population contributed to 
the resurgence of diphtheria in eastern Europe during the 
1990s.
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Table 4. Vaccination status of case-patients and clinical manifestations of toxigenic Corynebacterium diphtheriae and C. ulcerans
infections and epidemiologically linked cases without laboratory confirmation, DIPNET cases excluding Latvia, Europe, 2000–2009*
Vaccination status 
Classic respiratory 
diphtheria (with 
membrane) 
Mild respiratory 
diphtheria/severe 
pharyngitis Cutaneous Other Asymptomatic Not known Total 
Full 4 17 2 1† 2 0 26 
Partial 5 3 7 0 0 0 15 
Unvaccinated 14 3 4 0 1 0 22 
Not known 15 10 15‡ 1§ 12 11¶ 64 
Total 38 33 28 2 15 11 127 
*DIPNET, Diphtheria Surveillance Network. p = 0.001 by test for trend (vaccination status and disease severity). 
†Bacterial endocarditis (C. diphtheriae, fully vaccinated) 
‡One cutaneous case-patient also had a sore throat. 
§Isolation from blood (C. ulcerans, vaccination status not known). 
¶Includes 2 case-patients infected with C. diphtheriae who died and are assumed to have respiratory symptoms without specific details available. 
RESEARCH
Trends in diphtheria cases in Europe are encouraging, 
but continued striving for improved vaccination coverage 
is essential. Diphtheria has a socioeconomic component; 
outbreaks are typically seen in marginalized groups. In the 
current economic climate, more socially deprived groups 
that are vulnerable to infection will emerge. The economic 
crisis may also threaten supplies of vaccine and antitoxin and 
delivery of immunization programs. Because reductions in 
fi nances can limit the capacity for surveillance, decreases 
in case reporting need to be interpreted with caution. Every 
effort must be made to maintain high diphtheria vaccination 
coverage.
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Hospital, Athens, Greece); Suzanne Cotter (Health Services Executive–Health Protection 
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Sanità, Rome, Italy); Ruta Paberza and Jurijs Perevoscikovs (State Agency Infectology Center of 
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(Centre for Infectious Disease Control, Bilthoven, the Netherlands); Ernst Arne Høiby and Per 
Sandven (Norwegian Institute of Public Health, Oslo, Norway); Aleksandra A. Zasada (National 
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Health, Bucharest, Romania); Cerasela Dragomirescu (National Institute of Research and 
Development for Microbiology and Immunology Cantacuzino, Bucharest, Romania), Alenka 
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European Union Case Definition for National Diphtheria Surveillance, Community 
Decision of March 19, 2002 (under 2119/98/EC), Modified Version. 
Androulla  Efstratiou, Natasha S. Crowcroft, and Joanne M. White, on behalf of 
Diphtheria Surveillance Network, November 2002 
Clinical Description 
Clinical picture compatible with diphtheria, i.e., an upper respiratory tract illness 
characterized by sore throat, low-grade fever, and an adherent membrane of the tonsils, pharynx, 
or nose or nonrespiratory diphtheria; cutaneous, conjunctival, otic, and genital lesions. 
Laboratory Criteria for Diagnosis 
Isolation of diphtheria toxin–producing corynebacteria from a clinical specimen. 
Case Classification 
Possible: Not applicable 
Probable: A clinically compatible case that is not laboratory confirmed and does not have 
an epidemiologic link to a laboratory-confirmed case. 
Confirmed: A clinically compatible case that is laboratory confirmed with the isolation of 
a toxigenic strain of Corynebacterium diphtheriae, C. ulcerans, or C. pseudotuberculosis or has 
an epidemiologic link to a laboratory-confirmed case. 
Page 2 of 2 
Confirmed (other): Nonrespiratory/cutaneous diphtheria cases with isolation of toxigenic strains, 
or cases not meeting the specified clinical criteria but with isolation of toxigenic strains (e.g., 
mild respiratory diphtheria, or respiratory diphtheria with absence of membrane). 
Asymptomatic carriers: asymptomatic carriers (any anatomical site) with toxigenic strains. 
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. Diphtheria
Diphtheria is an acute bacterial disease with a considerable case
absorbed into the circulatory system where, when disseminated,
it is able to cause systemic complications such as myocarditis
and neuritis [1]. Three toxin-producing species have been iden-atality rate caused by toxigenic strains of corynebacteria. Diphthe-
ia toxin (DT) is the major virulence factor for these organisms,
nd contributes to the formation of a pseudomembrane in the
asopharynx of affected individuals. The colonising organisms are
arely found outside the local area of infection but the toxin is
∗ Corresponding author. Tel.: +44 0208 327 7446; fax: +44 0208 327 7404.
E-mail address: joanne.white@hpa.org.uk (J.M. White).
264-410X/$ – see front matter. Crown Copyright © 2009 Published by Elsevier Ltd. All ri
oi:10.1016/j.vaccine.2009.09.094tiﬁed; Corynebacterium diphtheriae is most commonly associated
with communicable disease in humans, Corynebacterium ulcer-
ans and Corynebacterium pseudotuberculosis are both less common
in humans globally and are traditionally associated with contact
with farm animals or dairy products. Recent cases of C. ulcerans
have been associated with companion animals [2–4]. Toxigenic C.
diphtheriae and C. ulcerans can cause both classic respiratory and
systemic diphtheria, as well as other clinical presentations such
as cutaneous diphtheria, which is more common in tropical areas
of the world. Toxigenic C. pseudotuberculosis infections are usu-
ghts reserved.
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lly associated with lymphadenitis [5]. The DT gene is carried by
family of closely related bacteriophages (corynebacteriophages)
hat can integrate into the bacterial chromosome and convert
on-toxigenic, non-virulent strains into toxigenic, highly virulent
pecies [6,7]. However, transformation of a non-toxin-producing
train to a toxigenic organism is believed to occur rarely in nature.
. Diphtheria toxin
Diphtheria toxin is synthesised and secreted as a single polypep-
ide, pro-enzyme that is cleaved and reduced in vivo to produce
toxic protein consisting of A and B fragments [8]. The B sub-
nit contains the receptor binding and translocation domains of
he toxin and the ﬁrst step in the intoxication of eukaryotic cells
y DT is the binding of toxin to speciﬁc cell surface receptors [9].
he receptor for DT was identiﬁed as the heparin-binding epi-
ermal growth factor-like growth factor precursor (pro-HB-EGF)
10,11]. After binding of the toxin B subunit to the receptor, the
oxin is internalised by receptor-mediated endocytosis. The lowpH
ithin the endosome causes a conformational change in the toxin
olecule, facilitating translocation of the catalytically active A sub-
nit of the toxin into the cytoplasm [12]. Once inside the cytoplasm,
he A subunit, an ADP-ribosyltransferase, exerts its cytotoxic action
y ADP-ribosylating elongation factor 2 (EF-2) thereby inhibiting
ellular protein synthesis. The toxin has an estimated lethal dose
or humans of ≤0.1g/kg [13]. The DTs of C. diphtheriae and C.
lcerans have been shown to be 95% identical; differences between
hese twoDTs aremainly located in the translocation and receptor-
inding domain of the B subunit. In contrast to C. diphtheriae DT,
he DT of C. ulcerans seems to be much more heterogeneous [14].
. Diphtheria therapy
Whilst diphtheria is an increasingly rare disease in the major-
ty of developed countries, when cases do arise they can be severe
nd require a rapid and robust public health response. Case fatal-
ty rates worldwide remain high (>10%) [15]; a recently reported
ase fatality ratio (CFR) for Latvia for 2002–2007 was 9% [16]. Out-
ide endemic areas CFRs can be even higher; delays in diagnosis
nd hence appropriate treatment have been reported [17]. The
ost effective treatment for diphtheria is early administration ofnhagen, 1904. With permission from Statens Serum Institut.
diphtheria antitoxin (DAT), along with appropriate antimicrobial
therapy to eliminate the corynebacteria from the site of infection
thus stopping ongoing toxin-production. The protective effect of
DAT has also been demonstrated in vitro and in vivo for C. ulcer-
ans and is a treatment option for diphtheria caused by C. ulcerans
[18]. However, in practice DAT is given based on clinical diagnosis,
usually prior to laboratory conﬁrmation [19]. DAT is a preparation
of immunoglobulins or immunoglobulin F(ab’)2 fractions produced
from immunisation of horses, that neutralises circulating DT. Emil
von Behring won the ﬁrst Nobel Prize for medicine in 1901 for
his work on “Serum Therapy in Therapeutics and Medical Science”
where he noted the importance of early use of diphtheria serum
in order to achieve successful “detoxication of the bacillus poison”
[20]. The antitoxin will only neutralise circulating toxin which has
not bound to tissue; it is therefore critical that DAT is administered
as soon as a presumptive diagnosis has been made without wait-
ing for bacteriological conﬁrmation [1]. A study of ﬁfty patients
with diphtheritic polyneuropathy in Riga, Latvia found antitoxin to
be ineffective if administered after the second day of diphtheritic
symptoms [21]. Aside from improved methods to reﬁne or purify
theequine serum, littlehas changed indiphtheria serotherapysince
its introduction in the late 19th century and its continueduse today,
over 100 years later.
4. Diphtheria antitoxin supplies
Historical documents suggest that even in the pre-vaccine era
the supply of DAT could be problematic, particularly in remote
areas. ‘The Serum Run of 1925’ describes life-saving supplies of
antitoxin being urgently ‘mushed’ across the snow by huskies in
Alaska to reach a diphtheria epidemic in Nome [22]. Later, in an
account of nursing during World War II, Barbara Brooks Tomblin
describes problems with the supply of DAT and waiting ‘as long as
forty hours’ for it to arrive [23].
In the early 1900smany countries (Denmark (Fig. 1), France [24],
Germany [25], Canada [26], USA (Fig. 2) and UK [27] to name a few)
produced their own therapeutic antitoxin preparation fromhorses.
Fig. 1 shows the bleeding of a horse for production of diphtheria
antitoxin at the Statens Serum Institut in Copenhagen, Denmark
in 1904. Except for the director, the complete staff of the institute
were present in the photograph. The description accompanying the
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tries are supplied internally by either a national institute (Turkey),Fig. 2. Headline from The New York Times, 7 June 1914.
hotograph stated that when bleeding, usually eight pots of blood
ere drawn corresponding to about eight litres. The bleeding had
o immediate effect on the horse and in the following days the
orses were usually more lively and playful; about 1 month later
he horse could be bled again. Fig. 2 shows an extract from the New
ork Times describing the employment of a retired cleaning-cart
orse at the Otisville Laboratory, New York. Following the intro-
uctionofmass vaccination in the1940s/1950s and the consequent
ecline in cases of diphtheria, several countries stopped manu-
acturing their own supplies, some relatively recently. Diphtheria
ntitoxin for therapeutic use was manufactured in the USA until
996, after which time supplies were imported from France (until
roduction there was stopped in 2002) and more recently from
razil [28]. Companies in Australia (Commonwealth SerumLabora-
ories Ltd.), Poland (BiomedSerumandVaccineManufacturers Ltd.)
nd Switzerland (Berna Biotech Ltd.) previously supplied several
ountries internationally but have recently ceased production of
AT (last stocks expired during 2007–2008). There are a number of
actors contributing to thedepletionof traditional sourcesof equine
AT, including economic viability (due to reduced demand and the
eed to manufacture pure products), the poor reputation of the
roduct based on the rates of adverse reactions to old un-puriﬁed
roducts, and public objection to the use of horses as blood donors
29]. Consequently, the supply of equine DAT for human therapeu-
ic usehas become increasingly problematic in recent years. Even in
he UK, a small country where antitoxin has been held in 10 sites, it
as proved challenging to transport antitoxin tomore remote areas
n a timelymanner (Health Protection Agency duty doctor personal
ommunication).
The potential consequences of a limited supply of DAT were
ighlightedduring the resurgenceofdiphtheria thatoccurred in the
ewly Independent States (NIS) of the former Soviet Union. During
his outbreak in the 1990s there were shortages of vaccine, DAT,
nd antibiotics across the NIS (except in the Russian Federation)
30]. At the time of the disintegration of the former Soviet Union
n 1991, all NIS relied on supplies of vaccine and DAT from Rus-
ia, and most lacked the ﬁnancial resources to procure them from
he international market. At the start of the epidemic, due to lack
f DAT and delayed treatment, the CFR was very high (>20%) [30].
nce the international community made available DAT and antibi-
tics from 1995, the CFR fell to around 5–10%. In Russia, where
AT was always available, the CFR was approximately 3%. Regional
nd secular differences in CFRs in Uzbekistan during the diphthe-
ia epidemic 1993–1996 may have been related to DAT availability
nd use. For example, in 1994, Qashqadaryo and Surkhondaryo
blasts (which reported the majority of cases), had CFRs of 9.6%
nd 21.5% respectively, and during this time 79 (93%) of 85 cases
n Qashqadaryo and 46 (50%) of 93 cases in Surkhondaryo received
AT. In SurkhondaryoOblast, DAT supplywas severely limited dur-
ng the latter half of 1994, and the CFR rose from 16% (the national
verage) for the ﬁrst 6months of 1994 to 26% in the latter 6months
31].
Today, the threat of diphtheria, even in countries with good
overage in their childhood immunisation programmes, has not
isappeared. As the resurgence of diphtheria in the NIS demon-
trated, it is possible for this disease to re-emerge in previously
ow-prevalence countries under particular conditions for exam-
le, gaps in childhood vaccination coverage combinedwithwaning
mmunity in adults [32,33]. A number of seroepidemiology studies
ave reported sizable proportions of adults with immunity lev-
ls below the putative protection threshold in countries with highe 28 (2010) 14–20
childhood immunisation coverage [34–39]. In addition, the poten-
tial for a case to be imported into any country, either as a national
acquiring an infection abroad or a new arrival/visitor to the coun-
try, will always exist whilst diphtheria is endemic in some parts of
the world. It is important that in these situations a supply of DAT
can be identiﬁed and the product distributed quickly.
5. Survey methods
As part of a work package assessing the surveillance and
incidence of diphtheria, a questionnaire was developed by the
UK Health Protection Agency, the lead partner of the European
Commission funded Diphtheria Surveillance Network (DIPNET),
to enquire about diphtheria surveillance practices within the 25
DIPNET member countries. It included a brief section on national
facilities for maintaining stocks of DAT and was completed by the
member countries in October 2007. Following the responses to this
initial questionnaire, a more detailed questionnaire about DAT was
developed with the assistance of colleagues at the National Insti-
tute for Biological Standards andControl. In February 2008 this DAT
questionnaire was circulated to the 11 DIPNET member countries
identiﬁed fromthepreviousquestionnaire asmaintaining a stockof
antitoxin, and to an additional 20 DIPNET collaborating countries,
as well as 12 countries within the WHO EURO region not covered
by DIPNET. Completed questionnaires were received from all DIP-
NET member countries, 12/20 DIPNET collaborating countries, and
two countries from the WHO Euro region not included within DIP-
NET. InOctober 2008 aRussian translation of the questionnairewas
sent to six of the countries within the original distribution list from
whom a response had not been received; this resulted in ﬁve addi-
tional returned questionnaires, giving an overall total (including
the original DIPNET responses) of 44 returned questionnaires from
57 countries.
6. Survey results
The results inFig. 3arebasedbothonresponses to the initialDIP-
NET questionnaire and the second DAT questionnaire. Responses
to the survey were not received from Brazil, Russia and Croatia but
it is assumed that these countries have a national stock because
they are known to produce and supply DAT to other countries. Of
the 47 countries where the status of DAT stocks was known for
2007–2008, 57% hold a current stock of antitoxin (this includes
countries that produce and supply internationally). In the majority
of countries the Ministry of Health is responsible for maintaining
the DAT stocks and these are held at national level, which may
involve distribution to regional holding sites. In Latvia, Kyrgyzstan
and Kazakhstan stocks are held at all levels of the health system
from national centres down to district hospitals and local health
centres. Some countries speciﬁed that rather than a national stock,
it is the responsibility of each state (Germany) to hold a stock, or
that a limited amount of DAT is known to be available in at least
one hospital (Austria).
All countries thatmaintain a stockofDATuseequineDAT. Expiry
dates of stock at the time of surveying ranged from recently expired
(2007) to 2015 (Japan) though most countries with current stock
have expiration dates in 2009 or 2010. The Japanese antitoxin is a
freeze-dried preparation, hence the long shelf life compared to the
other stockswhichare liquidpreparations and typicallyhavea shelf
life of 2–3 years (NIBSC unpublished observations). Some coun-state-owned company (Bulgaria) or private company (Japan); these
organizations may be able to supply internationally in the future
but were not currently supplying any of the other countries sur-
veyed. Three countries have stocks (one expired, two expiry dates
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Fig. 3. Distribution of stocks and international suppliers of DAT for therapeutic use: 2007–2008 (European region with global inset). The four countries displayed in dark
red in this ﬁgure produce DAT and supply internationally, those shown in lighter red (23) held a stock of DAT at the time of survey (either produced within their country or
obtained from one of the four countries identiﬁed on the map as supplying internationally), and those with no stock or expired stock (20) are in white. Countries that were
not surveyed or did not respond are shown in green. Note 1: in Tajikistan DAT was used during 1991–1999 thanks to humanitarian aid from the WHO/EURO. Currently, a
patient can buy DAT by prescription at a private pharmacy. Note 2: in Australia, patients may gain access to DAT through the Special Access Scheme (SAS) which refers to the
arrangements which provide for the import and/or supply of an unapproved therapeutic good for a single patient on a case by case basis.
Table 1
International suppliers of DAT amongst countries surveyed: 2007–2008.
Name of company Location of company Additional countries supplied
Mikrogen www.microgen.ru Russia Azerbaijan, Belarus, Estonia (some hospitals), Georgia,** Kazakhstan, Kyrgyzstan,
Latvia, Moldova, Ukraine
Institute of Immunology Inc.,a www.imz.hr Croatia Finland, Switzerland, Germany, Estonia
Instituto Butantan*** www.butantan.gov.br Brazil USA, Canada, UK, Israel
Serum Institute Ltd. www.seruminstitute.com India Uzbekistan
2009 updates: **Georgia is no longer supplied by Mikrogen and hence no longer has a stock of DAT. ***As of November 2008 and February 2009 France and Ireland respectively
have sourced supplies of DAT from Instituto Butantan. Note: It is important to clarify that it is not known whether or not all of the companies listed in the above table conform
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a The Institute of Immunology Inc also supplies more widely through a Canadian
ealth Organization (Intervax Ltd. email communication).
n 2008) from an Australian company (Commonwealth Serum Lab-
ratories Ltd.) which is no longer producing DAT; all three reported
ecent difﬁculty in ﬁnding a new supplier. Four current interna-
ional suppliers were identiﬁed as shown in Table 1.
Forty countries answered the question asking if they had had
ifﬁculties recently in obtaining a supply of DAT; 50% (10 with a
tock, 10 without a stock) had experienced recent difﬁculties. Six
f the 20 countries that had not experienced difﬁculties obtaining
tocks were countries without stocks where cases have not been
ecently reported, and no attempt to source DAT has been made.
hirty-eight of the 39 countries (97%) that answered the question
bout websites thought it would be useful to maintain a central
ist of current suppliers on a website. The websites of choice were
in order of preference) DIPNET, ECDC (European Centre for Disease
revention and Control), EMEA (EuropeanMedicines Agency), with
dditional suggestions of WHO and ESCMID (European Society of
linical Microbiology and Infectious Diseases) websites.. Discussion
This survey highlights both the range and absence of DAT stocks
cross participant countries. Importantly, those countries with the
urrent highest incidence of infection such as Latvia and India doof DAT, only the UK, Ukraine and Belarus test the stock for potency in a national
any (Intervax Ltd.) which supplies United Nations Agencies afﬁliated to the World
hold stocks and these are maintained at national, hospital and even
family doctor level. Countries which have reported sporadic cases
in the last 8 years such as the UK, Germany and Turkey hold stocks
of antitoxin at the state or national level. However, there are sev-
eral countries, including somewhich have reported cases in the last
8 years which do not hold stocks, or hold stocks which are close
to expiry. This is of public health concern – particularly consider-
ing the requirement for early administration of DAT when disease
is suspected. In Australia, the Special Access Scheme described
for importation of a therapeutic good is likely to be too time-
consuming to be of beneﬁt in the event of a case. The survey has
identiﬁed a need for easy access to information about current sup-
pliers of this product, aswell as theneed to raise awareness globally
of the importance of maintaining stocks. The survey was limited
to the WHO Euro region and some DIPNET collaborating countries
outside of this region; it would be interesting to know the situa-
tion regarding supplies of DAT in other WHO regions, particularly
in endemic areas.Lack of a DAT supply can increase the likelihood of mortality
as demonstrated during the shortages in the NIS epidemic [31].
In Lithuania in 2007, a case of classical respiratory diphtheria was
reported however, Lithuania does not currently hold a stock of DAT
so antitoxin treatment was not available for this patient, who sub-
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equently died (DIPNET unpublished data). In 2008, a suspected
ase of toxigenic C. ulcerans was identiﬁed in Ireland (although
oxigenicity was never conﬁrmed and the patient improved on
ntibiotic treatment alone). However, this resulted in an initia-
ion of discussions with the UK regarding possible mobilisation of
AT supplies from the UK Northern Ireland stock if required, since
he Irish stock had expired 6 months previously. Since then Ire-
and has procured new stock. Also in 2008, a cluster of diphtheria
ases occurred in Oslo, Norway, in an unimmunised family return-
ng from a visit to Latvia [40]. Norway does not maintain a stock of
ntitoxin, DAT treatmentwas not administered to the cases though
he possibility of receiving DAT from the Staten Serum Institute in
openhagen, Denmark was discussed (although Denmark does not
urrently maintain stockpile either). In November 2008 a case of
iphtheria was diagnosed in France and it took 4 days for DAT to be
elivered from the Instituto Butantan in Brazil after failed efforts to
btain this treatment from neighbouring countries. Currently it is
he responsibilityof each individual country to supply treatment for
iphtheria in the event of a case, which (as demonstrated by these
xamples) may necessitate negotiations with neighbouring coun-
ries if the case occurs in a country that does not hold DAT stocks.
uring the NIS epidemic, WHO Euro involved governmental and
on-governmental organizations such as the United States Agency
or International Development, European Community Humanitar-
anOfﬁce, and International FederationofRedCross in the initiation
f an effort, monitored by the Interagency Immunization Coordi-
ation Committee, to mobilize the needed materials (i.e. vaccine,
yringes, needles, DAT and antibiotics) [30]. There has been some
iscussion at European level regarding centralising stocks of essen-
ial medicines, speciﬁcally in the context of pandemic ﬂu, but as
et this does not exist on a practical level (personal communica-
ion 2008: ECDC). This approach could however present difﬁculties
n terms of timely transportation of DAT to the case and funding
ssues surrounding the cost of maintaining the central stock. The
otential for current suppliers to increase production of DAT in
he event of an epidemic has not been assessed here. For those
ountries that have experienced difﬁculties in sourcing a supplier
f antitoxin it would be useful to maintain a list of DAT producers
n a readily accessible website such as DIPNET, ECDC or the EMEA
ebsite. Countries can also email DIPNET (dipnet@hpa.org.uk) for
ore detailed information although DIPNET cannot recommend or
ndorse particular suppliers.
Itmay also be useful to review the current speciﬁcations for DAT
or therapeutic use (European Pharmacopoeia 1000 IU/ml). This
ay be addressed as part of the current review of the WHO manual
or the management and control of diphtheria (see Appendix A).
ny relaxation in these speciﬁcations may be useful in the short
erm for emergency situations where product that has recently
xpired is available immediately and there is likely to be a delay
n obtaining a replacement product in-date. However, this would
ot address the larger issue of maintaining adequate supplies on a
lobal scale.
The problems in obtaining equine DAT together with the poten-
ial for adverse side effects such as serum sickness (which was
eported to affect 9% of recipients receiving DAT in the US between
940 and 1950 [41]) mean alternative therapies for diphtheria
hould be investigated. The use of an antitoxin preparation from
uman rather than horse blood (as has been the case for tetanus)
ould be more satisfactory in terms of limiting the risk of hyper-
ensitivity reactions but may not be economical or practical on a
arge scale. In an American study reported by Sgouris et al. in 1969,
human DAT immunoglobulin preparation was produced which
aised theantibody titre in subjectswith less than0.001unitsperml
f serum to protective levels (0.01 IU/ml) without any local or gen-
ral reactions occurring. However, only onepercent of the outdated
uman plasma units that were tested as source material for thise 28 (2010) 14–20
production had sufﬁcient antitoxin for fractionation [42]. A simi-
lar study in 1979 using selected blood donations to the Australian
Red Cross Transfusion Services did not yield sufﬁcient concentra-
tions of antitoxin to allow use for therapy of established disease,
only for prophylaxis in asymptomatic contacts of diphtheria [43].
It should be noted though that since these studies were carried
out (prompted by the epidemic in the Newly Independent States)
diphtheria immunisation strategies in adults have been reviewed
in many countries in order to try to improve diphtheria immunity
among older age groups [44]. Additionally the CRM197 protein (a
non-toxic variant of diphtheria toxin) is now used as a conjugate
for several new vaccines (Haemophilus inﬂuenza type b, meningi-
tis C and pneumocccal vaccines) which may have a boosting effect
[45]; consequently future diphtheria antibody levelsmay be higher
in routine blood donations than they were in these early studies;
further studieswould be required to conﬁrm this. However, consid-
ering that thedoseofDAT required for evenmild cases of diphtheria
is 10,000 IU and the fact that normal human IgG for intravenous
use (IVIG) has a DAT potency of approximately 3 IU/ml (NIBSC,
unpublished observations), a volume in excess of 3 l of product
would be required, which makes rapid and early administration of
this kind of antitoxin preparation difﬁcult for therapeutic use (see
Appendix A for guidelines on administration of DAT). For severe
cases, in excess of 13 l would be required to achieve the recom-
mended dose of 40,000 IU, which is impractical. Recent guidelines
issued by the UK Health Protection Agency for the treatment of
tetanus do recommend the use of a human normal immunoglobu-
lin preparation where speciﬁc tetanus immunoglobulin cannot be
obtained. However, for tetanus, the antitoxin potency of IVIG is
approximately 20 IU/ml (NIBSC unpublished observations) and the
recommended treatment dose of 5000–10,000 IU can be achieved
using 250–500ml of antitoxin infused over a period of 3–6h [46].
Therefore, if similar or even higher DAT levels could be achieved in
a human-derived product the treatment dose of 10,000–40,000 IU
could be achieved. Research in Russia during the NIS epidemic
found that in an emergency situation it is possible to select donors
for speciﬁc anti-diphtheria plasma among convalescent patients
(approximately half of patients may be considered as donors),
and that booster vaccination of convalescent diphtheria patients
leads to enhanced antibody titres [47]. By selection of high-titre
donors for DAT from human plasma pools (as is done for anti-
D and anti-HepB IgG) and assuming an enrichment factor of 10
following puriﬁcation, itmay be possible to produce a product con-
taining 50 IU/ml. However, even in this scenario antitoxin volumes
of up to 800ml would be required for treatment of severe cases
of diphtheria. Furthermore, there is a global shortage of serum for
immunoglobulin production which is threatening all supplies [48]
and the higher economic costs involved in producing these types
of product may be prohibitive. Production of human or humanized
antibodies is a forward looking therapy for many toxin mediated
diseases [49–51] and it would be desirable to also consider such
products for diphtheria, if sufﬁcient market can be identiﬁed.
There are also possibilities for non-antitoxin based therapy of
diphtheria which could be explored. One example is the use of
soluble receptor analogues for blocking of the DT receptor. Pos-
sible options include using the mature form of HB-EGF, although
a truncated form of the protein would be necessary to avoid the
potent mitogenic (and hence tumourigenic) effects of wild type
HB-EGF [52]. It may also be possible to use other competitors for
DT-receptor binding such as the non-toxic mutant of DT, CRM197
which is licensed for human use in conjugate vaccines. Studies
have shown that this mutant toxin can bind to the pro-HB-EGF
receptor and prevent the mitogenic activity of the receptor [53]. In
each of these examples, the diphtheria antidote would need to be
administered early as is the case forDAT and the economics ofman-
ufacturing and supplying these materials may also be prohibitive.
Vaccin
A
d
c
[
n
n
t
8
f
f
p
r
d
D
s
t
o
n
p
s
s
o
I
r
t
I
e
u
e
c
A
n
T
r
U
R
R
S
m
s
A
p
a
1
2
3
[
[
[
[
[
[
[
[
[
[
[K.S. Wagner et al. /
nother possible future option may be the use of an extracorporeal
evice together with speciﬁc or non-speciﬁc adsorbents to remove
irculating DT from the blood of affected individuals (reviewed in
54,55]), although, as with the other treatments, therapy would
eed to be started rapidly after preliminary or presumptive diag-
osis of disease. Other drawbacks for this potential therapy include
he need for invasive techniques.
. Conclusions
One of the most critical aspects of current antitoxin therapy
or diphtheria (and potential future therapies) is the requirement
or rapid administration of the antidote. Toxin must be neutralised
rior to binding to its receptor (or prevented from binding to the
eceptor by competition) resulting in a narrow therapeutic win-
ow. Current diphtheria therapy, based on the administration of
AT, is effective but compromised by a difﬁculty in maintaining
upply of the therapeutic product. Until equally effective alterna-
ive therapies are identiﬁed andbrought into use, the focus remains
nhowtoensureantitoxin therapycanbesupplied ina timelyman-
er to patients with diphtheria. The use of a freeze-dried antitoxin
reparation, as is the case in Japan, would allow for an extended
helf life for the product, making it easier to maintain an in-date
tock. However, there may be a reduced incentive for production
f a relatively low-demand product that has an extended shelf life.
f large scale production of antitoxin with a long shelf life on a
olling contract could be negotiated on a European or global scale
his would facilitate the maintenance of individual country stocks.
n the meantime information about current international suppli-
rs of DAT will be made available and countries without stocks are
rged to procure this treatment. The scarcity of DAT stock piles also
mphasises the importance of maintaining high diphtheria vaccine
overage in all countries.
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ppendix A. European and international standards for the
roduction of DAT
Relevant European guidelines concerning the production ofDAT
re listed below:
. Minimum requirements for potency are prescribed in the
Ph Eur monograph for Diphtheria Antitoxin (01/2008:0086)
http://www.pharmacopoeia.co.uk/ixbin/bp.cgi?tab=search&a=
query&all=&qa=&title=diphtheria+antitoxin [restrictedwebsite:
login required].
. European Medicines Agency (EMEA): Note for Guidance on
Production and Quality Control of Animal Immunoglobu-
lins and Immunosera for Human Use http://www.who.int/
bloodproducts/publications/EMEA-animal%20sera.pdf.
. Ph Eur monograph for Immunosera for Human Use, Animal
(01/2008:0084) http://www.pharmacopoeia.co.uk/ixbin/bp.
[
[e 28 (2010) 14–20 19
cgi?r=7b1NI5Bj39O&id=4575&a=display&tab=search [restricted
website: login required].
A.1. Administration of DAT
Guidelines for the administration of DAT are described
in the WHO manual for the management and control of
diphtheria (ICP/EPI 038 (B), 1994) (http://www.who.int/vaccines-
documents/DocsPDF05/0602170624 001.pdf). Prior to administra-
tion, tests to exclude hypersensitivity of the patient to horse
serum should be carried out. DAT should be given according to the
manufacturer’s instructions, the dosage depending on the clinical
condition of the patient. Concurrent administration of antimi-
crobial treatment is also essential to halt toxin-production. This
manual is currentlybeing reviewedandupdatedunder theauspices
of DIPNET.
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Screening for Corynebacterium diphtheriae and Corynebacterium ulcerans
in patients with upper respiratory tract infections 2007–2008: a
multicentre European study
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Abstract
Diphtheria is now rare in most European countries but, when cases do arise, the case fatality rate is high (5–10%). Because few coun-
tries continue to routinely screen for the causative organisms of diphtheria, the extent to which they are circulating amongst different
European populations is largely unknown. During 2007–2008, ten European countries each screened between 968 and 8551 throat
swabs from patients with upper respiratory tract infections. Six toxigenic strains of Corynebacterium diphtheriae were identified: two from
symptomatic patients in Latvia (the country with the highest reported incidence of diphtheria in the European Union) and four from
Lithuania (two cases, two carriers); the last reported case of diphtheria in Lithuania was in 2002. Carriage rates of non-toxigenic organ-
isms ranged from 0 (Bulgaria, Finland, Greece, Ireland, Italy) to 4.0 per 1000 (95% CI 2.0–7.1) in Turkey. A total of 28 non-toxigenic
strains were identified during the study (26 C. diphtheriae, one Corynebacterium ulcerans, one Corynebacterium pseudotuberculosis). The
non-toxigenic C. ulcerans strain was isolated from the UK, the country with the highest reported incidence of cases due to C. ulcerans.
Of the eleven ribotypes detected, Cluj was seen most frequently in the non-toxigenic isolates and, amongst toxigenic isolates, the major
epidemic clone, Sankt-Petersburg, is still in circulation. Isolation of toxigenic C. diphtheriae and non-toxigenic C. diphtheriae and C. ulcer-
ans in highly-vaccinated populations highlights the need to maintain microbiological surveillance, laboratory expertise and an awareness
of these organisms amongst public health specialists, microbiologists and clinicians.
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Introduction
In the European region, diphtheria is rarely suspected in
patients presenting with an upper respiratory tract infection
due to the success of widespread immunization programmes.
The disease is caused by toxin-producing Corynebacterium
species: Corynebacterium diphtheriae, Corynebacterium ulcerans,
or very rarely Corynebacterium pseudotuberculosis. In vacci-
nated or partially-vaccinated individuals, diphtheria can
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present simply as a sore throat without the classic pseudo-
membrane; clinically, the disease may not be suspected, or
can be confused with other more common conditions such
as severe streptococcal sore throat [1]. Most European labo-
ratories no longer routinely screen throat swabs for coryne-
bacteria, resulting in a loss of laboratory capability in this
field [2]. It is therefore often difficult to differentiate
between surveillance systems that report low numbers
because there are genuinely few cases and surveillance sys-
tems that have low sensitivity.
In the 1990s, a dramatic resurgence of diphtheria
occurred in the newly-independent states of the former
Soviet Union. Many factors are considered to have contrib-
uted to the epidemic: reductions in vaccination coverage,
numerous contraindications to vaccination, increased adult
susceptibility, large-scale population movements, and a lack
of adequate supplies for prevention and treatment in most
affected countries [3,4]. Intensive vaccination strategies
helped to bring the resurgence under control in most areas;
however, of the countries participating in the present study,
relatively high numbers of cases (an average of 28 symptom-
atic cases each year between 2002 and 2006) are still being
reported in Latvia, predominantly from the capital city, Riga.
No cases of diphtheria were reported to the Diphtheria
Surveillance Network (DIPNET; http://www.dipnet.org) from
Bulgaria, Estonia, Finland, Greece, Ireland and Turkey in the
5 years preceding this study (2002–2006). One case of
toxigenic C. ulcerans was reported in Italy in 2002 and five
isolates of C. diphtheriae were reported in Lithuania in 2002,
but none subsequently. The UK reported between one
and eight toxigenic isolates (including respiratory/cutaneous
infections and asymptomatic carriage) of C. diphtheriae and/or
C. ulcerans each year between 2002 and 2006.
Carriage rates in highly-vaccinated populations are
expected to be low; a strong statistical association has been
demonstrated between carriage of corynebacteria and non-
protective levels of antitoxin antibodies [5]. European studies
conducted in the last decade have documented carriage rates
of 0.5 per 1000 (for toxigenic C. diphtheriae within routine
throat swabs from Greek children) [6], and 0.7 per 1000
population (for non-toxigenic C. diphtheriae in an Italian pop-
ulation with sore throats) [7]. A Latvian study, which
screened 38 157 throat swabs from both healthy and non-
healthy individuals between 2002 and 2006, generated 140
C. diphtheriae isolates; 86% were toxigenic strains giving a
carriage rate for C. diphtheriae in Latvia (both toxigenic and
non-toxigenic organisms) of 3.7 per 1000 population [8]. Of
the countries participating in this study, only clinicians in Lat-
via routinely request screening for corynebacteria when sub-
mitting a throat swab. In the UK, routine screening for
corynebacteria is only undertaken by selected laboratories;
in the remaining participant countries, screening would only
be undertaken to investigate a suspected case, although
some countries (Lithuania, Ireland) have increased their
screening practices subsequent to the present study being
undertaken.
Widening membership of the European Union has lead to
significant migration of Eastern European populations to live
and work in many parts of Western Europe. The present
study attempts to determine the current prevalence of
potentially toxigenic corynebacteria in different European
populations to help with the interpretation of any future
changes in the epidemiology of these infections in Europe.
Materials and Methods
Ten countries participated in this screening study, represent-
ing Baltic (Estonia, Latvia, Lithuania), Northern (Finland),
Western (Ireland, UK), Southern (Italy, Greece) and Eastern
(Bulgaria, Turkey) European countries.
Between December 2007 and June 2008, participating lab-
oratories in each country processed throat swabs routinely
received from patients with upper respiratory tract infec-
tions for potentially toxigenic corynebacteria, regardless of
any other clinical indication. The exact screening periods for
each individual laboratory varied in the range 1–5 months.
The number of participating laboratories in each country
ranged from one (in Finland) to 16 (in Greece) (Table 1).
Information on symptoms, vaccination history, travel his-
tory, and management of the case and contacts was com-
pleted for each patient in whom a toxigenic strain was
identified using a case follow-up questionnaire. Patients from
whom a non-toxigenic strain was isolated were not fol-
lowed-up.
Statistical analysis
It was calculated that a minimum sample size of 2700 swabs
per country was required to estimate, with reasonable preci-
sion, a prevalence similar to that previously seen in Latvia
(described above) of 3.7 per 1000 population (a 95% CI length
of <5 per 1000) [8]. Exact 95% CIs for carriage rates were cal-
culated and the effects of country, age and sex were investi-
gated in univariable analyses using Fisher’s exact test and, in
multivariable analyses, by logistic regression, using STATA soft-
ware, version 8.0 (Stata Corp., College Station, TX, USA).
Laboratory analysis
All participating countries processed throat swabs for poten-
tially toxigenic corynebacteria according to their standard
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protocols and WHO guidelines [9]. Most countries per-
formed primary screening using Hoyle’s tellurite at the local
laboratory level, and suspect colonies were sent to the coun-
try’s reference centre for further confirmation of identifica-
tion and toxigenicity.
At the end of the screening period, all C. diphtheriae,
C. ulcerans and C. pseudotuberculosis isolates identified during
the study were sent to the HPA Respiratory & Systemic
Infections Department in London, UK, for confirmation and
molecular typing (ribotyping) [10].
Results
The number of swabs examined by each country during the
screening period ranged from 968 (Italy) to 8551 (UK)
(Table 2). Generally, more throat swabs were screened from
females than males. Swabs submitted from children’s hospi-
tals were included for Estonia, Ireland, Lithuania, Latvia and
Turkey; in Greece, only children were screened.
Toxigenic C. diphtheriae strains were isolated in Latvia
and Lithuania, giving carriage rates of 0.8 per 1000 (95% CI
0.1–2.9) and 0.7 (95% CI 0.1–2.4), respectively. Carriage
rates of toxigenic strains were zero in all other countries,
although the upper 95% CI ranges varied from 0.4 per
1000 in the UK to 3.8 per 1000 in Italy. Toxigenic C. diph-
theriae carriage rates did not significantly differ by country,
age or sex.
Non-toxigenic C. diphtheriae carriage estimates ranged
from 0 (Bulgaria, Finland, Greece, Italy, Ireland) to 4.0 per
1000 in Turkey (95% CI 2.0–7.1). In the multivariable analy-
sis (including all countries), non-toxigenic C. diphtheriae car-
riage rates varied between countries (p <0.001), sex (p
0.03) and age (p 0.03); however, after excluding Turkey,
which had a cluster of seven males and two females aged
5–14 years, there was no difference by sex (p 0.14) but dif-
ferences remained between countries (p <0.001) and there
was some evidence, although not significant, of a difference
by age (p 0.05), with the highest rates in the 15–44 years age
groups.
Toxigenic cases: additional information from follow-up
questionnaires
Both Latvian cases were 14 year olds presenting with sore
throats; one (CaseLV2) also had a fever. CaseLV1 had
completed primary diphtheria vaccinations, whereas
CaseLV2 had received only two doses (in 2002 and 2003,
respectively). In Latvia, primary diphtheria vaccination is
scheduled at 3, 4 and 6 months of age, with boosters at
18 months, 7 and 14 years. The cases were unlinked and
there was no history of travel or known risk factors identi-
fied. Both patients received antibiotics. No diphtheria anti-
toxin was administered due to the mild clinical course,
although Latvia does maintain a stock. Close contacts for
both cases (two for CaseLV1, 37 for CaseLV2) were nega-
tive for C. diphtheriae. Contact tracing swabs are not
included in Table 2.
Both Lithuanian cases presented with classic respiratory
diphtheria with a pseudomembrane; neither had a history of
travel, nor a link to another confirmed case. The fatal case
was an unvaccinated 61-year-old woman (CaseLT1) who
lived in crowded conditions with inadequate nutrition. She
presented with a sore throat, pseudomembrane and fever,
swelling and oedema of the neck, and submucosal or skin
petechial haemorrhages; she also had underlying autoimmune
thyroiditis and grade 4 aortic atherosclerosis. Eighty contacts
were swabbed, two of whom were carriers of toxigenic
C. diphtheriae (CarrierLT1 and CarrierLT2); one unimmu-
nized and the other with vaccination status unknown. The
second Lithuanian case, a 15-year-old female (CaseLT2), was
immunized (completed primary immunization, last high dose
booster of diphtheria was received in 2001, next booster
would be scheduled at 15–16 years of age) with no other
known risk factors. All twenty-two close contacts for
TABLE 1. Participating laboratories and regions in each country
Country
Number of
laboratories Areas served by participating laboratories
Bulgaria 4 Sofia area
Estonia 11 Whole country
Finland 1 Helsinki area
Greece 16 Ten laboratories from the Greater Athens area, other laboratories from Central and Northern Greece, Thessalia, and Crete
Italy 3 Rome, Perugia and Palermo
Ireland 3 Dublin North, Dublin South West, and part of Cork
Latvia 2 Whole country
Lithuania 13 Kaunas, Panevezys, Alytus, Vilnius, Siauliai, Marijampole and Klaipeda counties
Turkey 12 Adana, Ankara, Diyarbakir, Erzurum, Izmir, Istanbul, Samsun and Sanliurfa provinces
UK 12 Central and South Manchester, South and West Bristol, Cambridge, West Suffolk, Leicestershire, Southampton,
East Birmingham, Newcastle, North East Derbyshire and part of South Yorkshire, Mid Essex, West Norfolk and Fenland, Bedfordshire
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CaseLT2 were negative for C. diphtheriae. Both patients
received antibiotics [CaseLT1 Cefuroxime (1 day) then imip-
enem and cilastatin sodium (½ day), CaseLT2 Cefazolin
(15 days) then Gentamicin (10 days)]. The carriers received
antibiotics (erythromycin) and diphtheria vaccine. Neither
case received diphtheria antitoxin; Lithuania does not cur-
rently hold a stock of diphtheria antitoxin because of pro-
curement difficulties [11].
Microbiological characterization of isolates
All toxigenic isolates were biotype gravis; one Latvian strain
was not available to ascertain the ribotype and the other
(CaseLV2) was Sankt-Petersburg; all four Lithuanian strains
were also Sankt-Petersburg (Table 3). Biotyping and ribo-
typing was also performed on the non-toxigenic isolates: 12
of 26 C. diphtheriae were biotype var gravis, ten of 26 were
var mitis, and two of 26 were var belfanti (two were not avail-
able for further characterization). Of the 86 ribotypes that
have been previously identified and validated from over 25
countries, Cluj was detected in Latvia and Turkey, Buzau in
the UK, Moskva in Lithuania, Romania in Estonia, and Lithua-
nia and Lyon in Turkey. A new ribotype was also identified
in Turkey, which matched closest to Constantine. The non-
toxigenic C. ulcerans isolate detected in the UK was ribotype
U4 (a different nomenclature to C. diphtheriae ribotyping)
[12]. The C. pseudotuberculosis isolate from Latvia did not
undergo ribotyping. The non-toxigenic isolates were also
tested for the presence of the diphtheria toxin gene; the
two isolated from Lithuania (ribotype: Moskva) were toxin-
gene positive, all the others were negative. These two strains
are designated as non-toxigenic toxin-gene bearing strains
(NTTBs); the gene is present but the toxin is not expressed
and are thus negative when examined in the Elek phenotypic
test [9].
TABLE 3. Isolates detected during screening period
Country Age group (years) Sex Organism Biotype Ribotype Comment
Toxigenic isolates
Latvia 5–14 M Corynebacterium diphtheriae var gravis NA CaseLV1
Latvia 5–14 F C. diphtheriae var gravis Sankt-Petersburg CaseLV2
Lithuania 45–64 F C. diphtheriae var gravis Sankt-Petersburg CaseLT1
Lithuania 25–44 M C. diphtheriae var gravis Sankt-Petersburg CarrierLT1 (Contact of CaseLT1) - not included
in the screening study as asymptomatic
Lithuania 15–24 M C. diphtheriae var gravis Sankt-Petersburg CarrierLT2 (Contact of CaseLT1) - not included
in the screening study as asymptomatic
Lithuania 15–24 F C. diphtheriae var gravis Sankt-Petersburg CaseLT2
Country Age group (years) Sex Organism Biotype Ribotype Tox PCR result
Non-toxigenic isolates
Estonia 15–24 F C. diphtheriae var belfanti Romania Negative
Latvia 0–4 M C. diphtheriae var gravis Cluj Negative
Latvia 5–14 M C. diphtheriae var mitis Cluj Negative
Latvia 15–24 M C. diphtheriae var gravis Cluj Negative
Latvia 15–24 M C. diphtheriae var gravis Cluj Negative
Latvia 45–64 M C. diphtheriae NA NA NA
Latvia 15–24 F C. diphtheriae NA NA NA
Latvia 25–44 F Corynebacterium pseudotuberculosis – – Negative
Latvia 45–64 F C. diphtheriae var gravis Erlabrunn Negative
Lithuania 15–24 M C. diphtheriae var mitis Moskva Positive; NTTB
Lithuania 25–44 M C. diphtheriae var mitis Otchakov Negative
Lithuania 25–44 F C. diphtheriae var mitis Moskva Positive; NTTB
Lithuania 25–44 F C. diphtheriae var befanti Romania Negative
Turkey 5–14 M C. diphtheriae var gravis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis St Albans Negative
Turkey 5–14 M C. diphtheriae var gravis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis Cluj Negative
Turkey 5–14 M C. diphtheriae var mitis Cluj Negative
Turkey 5–14 M C. diphtheriae var gravis Cluj Negative
Turkey 45–64 M C. diphtheriae var gravis Lyon Negative
Turkey 5–14 F C. diphtheriae var mitis Closest to
Constantine/NT
Negative
Turkey 5–14 F C. diphtheriae var gravis Cluj Negative
Turkey 45–64 F C. diphtheriae var gravis Lyon Negative
UK 25–44 M C. diphtheriae var mitis Pamiers Negative
UK 25–44 M C. diphtheriae var gravis Buzau Negative
UK 15–24 F C. diphtheriae var gravis Buzau Negative
UK 5–14 M Corynebacterium ulcerans – – Negative
NA, not available; NT, new type; NTTB, non-toxigenic toxin-gene bearing.
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Discussion
This is the first large multicentre European screening study
to be undertaken for corynebacteria, with throat swabs col-
lected and screened during a 7-month period. The differing
numbers of swabs screened by each country were influenced
by population size, consulting rates, and the different proba-
bilities of a throat swab being taken for patients presenting
with a sore throat. None of the countries with sample sizes
below 1300 detected any C. diphtheriae or C. ulcerans, sug-
gesting that there may have been insufficient power in these
studies to detect the low levels of carriage found in the
other countries.
All participating countries schedule at least five doses of
diphtheria vaccine in their vaccination programmes, although
the composition (low/high dose) and administration age var-
ies. Vaccination coverage estimates for participating countries
are high; estimates for Latvia and Lithuania over the last dec-
ade show over 90% coverage at 2 years of age for the first
three doses of DTP (diphtheria, tetanus, pertussis) vaccine,
with 98% and 95% coverage respectively reported in 2007
(http://www.who.int/immunization_monitoring/en/globalsum-
mary/timeseries/tscoveragedtp3.htm; accessed 30 July 2009).
It should be noted, however, that different methods of
assessment of coverage are employed in different countries
and, although the overall coverage may be high, pockets of
low coverage can still exist. A large-scale seroepidemiology
study conducted across seven European countries between
1995 and 1998 found that 70–75% of adults aged 50–
60 years from the UK had diphtheria antitoxin antibody
titres below the putative lower protection threshold com-
pared to approximately 35% of Finnish adults of the same
age [13]. The proportion of seronegative adults (aged
30 years and above) in Italy was approximately 28% at the
time of the study, and expected to increase. Waning immu-
nity with age coupled with proportions of unvaccinated
adults can lead to a susceptible population in older age
groups.
Training workshops were conducted just prior to this
study in Turkey and Estonia, and during the final stages of
the study in Latvia; these countries all detected C. diphtheriae
strains. In the UK, three of four non-toxigenic organisms
detected were isolated by the West Suffolk microbiology lab-
oratory, which screened the second largest number of swabs
and was the only laboratory from which a microbiologist had
recently attended a diphtheria diagnostics workshop. The
other non-toxigenic C. diphtheriae was isolated from a UK
laboratory that has a routine screening policy for corynebac-
teria. The absence of a screening policy and a lack of recent
training in other centres may have resulted in an overall
under-estimation of carriage rates nationally.
One of the major clones causing the 1990s epidemic in
the European region was a toxigenic C. diphtheriae var gravis,
ribotype Sankt-Petersburg [14]. Recent studies have shown
that this ribotype is still circulating and causing disease in
Russia, Belarus and Latvia [15,16]. This screening study
detected Sankt-Petersburg isolates from Latvia and Lithuania.
In addition, ribotyping of concurrent isolates from Latvia that
had caused diphtheria-like disease revealed the Sankt-Peters-
burg ribotype, highlighting the persistence of a highly success-
ful and virulent clone. The majority of the ribotypes seen
amongst the non-toxigenic isolates are more commonly asso-
ciated with toxigenic isolates (Cluj, Moskva, Otchakov,
Pamiers and St Albans) [10]; some have also been detected
recently from Belarus (Cluj and Moskva) [16]. These data
illustrate that persistent ribotypes are still circulating, and the
bacterial population is evolving despite high vaccine coverage,
resulting in a C. diphtheriae population that remains diverse
enough to cause both epidemic and sporadic diphtheria.
Antibiotic susceptibility testing was not undertaken on iso-
lates sent to the reference centre; these tests are usually
undertaken locally. No unusual findings were reported to
the co-ordinating centre, although this information was not
specifically requested. It may be interesting to explore this
area in a future study; however, the incidence of antibiotic
resistance amongst potentially toxigenic corynebacteria is
low [17].
The identification of two cases of diphtheria from Lithua-
nia, neither of whom had any history of travel or contact
with travellers, indicates that toxigenic C. diphtheriae is circu-
lating within Lithuania. Examination of throat swabs for diph-
theria is usually funded by the state in Lithuania but, in some
cases, transportation of swabs requires payment, which may
reduce the submission of samples to diagnostic laboratories;
this could have influenced the lack of cases reported in
recent years. A similar situation exists in Latvia. One of the
toxigenic C. diphtheriae strains detected in Lithuania would
have been missed in the absence of this screening study,
highlighting the importance of screening for these organisms.
The present study has shown that NTTBs are circulating
in Lithuania; these strains have the potential to become toxi-
genic and cause more serious illness [18,19]. The isolation of
nine non-toxigenic C. diphtheriae strains in Turkey in geo-
graphically unrelated 5–14 year olds may not be unusual; in
the UK, non-toxigenic C. diphtheriae strains are often isolated
from unlinked young adults with a preponderance of females
and may reflect consultation rates in the general population
[20]. There is currently no direct evidence of person-to-
person transmission of C. ulcerans or C. pseudotuberculosis, so
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there is less public health concern surrounding the isolation
of these zoonotic organisms, particularly non-toxigenic
strains. Although not collected as part of the present study,
the Latvian patient from whom non-toxigenic C. pseudotuber-
culosis was isolated was known to have had contact with cats
and dogs and had also consumed untreated milk products.
The results of the present study, particularly the finding of
toxigenic C. diphtheriae in Lithuania, highlight the importance
of routine screening or further ‘snapshot’ studies within the
European Region. In addition, they reinforce the need to
achieve and maintain high vaccination coverage across the
European region, as well as to maintain laboratory expertise in
this specialized area. One of four cases identified in the study
was fatal, demonstrating the severity of this disease in unim-
munized patients, and the need to remain vigilant and aware of
its possible clinical presentations. Larger studies in the future
are essential for providing improved estimates of carriage in
European countries, and for monitoring any changes in the cir-
culation of these organisms against these baseline data.
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Introduction:  This  study  aimed  to estimate  the  immunity  of  the  UK  population  to  tetanus  and  diphtheria,
including  the  potential  impact  of  new  glycoconjugatate  vaccines,  and  the  addition  of diphtheria  to  the
school  leaver  booster  in  1994.
Methods:  Residual  sera  (n =  2697)  collected  in England  in 2009/10  were  selected  from  18 age  groups  and
tested  for  tetanus  and  diphtheria  antibody.  Results  were  standardised  by  testing  a  panel  of  sera (n = 150)
to enable  comparison  with  a  previously  (1996)  published  serosurvey.  Data  were  then  standardised  to  the
UK population.
Results:  In 2009,  83%  of the  UK  population  were  protected  (≥0.1  IU/mL)  against  tetanus  compared  to
76%  in 1996  (p = 0.079),  and  75%  had  at least  basic  protection  against  diphtheria  (≥0.01  IU/mL)  in  2009
compared  to 60%  in  1996  (p < 0.001).  Higher  antibody  levels  were  observed  in those  aged  1–3 years  in
2009  compared  to 1996  for both  tetanus  and  diphtheria.  Higher  diphtheria  immunity  was  observed  in
those  aged  16–34  years  in  2009  compared  to 1996  (geometric  mean  concentration  [GMC]  0.15  IU/mL  vs.
0.03  IU/mL,  p  < 0.001).  Age  groups  with  the  largest  proportion  of susceptible  individuals  to both  tetanus
and  diphtheria  in  2009  were  <1 year  old  (>29%  susceptible),  45–69  years  (>20%  susceptible)  and  70+  years
(>32%  susceptible).  Low  immunity  was  observed  in  those  aged 10–11 years  (>19%  susceptible),  between
the  scheduled  preschool  and  school  leaver  booster  administration.
Discussion:  The  current  schedule  appears  to induce  protective  levels;  increases  in  the  proportions  pro-
tected/GMCs  were  observed  for  the  ages  receiving  vaccinations  according  to UK  policy.  Glycoconjugate
vaccines  appear  to have  increased  immunity,  in  particular  for diphtheria,  in preschool  age  groups.  Diph-
theria immunity  in  teenagers  and  young  adults  has  increased  as  a  result  of the addition  of  diphtheria
to  the  school  leaver  booster.  However,  currently  older  adults  remain  susceptible,  without  any  further
isatioopportunities  for  immun
. Introduction
The current UK immunisation policy recommends ﬁve doses of
etanus and diphtheria toxoid; an accelerated primary course at
ges 2, 3 and 4 months (given as DTaP/IPV/Hib vaccine), followed
y booster doses at age 3 years 4 months to 5 years (pre-school
ooster, DTaP/IPV vaccine) and between 13 and 18 years of age
school leaver booster, Td/IPV vaccine) [1].  Vaccination coverage
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of primary immunisations evaluated at one and two years has
remained at around 91–95% in the UK since the beginning of the
1990s [2].  Assessment of the coverage of the preschool booster
started in 1999/2000 and remained stable, between 78% and 82%,
during the following decade, before increasing to 86% in 2009/2010.
Vaccination coverage of the school leaver booster is unclear (data
are collected only as number of doses given). For adults who have
completed the ﬁve dose schedule there are no scheduled boosters
for tetanus and diphtheria. Prior to 2002 a tetanus-containing vac-
cine was  recommended following presentation of a tetanus prone
wound if the last tetanus vaccine was  received more than ten years
previously, although a survey of accident and emergency depart-
ments in 2004 found that this practice was  still continuing contrary
to Department of Health guidance [3]. Currently vaccination should
occur following presentation of a tetanus prone injury to health
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ervices if the patient is not already fully immunised [1].  Opportu-
ities for additional vaccination may  occur during a travel health
onsultation for example for those who are going to live or work
n diphtheria epidemic or endemic areas (the same UK policy is
lso followed by the military), or for occupational reasons (e.g. if
orking in a microbiology laboratory) [1].  A recent survey of vac-
ination policies across 29 EU/EEA countries reported that tetanus
nd diphtheria vaccines are recommended to all adults in 22 and
1 countries respectively although only six countries have data on
overage of tetanus adult boosters, and ﬁve on diphtheria cover-
ge [4].  The UK is one of the few European countries where routine
dult booster doses are not recommended; other countries may
herefore ﬁnd the UK experience of interest in relation to their own
olicy.
Clinical cases of either disease are now rare in the UK. Tetanus
as occurred mainly in unimmunised older adults [5] with 17/27
ases in the last ﬁve years being aged >45 years. A cluster of 25
etanus cases was  reported in 2003/04 among young adult inject-
ng drug users [6] and sporadic cases are occasionally reported
n this risk group (three cases in the last ﬁve years). Toxigenic
orynebacterium diphtheriae infection reported in the UK is usually
cquired overseas in countries where the disease is still endemic
nd is transmitted from person to person via respiratory droplets
nd close contact [7].  In contrast, toxigenic Corynebacterium ulcer-
ns is a zoonotic infection, and although traditionally associated
ith exposure to cattle, raw milk or dairy products, in recent years
as been associated with contact with companion animals [7–10].
ive classic respiratory diphtheria cases were reported in the UK in
he last decade, four of whom were aged >45 years.
Since 1992, glycoconjugate vaccines containing tetanus toxoid
TT) or CRM197 (a non toxigenic natural variant of diphtheria toxin)
arrier proteins have been introduced into routine and catch-up
mmunisation programmes in the UK (Appendix A). In clinical tri-
ls administration of TT or CRM197 glycoconjugate vaccines has
ncreased immunity to tetanus or diphtheria respectively [11–13].
n the Netherlands, increased tetanus antitoxin antibody levels
ave been observed in some age groups following the introduction
nto the national immunisation programme and catch-up campaign
f meningococcal serogroup C glycoconjugate (MCC) vaccine, using
T as the carrier protein [14,15].
In 1994, low dose diphtheria toxoid (d) was added to the school
eaving booster in the UK (which previously only contained tetanus
nd polio vaccine). This action was prompted by the epidemics of
iphtheria in eastern Europe and the concern about waning of vac-
ine induced immunity of adults in the UK. Gaps in immunity have
reviously been identiﬁed in older adults in the UK; in 1996 only
3% and 29% of those aged >60 years were protected against tetanus
nd diphtheria respectively [16]. Other European countries have
lso identiﬁed lower immunity to tetanus and diphtheria in older
dults [17–19].
Given these programme changes since the previous tetanus and
iphtheria seroepidemiologic study undertaken in England and
ales in 1996 [16], there is uncertainty about the current immu-
ity proﬁle. Consequently, this study was undertaken to estimate
he immunity of the UK population to tetanus and diphtheria, and
nterpret the ﬁndings in order to inform vaccination policy.
. Methods
.1. Serum samplesSerum samples representing the entire ranges of age and most
eographical regions of the population of England were selected
rom the Health Protection Agency (HPA) seroepidemiology col-
ection. Brieﬂy, participating NHS and HPA laboratories submit30 (2012) 7111– 7117
residual sera from routine diagnostic testing to the HPA Seroepi-
demiology Unit. All samples are anonymised, a unique identity
number is assigned and details of age, gender and geographical
location are collated on a database. Approximately 150 samples
were randomly selected from each of 18 age groups (total n = 2697),
in order to allow the proportions protected within each age group to
be estimated with 95% conﬁdence intervals (CIs) to within ±8%. The
majority of samples with valid results had a sample date between
January and December 2009 (98%, 2640/2688 for tetanus, 98%,
2641/2689 for diphtheria), with the remainder from January to
February 2010.
2.2. Standardisation panel
In addition, a panel of 150 sera (50 selected randomly from each
of those which had full, basic protection and susceptible results)
from the original 1996 samples were tested using the same mul-
tiplexed ﬂuorescent bead assay as the main 2009 serum survey.
These results were then used to standardise the 2009 data to enable
comparisons with 1996 results. For the 1996 sera, antibody to TT
was originally measured by an in house, indirect enzyme linked
immunosorbent assay (ELISA) and antibody to diphtheria toxin was
measured by a time resolved ﬂuorimetric immunoassay system
commonly known as DELFIA (dissociation enhanced lanthanide ﬂu-
orescence immunoassay) [16].
2.3. Serology
All serum samples were assayed in the Vaccine Evaluation Unit
(VEU) at the HPA Public Health Laboratory, Manchester, using a
multiplexed ﬂuorescent bead assay to quantify IgG antibodies to
tetanus and diphtheria toxoid, based upon previously published
methodology [20]. Similar methods have also been used in the VEU
to quantify antibodies to meningococcal serogroups A, C, W135 and
Y [21] and multiple pneumococcal serotypes [22].
2.4. Data analysis
Standardisation of 2009 data with 1996 data via the selected
1996 panel of 150 sera was conducted using methodology previ-
ously described [23]. Panel results from 1996 were plotted against
those obtained in 2009 to derive standardisation equations, which
were applied to the 2009 quantitative results.
Geometric mean concentrations (GMC) were calculated for each
age group for 1996 and 2009, apart from <1 year olds in 1996
as immunity in this age group was  not assessed at that time. In
addition, GMCs were calculated for males and females separately.
Changes in serological proﬁles by age were interpreted with the
aid of 95% CIs on the proportions. For comparison of GMCs for
males and females for each age group the Bonferroni correction
for multiple comparisons was  used, so that only signiﬁcant differ-
ences where p < 0.0028 were accepted (0.05/18, since there were
18 age groups).
For tetanus, antitoxin levels <0.1 IU/mL denote susceptibil-
ity, antitoxin levels of 0.1–1.0 IU/mL are protective and levels
>1.0 IU/mL are considered as giving long term protection as
per the previous 1996 study [16,24]. For diphtheria, anti-
toxin levels <0.01 IU/mL denote susceptibility, antitoxin levels
0.01–0.099 IU/mL provide basic protection, and antitoxin levels
≥0.1 IU/mL are fully protective, as per the international standard
[25].For both the 2009 data and the previous 1996 results, the pro-
portions protected were standardised by age and sex to the 2009
and 1996 UK populations respectively [26]. Although samples were
only collected in England, the vaccination schedule applies to the
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.5. Ethical approval
National Research Ethics Service approval for the seroepidemio-
ogical surveillance of the National Immunisation programme of
ngland and Wales, REC number 05/Q0505/45 was  granted by the
oint University College London/University College London Hospi-
al Committees on the Ethics of Human Research.
. Results
.1. StandardisationThe 2009 panel results regressed well against the 1996 reference
esults (R2 was 0.92 for tetanus, 0.78 for diphtheria). The stan-
ardisation line was linear for tetanus (Fig. 1) and quadratic for
Fig. 2. Comparison of diphtheria 1996 sample panel results for 19se indirect ELISA) and 2009 (multiplexed ﬂuorescent bead assay).
diphtheria (Fig. 2). The effect of standardisation of the 2009 panel
results to the 1996 unitage was  the same qualitatively as changing
the categories described above to <0.088 IU/mL (susceptibility) and
>0.99 IU/mL for tetanus (long term protection), and <0.021 IU/mL
(susceptibility) and >0.098 IU/mL (full protection) for diphtheria,
for the 2009 data. The horizontal dashed lines on Figs. 1 and 2 indi-
cate the cut off values for 2009 data standardised against the 1996
data.
3.2. Tetanus results
In 2009, 83% of the UK population was protected (≥0.1 IU/mL)
against tetanus (vs. 76% in 1996, p = 0.079), and 44% had long term
protection (>1 IU/mL) (vs. to 39% in 1996, p = 0.277). In 2009, the
proportion with long term protection increased throughout early
childhood to 57% at aged 5 years (Fig. 3). The proportion with long
term protection then declined from age 5 to 10–11 years before a
second increase was observed for teenagers, peaking at age 25–34
96 (DELFIA) and 2009 (multiplexed ﬂuorescent bead assay).
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ears (63%), then declining with age. The age group speciﬁc pat-
ern of tetanus immunity in 2009 resembled that observed in 1996
Fig. 4), however, higher antibody levels were observed in the 1–3
GMC 0.49 IU/mL vs. 0.20 IU/mL, p < 0.001) and 35–69 years age
roups in 2009 compared to 1996, and lower antibody levels were
bserved in the 12–19 year olds in 2009 compared to 1996.
The largest proportions susceptible in 2009 were observed in
he age groups 70+ years (36%), and <1 year (29%). Similarly, the
owest proportions with long term protection were in those aged
1 year (15%), 10–11 years (17%) and 70+ years (23%). Those with
he highest proportions susceptible in 1996 were aged 45+ years
>43%). In 1996, the lowest proportions with long term protection
ere aged 1–3 years (<16%), 10–11 years (19%), and 70+ years (15%).
Overall, after adjusting for age group, the anti-TT IgG GMC  for
ales was 26% higher than for females (95% CI 12–42%, p < 0.001) in
009, compared to 49% higher in 1996 (95% CI 34–65%, p < 0.001).
here was some interaction between age group and gender for
etanus in both 2009 (p = 0.0015, test for interaction) and 1996
p = 0.0219, test for interaction). In 2009, the anti-TT IgG GMC
as signiﬁcantly higher for males in the 70+ years age group
p = 0.0011), and almost signiﬁcantly higher for males in the 45–69
ears age group (p = 0.0029), when the Bonferroni correction was
pplied. In 1996, the GMC  for males was almost signiﬁcantly higher
Fig. 4. Tetanus GMCs by age group, 1996 and 2009 resuor bars indicate 95% conﬁdence intervals for long-term protection.
for those aged 16–19 years (p = 0.0029), and signiﬁcantly higher for
adults aged 25–44 years (p < 0.001).
3.3. Diphtheria results
In 2009, 75% of the UK population had at least basic
(≥0.01 IU/mL) diphtheria protection (vs. 60% in 1996, p < 0.001), and
41% had full (≥0.1 IU/mL) diphtheria immunity (vs. 16% in 1996,
p < 0.001). The proportion fully protected in 2009 remained stable
(64–71%) between ages 1 and 9 years, declining afterwards to a
low of 44% fully protected amongst those aged 10–11 years (Fig. 5).
The proportion fully protected increased again for teenagers and
young adults, before declining in older adults. In contrast, in 1996
immunity declined from age 6 years onwards (Fig. 6).
Higher diphtheria antibody levels were observed in those
aged 1–3 years in 2009 compared to 1996 (GMC 0.20 IU/mL vs.
0.03 IU/mL respectively, p < 0.001). In 2009 the largest proportions
susceptible were observed in the age groups <1 year (37%), 35–44
years (27%), 45–69 years (41%) and 70+ years (33%). In 1996 the pro-
portions susceptible in these corresponding age groups in adults
were larger (ranging from 47 to 70%). In addition, in 1996, 37% of
those aged 25–34 years were susceptible. The lowest proportions
fully protected in 2009 were those aged 35+ years; the proportion
lts. Error bars indicate 95% conﬁdence intervals.
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ully protected ranged from 24 to 31% in these older age groups (vs.
10% in 1996).
Overall, after adjusting for age group, the anti-diphtheria GMC
or males was 26% higher than for females (95% CI 9–46%, p = 0.001),
ompared to 16% higher in 1996 (95% CI 3–30%, p = 0.011). There
as no signiﬁcant interaction between gender and age group in
009 (p = 0.8200, test for interaction), unlike in 1996 (p = 0.01, test
or interaction). The anti-diphtheria IgG GMC  for males and females
as not signiﬁcantly different across any age groups in 2009 when
he Bonferroni correction was applied. In 1996, male teenagers
6–19 years had a higher GMC  than females (p < 0.001).
. Discussion
This is the second large scale sero-survey undertaken in the UK
o assess immunity of the general population to tetanus and diph-
heria. The key ﬁndings of this study include the increase between
996 and 2009 in overall diphtheria population immunity, the iden-
iﬁcation of higher tetanus and diphtheria antibody levels in males,
 decrease in tetanus antibody levels in teenagers and young adults
n 2009 compared to 1996, an increase in antibody levels between
996 and 2009 for tetanus and diphtheria in preschool age groups
nd diphtheria in teenagers and young adults, as well as gaps in
mmunity to both infections in the youngest and oldest age groups
nd those aged 10–11 years.
Fig. 6. Diphtheria GMCs by age group, 1996 and 2009 re. Error bars indicate 95% conﬁdence intervals for full protection.
There are several potential limitations to the study. Firstly,
in contrast to diphtheria, for tetanus established criteria for
interpreting antitoxin levels are lacking, however, using the same
criteria as the previous serosurvey has enabled comparisons. Sec-
ondly, different assays were used in 1996 and 2009, but the
results standardised well and this methodology has previously
been applied when comparing results from different laboratories
[27–29]. Thirdly, this study used residual sera, which has been col-
lected typically as a result of patients presenting with symptoms
requiring diagnostic testing. However, serum from patients known
to be immunocompromised is excluded from the archive collection,
and previous studies using this sampling base have shown it to be
representative of the wider population [30]. Routine vaccination
coverage has been relatively stable so any changes in immunity
over time due to changes in coverage would be too slight to be
detected in these data.
Diphtheria antibody levels for the UK population are now
above the >70% level generally considered protective [31,32]. This
increase in immunity can largely be attributed to the addition
of diphtheria to the school leaver booster vaccine, as well as
the introduction of glycoconjugate vaccines (in particular PCV).
Improvements in opportunistic vaccination in older individuals
following the introduction of routine immunisation in the 1940s
(reﬂected in the higher immunity in the 2009 cohorts aged 45+
years) may  also have contributed.
sults. Error bars indicate 95% conﬁdence intervals.
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Higher tetanus immunity in males has previously been
ttributed to males presenting more commonly with tetanus prone
njuries and receiving tetanus toxoid for this reason, as well as
ctive immunisation of males taking part in military service, until
onscription ended in the UK in 1960. The lower tetanus immunity
n teenagers and young adults in 2009 compared to 1996 may  be
ue to the change in the tetanus toxoid content of the school leaver
ooster which occurred in 2004. The Td/IPV vaccine currently used
n the UK contains half the international units of tetanus toxoid of
he Td vaccine which was previously in use. Over time, this can be
xpected to also reduce immunity in older adults as teenagers and
oung adults with lower immunity induced by the current school
eaver booster move into the older age groups. The reason for over-
ll higher diphtheria immunity in males is not known but has been
eported previously [33,34].
Both the 1996 and 2009 cohorts aged 1–3 years would have
eceived the Hib component of their primary immunisations conju-
ated with a TT carrier protein which does not explain the increase
n antibody between the two surveys. The 2009 cohort would also
ave received MCC  (TT or CRM197 conjugate) at 3, 4 and 13 months
hich may  explain the observed higher tetanus immunity in the
–3 year olds in 2009 compared to 1996 (as also observed in the
etherlands [14,15]). The higher diphtheria immunity in those
ged 1–3 years in 2009 compared to 1996 is likely due to the intro-
uction of PCV (containing CRM197) in 2006 which only the 2009
ohort for these ages would have received (at 2, 4 and 13 months),
n addition to MCC  vaccine as described above.
The increase in diphtheria immunity in teenagers and young
dults is mainly due to the addition of low dose diphtheria toxin to
he school leaver booster from 1994. All those in the 16–24 years
ge groups in 2009 and approximately half of those in the 25–34
ears age group would have been scheduled to receive this vaccine.
eenagers and young adults in the 2009 cohort up to age 31 years
ould also have received MCC  vaccine (CRM197 or TT conjugate)
rom late 1999 to 2002 in catch-up campaigns [35]. However, the
mpact of this glycoconjugate vaccine on diphtheria immunity at
his age appears negligible, as evidenced by the low immunity in
hose aged 10–11 and 12–15 years who would also have received
CC  vaccine in 2000.
For both diphtheria and tetanus, the interval between the
reschool booster and school leaver booster appears to leave those
ged 10–11 years exposed. This relates particularly to a drop in full
rotection; levels of basic protection are less markedly affected.
abies aged <1 year include those midway through or about to start
heir primary immunisations which explains the lower immunity in
his age group. As national tetanus immunisation was introduced
routinely for children between 1956 and 1961, initially in some
reas as a monovalent vaccine and nationally in 1961 as part of
TP vaccine) and cumulative coverage improved, a greater propor-
ion of adults aged 35–69 years in the 2009 cohort received vaccine
han the corresponding age groups in 1996. Similar improvements
ere observed for diphtheria and increasingly, cohorts moving into
he adult age groups will have received diphtheria in the school
eaver booster. However, adults currently in these older age groups
emain exposed.
. Conclusions
The current tetanus and diphtheria vaccine schedule appears
o protect well; increases in the proportions protected/GMCs were
bserved for the ages scheduled to receive vaccinations according
o the UK schedule for both tetanus and diphtheria. This is sup-
orted by surveillance data which shows that few cases of either
isease are reported each year.30 (2012) 7111– 7117
As  observed in previous studies, males generally have higher
immunity than females, particularly older adults in the case of
tetanus immunity, relating to the receipt of vaccine for tetanus-
prone injuries and possible vaccination during military service
for those aged 70+ years. The unintentional added beneﬁt of
glycoconjugate vaccines is observed in the higher diphtheria
immunity in preschool ages in 2009 compared to 1996. Higher
antibody levels are also observed for tetanus in these age groups,
though this is less pronounced. A clear impact of the change
to including low dose diphtheria toxoid in the school leaving
booster from 1994 was observed on diphtheria immunity in
teenagers and young adults; this should continue to improve
immunity in adults. The pattern of immunity for diphtheria
now more closely resembles that of tetanus which, with polio,
has been part of the school leaver booster vaccine for several
decades.
The age groups with lowest immunity are babies <1 year, and,
as also identiﬁed in 1996, children approaching the age for admin-
istration of the school leaver booster for whom immunity from
the primary series is waning. In addition, adults too old to have
received routine immunisations have low antibody levels, though
there have been some improvements since 1996. Those aged <1
year and 10–11 years will have opportunities for further rou-
tine tetanus and diphtheria immunisation. In contrast, although
immunity in adults should gradually improve as those moving into
older age groups will increasingly have received routine immu-
nisations, including the school leaver booster, currently there is
a gap in immunity in older adults which is not addressed by the
present UK schedule. Given that immunity is known to wane with
time, further boosting in adulthood may  be of value for older
adults. However, although surveillance data shows that the sever-
est infections are in older, unimmunised adults, the number of
cases of tetanus and diphtheria reported in the UK remains very
small.
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ppendix A. Glycoconjugate vaccine additions to the UK
mmunisation schedule since 1996
Vaccine Glycoconjugate Date introduced Age groups of 2009 cohort
offered glycoconjugate
Meningococcal serogroup C (MCC)
glycoconjugate vaccine
CRM197 and TT conjugate
vaccines have been available
although approximately 80% of
MCC  vaccine used was
conjugated with the CRM197
carrier protein
Autumn 1999 0–31 years
Pneumococcal glycoconjugate
vaccine (PCV) to protect against
seven serotypes of Streptococcus
pneumoniae
CRM197 September 2006 0–5 years
Hib/MCC booster doses for
Haemophlius inﬂuenzae type b
and Neisseria meningitidis
serogroup C
TT September 2006 1–4 years
Hib  glycoconjugate catch-up
campaigns
TT 2003 and 2007–2009 4–10 years
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ABSTRACT
Objectives To assess childhood vaccination coverage
at ﬁrst, second and ﬁfth birthdays by ethnicity in London
between 2006/2007 and 2010/2011 and identify factors
relating to lower coverage.
Design Data concerning receipt of diphtheria-
containing vaccines were extracted from child health
information systems (CHISs) and sent to the Health
Protection Agency.
Setting Nine London Primary Care Trusts (PCTs).
Participants Records for 315 381 children born April
2001–March 2010.
Main outcome measures Receipt of a full primary
course of diphtheria-containing vaccines at ﬁrst and
second birthdays, and a primary course and preschool
booster at ﬁfth birthday.
Results Consistently good vaccine coverage of the
primary course (>88% at ﬁrst birthday, >89% at second
birthday) was achieved across the ﬁve largest ethnic
groups. Coverage of the preschool booster at ﬁfth
birthday was >65% across the ﬁve largest ethnic
groups. Lowest coverage was observed in smaller ethnic
groups. Deprivation was not a strong indicator of
coverage overall, and for most ethnic groups there was
no relationship between deprivation and coverage.
Coverage was signiﬁcantly lower in children not assigned
to a general practitioner practice in the CHIS.
Conclusions Smaller, less well-established ethnic
groups within a PCT may require speciﬁc targeting to
ensure children are fully immunised and to improve
record keeping. Unregistered children need particular
attention and may be missed by current scheduling
processes in London. In order to monitor the impact of
the current National Health Service (NHS) reorganisation
on inequalities in access to healthcare data on country
of birth, in addition to ethnicity, should be available for
analysis.
INTRODUCTION
The UK childhood immunisation programme cur-
rently includes a 5-in-1 vaccine that protects
against diphtheria, tetanus, pertussis, polio and
Haemophilus inﬂuenzae type b (DTaP/IPV/Hib)
offered at 2, 3 and 4 months of age (primary course)
and a preschool booster between 3 years 3 months
and 5 years of age (dTaP/IPV or DTaP/IPV).1
Diphtheria-containing vaccines have been routine for
decades and are uncontroversial, thus providing an
indication of primary care access in children.
Child health information systems (CHISs) are
managed by child health departments and one of
their many functions is to schedule and record the
immunisations given to children,2 although this
varies locally3; in London, general practitioners
(GPs) are often responsible for scheduling. Since
2006, the majority of Primary Care Trusts (PCTs,
statutory bodies responsible for ensuring the avail-
ability of health services in a geographical area) in
London have transferred to RiO CHIS. Vaccination
coverage across the UK is currently monitored by
the Cover of Vaccination Evaluated Rapidly
(COVER) programme.4 Coverage is not uniform
throughout the country; in particular coverage in
London is lower,5 6 but recent increases, correlated
with the introduction of National Health Service
(NHS) London’s Immunisation Improvement
Programme, have reduced the gap between London
and the rest of England.7
In 2010, 34% of people living in London were
estimated to have been born abroad and 56% of
children born in London were born to non-UK
What is already known on this topic
▸ The UK has a universal childhood immunisation
programme with overall high vaccine coverage
rates; these are lower in London where there is
also an increasingly ethnically diverse
population.
▸ Previous studies have identiﬁed differences in
vaccination coverage by ethnicity, but the
capacity for monitoring this using data
routinely collected within London has not been
assessed.
▸ Reducing inequalities in childhood
immunisation has been identiﬁed as a priority
by the National Institute for Clinical Excellence.
What this study adds
▸ In general, the largest ethnic groups have good
vaccination coverage, but newer, smaller
communities within a PCT may need particular
attention.
▸ Improvements in record keeping and transfer of
information are associated with improvements
in reported vaccination coverage.
▸ Children not registered with a general
practitioner, or without up-to-date GP practice
details in the child health information system,
have lower recorded vaccination coverage and
are at risk of missing out on key primary care
initiatives.
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born mothers.8 9 London has an increasingly ethnically diverse
population.10 Reducing differences in immunisation uptake
among children is a priority identiﬁed by the National Institute
for Clinical Excellence.11 This study explored the capacity for
routine CHIS data in London to monitor vaccination coverage
by ethnicity.
METHODS
Nine London PCTs, who responded to a request at a London
Immunisation Network (a group of London immunisation coor-
dinators) meeting and via email, participated (ﬁgure 1).
Participation was voluntary. The study PCTs represented a range
of London PCTs in terms of vaccination coverage (coming from
all four quartiles of 2010/2011 London PCT COVER data for
diphtheria-containing vaccines at ﬁrst, second and ﬁfth
birthdays).
A script written for the RiO CHIS was used to extract the fol-
lowing ﬁelds for each PCT’s responsible population (children
registered with a GP in the PCT or unregistered children living
within the PCT’s geographical boundary): month and year of
birth, date of receipt of each diphtheria-containing vaccine (see
appendix 1—web only), gender, ethnic group, nationality, post-
code and GP practice code. Where the child’s record was linked
to a maternal record, basic demographic data were extracted
from the mother’s record.
In total records for 315 381 children born April 2001–March
2010 were extracted. There were 185 534 children born April
2005–March 2010 (ﬁrst birthday cohort), 180 477 born April
2004–March 2009 (second birthday cohort) and 164 000 born
April 2001–March 2006 (ﬁfth birthday cohort).
To maintain anonymity, postcodes were replaced by lower
super output area codes12 prior to sending to the Health
Protection Agency. Deprivation scores for each area were
assigned using the Income Deprivation Affecting Children Index
2010.13 The following deprivation quintiles were created: 0–
0.130 (least deprived), 0.131–0.250, 0.251–0.340, 0.341–0.440
and 0.441–0.960 (most deprived).
Vaccination status was computed for each child at each age
evaluated; either fully immunised or not fully immunised
(including completely unimmunised and partially immunised).
Only month and year of birth were extracted, therefore a child
born in April 2005 was considered to have received a dose
within 1 year (by ‘ﬁrst birthday’) if the vaccine was received
between April 2005 and April 2006 inclusive. Fully immunised
status was assigned at ﬁrst and second birthdays if at least three
primary immunisations (vaccines containing high-dose diph-
theria; ‘D’) were recorded within 1 and 2 years, respectively.
Fully immunised was assigned at ﬁfth birthday if at least four
high-dose diphtheria-containing vaccines were recorded, with
the fourth (or subsequent) dose received between ages 3 and
5 years. The fourth (or subsequent) dose could also be the
low-dose diphtheria dTaP/IPV vaccine. This coding is more con-
servative than some COVER extractions, which may only
require the ﬁnal vaccine (‘Part 3’ for a primary course or pre-
school booster within the appropriate age range for ﬁfth birth-
day assessment) to be recorded for a child to be considered fully
immunised.
Individual RiO ethnicity categories were used for larger
groupings and combined into broader categories for those with
small numbers of children (see appendix 2—web only).
Statistical methods
Analyses were conducted in STATA SE/V.12.0 statistical software.
Crude coverage proportions with exact 95% CIs were calculated
for each variable. Multivariable logistic regression was used to
determine whether ethnicity differences were due to other
Figure 1 Participating Primary Care Trusts, London, including the total number of records extracted from each trust for analysis (number of
children born April 2001–March 2010).
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available data on gender, deprivation, PCTand year of birth. We
also tested for interactions in the model between ethnicity and
PCTand ethnicity and deprivation.
RESULTS
Overall, vaccination coverage was 87% at ﬁrst birthday, 87% at
second birthday and 60% at ﬁfth birthday. An increase in cover-
age over the study period was seen for all cohorts by year of
birth. In general, individual PCT coverage in this study was
similar or lower than COVER data for the same period due to
more conservative coding; the coverage in this data set also
reﬂects low coverage in London.
Nationality was available for <2.5% of all children. Ethnicity
was recorded for 66% (121 657) of children at ﬁrst birthday,
64% (115 941) at second birthday and 56% (91 877) at ﬁfth
birthday. To examine representativeness of recorded ethnicity
data, known ethnicity data for children born 2005–2009 in each
PCT were compared with Greater London Authority ethnicity
projections for children aged 0–4 years in 2009.14 The propor-
tion in black and minority ethnic (BME) groups in the study
data set was within 5% of the Greater London Authority pro-
jected BME proportion for all PCTs except one, which had a
higher proportion of BME children in the data set (63%) than
projected (49%). Overall, the study PCTs had a similar propor-
tion of BME children (51%) to the projection for Greater
London (53%).
Consistently good coverage of the primary course (>88% at
ﬁrst birthday, >89% at second birthday) was achieved across the
ﬁve largest ethnic groups. Coverage of the preschool booster at
ﬁfth birthday was >65% across the ﬁve largest ethnic groups
(ﬁgure 2). Although some of the smallest ethnic groups had
good coverage, the lowest coverage in each cohort was among
the smaller ethnic groups and those with unknown ethnicity.
Adjusting for gender, deprivation, PCTand year of birth did not
substantially change the ethnicity patterns in coverage (model
details in appendix 3—web only). There was evidence of inter-
action between PCT and child ethnicity for all three age cohorts
(p<0.001); this was most pronounced for white-Polish popula-
tions and related to the size of the white-Polish population
within a PCT. Where white-Polish populations were larger (410
and 383 children), coverage at ﬁrst birthday in this group (90%
and 88%, respectively) was closer to the average for the PCT.
Two PCTs with smaller white-Polish populations (77 and 140
children; all other PCTs had <50 children in this group) had
signiﬁcantly lower coverage at ﬁrst birthday in their white-Polish
populations (67% and 69%, respectively) than the average for
their PCT. Similar interactions relating to the white-Polish popu-
lation size were observed at second and ﬁfth birthdays.
Gender was recorded for >99.9% of children overall. There
was no difference in coverage between males and females at ﬁrst
birthday, although coverage was fractionally higher (<1%) for
females at second and ﬁfth birthdays (p<0.01).
Deprivation scores were assigned to 98% (309 552) of
records overall. Coverage across quintiles ranged between 86%
and 88% at ﬁrst birthday, between 87% and 88% at second
birthday and between 59% and 63% at ﬁfth birthday, lower
coverage in general relating to higher deprivation. Interaction
between ethnicity and deprivation was signiﬁcant in each cohort
(p<0.001). Across each age cohort, a trend of reducing cover-
age by increasing deprivation was seen only for white-British
and Not known groups. The opposite trend was observed for
Indian and white-Other/Mixed/Unspeciﬁed at ﬁrst and second
birthdays only. Trends were not seen for other ethnicities.
At the time of data extraction 14 022 (4.4%) children in the
data set were not assigned to a GP (ie, did not have a GP prac-
tice code recorded because they were unregistered, moving
between practices or records were not current). The proportion
of children not assigned to a GP in each PCTat the time of data
extraction ranged from 1.1% to 7.0%. Vaccination coverage was
52% versus 88% in children without a GP practice code versus
those with a GP practice code at ﬁrst birthday, 55% versus 89%
at second birthday and 21% versus 63% at ﬁfth birthday.
Signiﬁcant differences in coverage between children with and
without a GP practice code assigned were seen across all PCTs
in all three cohorts. Overall, 2.2% of white-British children
were not assigned to a GP practice compared with 4.2% of
non-white-British and 5.8% of children without ethnicity
recorded.
Maternal records
Overall 42% (131 077) of records in the data set were linked to
a maternal record. This varied considerably by age and PCT. At
ﬁrst birthday, 112 306 (61%) child records were linked to a
maternal record, 87 998 (49%) at second birthday and 32 395
(20%) at ﬁfth birthday. At ﬁrst birthday, linkage to a maternal
record varied across PCTs from 16% to 87%. However, in all
PCTs the proportion of children linked to a maternal record
improved over time, sometimes dramatically (eg, in one PCT
from 2% (children born 2005/2006) to 61% (children born
2009/2010)). Overall, vaccination coverage at ﬁrst birthday was
higher for linked (90.8%) children versus unlinked (81.3%)
children (p<0.001) (further subanalyses of maternal data for
linked children were not conducted as they were not considered
representative). As linkage improved over time for each PCT,
the difference in coverage between linked and unlinked children
became more pronounced. Of those children in the data set
with ethnicity recorded, 51% were linked to a maternal record
compared with 27% of children without ethnicity recorded.
DISCUSSION
Main ﬁndings
The largest ethnic groups in each cohort had good vaccination
coverage. Ethnic groups with lowest coverage were generally
smaller and those with unknown ethnicity. Interactions between
PCT and ethnicity were observed for a minority of ethnic
groups, for white-Polish populations (for whom migration to
the UK has increased since Poland joined the European Union
in 2004) this related to the size of the population in a PCT.
Differences in coverage between ethnic groups were not
explained by adjustment for gender, deprivation, PCTor year of
birth. Deprivation was not a strong indicator of coverage
overall, and for most ethnic groups there was no relationship
between deprivation and coverage. Data completeness was a key
factor in determining the vaccination coverage recorded (as evi-
denced by the low coverage in children with unknown ethnicity
and those not linked to a maternal record). Children not
assigned to a GP in the CHIS had lower vaccination coverage
than those with a GP practice code recorded. Routinely col-
lected data from the RiO CHIS can be used for basic analysis of
vaccination coverage by ethnicity, with adjustment for certain
factors.
Strengths and limitations of study
This is the ﬁrst study to explore the capacity for data routinely
collected within the RiO system to provide vaccination coverage
data by ethnicity for London and includes smaller ethnic groups
such as Somali and white-Polish. However, some ethnicities, for
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example, Romanian, are not captured individually. In other pub-
lished analyses, additional factors have been studied such as
family size, maternal smoking, maternal education and lone par-
enthood,15 16 but this study was restricted to CHIS ﬁelds.
Deprivation in this study was assigned based on postcode, relat-
ing deprivation to a geographical area.
Although vaccination is unlikely to be recorded incorrectly,
no record of vaccination could reﬂect failure to immunise or
failure to record. This is more likely where immunisations were
given in other geographical areas and would lead to lower mea-
sured coverage in those who move into the PCT, particularly at
an older age. This may therefore explain the lower coverage in
population groups more likely to have moved since birth,17
including recent migrants to the UK. Failure to record vaccin-
ation is also often associated with missing demographic data. It
is difﬁcult to disentangle true improvements in coverage from
Figure 2 Vaccination coverage by
ethnicity for children at ﬁrst birthday
(born April 2005–March 2010), second
birthday (born April 2004–March
2009) and ﬁfth birthday (born April
2001–March 2006), with 95% CIs.
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improvements in data quality. Data quality issues relating to
information migrated from legacy systems have previously been
identiﬁed.18 The lower vaccination coverage observed among
children without a link to a maternal record may result from
data relating to the mother and immunisations either not being
added or transferred across to the current PCT records for chil-
dren born outside the PCT (either in another PCT or abroad).
Other information such as a child’s ethnicity may also not have
been transferred across. Obtaining a vaccination history from
children arriving from abroad can be problematic; even if the
vaccines received abroad are known, they may not be coded
within the CHIS and so may be omitted from the record.
Children who are not linked to a maternal record may also be
those who are living with relatives, possibly moving frequently,
or are looked-after children. More information such as country/
area of birth/previous residence would aid understanding.
Comparison with other studies
Improvements in vaccination coverage over time, differences in
coverage between PCTs and lower coverage of the preschool
booster at ﬁfth birthday compared with coverage of primary
vaccines at ﬁrst and second birthdays were expected.5
Previously, the Millennium Cohort Study identiﬁed differences
in coverage by ethnicity.16 A study in Manchester found that
white infants were least likely to be vaccinated with primary
vaccines, and that for white infants (as found here) lower cover-
age was signiﬁcantly associated with living in a deprived area.15
For black infants or black British infants and Pakistanis, there
was no signiﬁcant association between deprivation and
immunisation.15
Conclusions and policy implications
We have shown that monitoring coverage by ethnicity is possible
and could be used to identify groups with low recorded immun-
isation coverage. Such ﬁndings should be explored to determine
whether there is a genuine need to improve coverage or a need
to improve data quality. London’s population is highly mobile
making it challenging to maintain accurate health records as
children move across PCT boundaries and change GP, particu-
larly in the ﬁrst year of life when the primary vaccine course is
offered. The absence of data could indicate less contact with the
health system, both in terms of opportunities for immunisation
and maintaining records. Children in London are invited for
vaccination by GPs; those not registered with a GP are at serious
risk of missing out on immunisations and need particular atten-
tion. Registration with a GP can be particularly low among
certain migrant populations.19
Although it is encouraging to see data completeness and vac-
cination coverage improving, the NHS is currently undergoing a
major reorganisation and previous experience has shown that
reorganisation negatively impacts on the quality of data20; this
is therefore likely to continue to present challenges. However, it
is also an opportunity to inﬂuence the CHIS service speciﬁca-
tion to ensure that ﬁelds such as ethnicity and country of birth
are accurately recorded. Directors of Public Health in Local
Authorities will have a duty to scrutinise and challenge the NHS
for how well and how equitably it provides immunisation ser-
vices—coverage by ethnicity should be one of the key metrics
by which this role is undertaken.
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Appendix 1: Vaccine codes and application of coding of fully/not fully immunised status 
 
A = acceptable vaccine for primary and/or pre-school booster within coding framework 
B = acceptable vaccine only for pre-school booster (4
th
 or higher dose) within coding 
framework 
C = not counted within coding framework 
 
Vaccine code* Vaccine description 
Application of 
coding 
D_P Diphtheria primary course A 
DT_P Diphtheria/Tetanus Primary Course A 
DTaP_P 
Diph/Tetanus/Acellular Pertussis 
Primary 
A 
DTaPIPVH 
Dip/Tet/Pert/Polio/Hib Primary (< 
10yrs) 
A 
DTaPIPVH4 Dip/Tet/Pert/Polio/Hib Primary part 4 A 
DTP_P Dip/Tet/Pert Primary course A 
DT_B Dip/Tet preschool booster A 
DTaP_B 
Diph/Tetanus/Acellular Pertussis 
Booster 
A 
dTaPIPV Dip/Tet/Pert/Polio Preschool booster B 
DTaPIPVHiB 
Dip/Tet/Pert/Polio/HiB Preschool 
booster 
A 
DTP_B Dip/Tet/Pert Pre-School Booster A 
  
DTPH Dip/Tet/Pert/Hib A 
DTPP4 Dip/Tet/Pert/Polio/ Primary 4 A 
SUP_D Supplementary Diphtheria A 
SUP_DT Supplementary Diphtheria/Tetanus A 
SUP_DTP Supplementary Dip/Tet/Pert A 
Td/IPV_B Dip/Tet/Polio Booster (> 10yrs) C 
Td/IPV_B10 Dip/Tet/Polio Booster C 
Td/IPV_P Dip/Tet/Polio Primary course (> 10yrs) C 
TDL_B 
Low dose Diph/Tet School Leavers 
Booster 
C 
*_P = primary, _B = booster 
 
Note: several vaccine codes/combinations were possible within this study because the remit 
was to assess coverage of diphtheria-containing vaccines. Diphtheria vaccine is administered 
globally and children arriving from abroad may have received vaccines different from those 
that are scheduled in the UK. In addition, there have been some changes in scheduling/supply 
within the UK so a number of options are possible*. However, the majority of children within 
this study dataset born on or after September 2004 received DTaPIPVH (DTaP/IPV/Hib) as 
their first (96% of first doses received), second (98% of second doses received), and third 
(97% of third doses received) vaccine. Prior to September 2004 first, second and third doses 
received were usually DTPH (approximately 70%) or DTP_P (approximately 18%). The 
majority of children evaluated at fifth birthday had dTaPIPV (61%) recorded as their 4
th
 
vaccine (there is no ‘DTaP/IPV’ code in RiO; this code is used for both dTaPIPV and 
DTaPIPV), 29% received DTaPIPVHiB. 
  
 
*The current accelerated primary schedule in the UK has been in place since 1990, but before 
2004 a vaccine containing whole cell pertussis (DTwP-Hib) and a separate oral polio vaccine 
(OPV) were used (Chief Medical Officer, Chief Nursing Officer, Chief Pharmaceutical 
Officer. New vaccinations for the childhood immunisation programme [letter] 10
th
 Aug 2004. 
Department of Health. 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digital
asset/dh_4087347.pdf ) 
 
Appendix 2: Ethnicity codes and grouping categories [abbreviation] 
 
Grouping Code CodeDescription 
White-British 
  
  
  
  
A White - British 
CA White - English 
CB White - Scottish 
CC White - Welsh 
CD White - Cornish 
White-Polish CP White - Polish 
White-Irish B White - Irish 
White-Other/Mixed/Unspecified 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
C2 White - Northern Irish 
C3 White - Other/Unspecified 
CE White - Cypriot (part not stated) 
CF White - Greek 
CG White - Greek Cypriot 
CJ White - Turkish Cypriot 
CH White - Turkish 
CK White - Italian 
CL White - Irish Traveller 
CM White - Traveller 
CN White - Gypsy/Romany 
CQ White - All Republics of former USSR 
CR White - Kosovan 
CS White - Albanian 
CT White - Bosnian 
  
  
  
  
  
  
CU White - Croatian 
CV White - Serbian  
CW White - Other Republics of former 
Yugoslavia 
CX White - Mixed White 
CY White - Other European 
C White - Any other background 
Mixed 
  
  
  
  
  
  
  
  
  
D Mixed - White & Black Caribbean 
E Mixed - White & Black African 
F Mixed - White & Asian 
G Mixed - Any other mixed background 
GA Mixed - Black and Asian 
GB Mixed - Black and Chinese 
GC Mixed - Black and White 
GD Mixed - Chinese and White 
GE Mixed - Asian and Chinese 
GF Mixed - Other/Unspecified 
Asian or Asian British-Indian 
[Indian] 
  
H Asian or Asian British - Indian 
LB Asian or Asian British - Punjabi 
Asian or Asian British-Pakistani 
[Pakistani] 
  
J Asian or Asian British - Pakistani 
LC Asian or Asian British - Kashmiri 
Asian or Asian British-Bangladeshi 
[Bangladeshi] 
K Asian or Asian British - Bangladeshi 
Asian or Asian British- L Asian or Asian British - Any other 
Other/Mixed/Unspecified 
  
  
  
  
  
  
  
background 
LA Asian or Asian British - Mixed Asian 
LD Asian or Asian British - East African Asian 
LF Asian or Asian British - Tamil 
LG Asian or Asian British - Sinhalese 
LE Asian or Asian British - Sri Lanka 
LH Asian or Asian British - British 
LJ Asian or Asian British - Caribbean Asian 
LK Asian or Asian British - Other/Unspecified 
Black or Black British-Caribbean 
[Caribbean] 
M Black or Black British - Caribbean 
Black or Black British-African 
[African] 
N Black or Black British - African 
Black or Black British-Nigerian 
[Nigerian] 
PC Black or Black British - Nigerian 
Black or Black British-Somali 
[Somali] 
PA Black or Black British - Somali 
Black or Black British-
Other/Mixed/Unspecified 
  
  
PB Black or Black British - Mixed 
P Black or Black British - Any other 
background 
PD Black or Black British - British 
PE Black or Black British - Other/Unspecified 
Other Ethnic Groups-
Chinese/Vietnamese 
[Chinese/Vietnamese] 
R Other Ethnic Groups - Chinese 
SA Other Ethnic Groups - Vietnamese 
Other Ethnic Groups-Other [Other] S Other Ethnic Groups - Any Other Group 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
SB Other Ethnic Groups - Japanese 
SC Other Ethnic Groups - Filipino 
SD Other Ethnic Groups - Malaysian 
SE Any Other Group 
SK Other Ethnic Groups - Arab 
SL Other Ethnic Groups - North African 
SM Other Ethnic Groups - Other Middle East 
SN Other Ethnic Groups - Israeli 
SO Other Ethnic Groups - Iranian 
SP Other Ethnic Groups - Kurdish 
SQ Other Ethnic Groups - Moroccan 
SR Other Ethnic Groups - Latin American 
SS Other Ethnic Groups - South/Central 
American 
ST Other Ethnic Groups - 
Maur/SEyc/Mald/StHelen 
SG Other Ethnic Groups - Hindu 
SJ Other Ethnic Groups - Sikh 
SF Other Ethnic Groups - Buddhist 
SI Other Ethnic Groups - Muslim 
Not known 
  
  
  
Z Not Stated 
ZZ Not Known 
ZZZ Information not yet obtained 
ZZZ
Z 
Refused 
 
Appendix 3a: 
Multivariable logistic regression model results for vaccination coverage at first birthday
Factor Sub-group OR (95% CI)
Ethnicity White-British 1.00 (baseline)
White-Polish 0.39 (0.33-0.47)
White-Irish 0.57 (0.46-0.7)
White-Other/mixed/unspecified 0.66 (0.62-0.71)
Mixed 0.8 (0.74-0.87)
Asian or Asian British-Indian 0.94 (0.87-1.03)
Asian or Asian British-Pakistani 0.78 (0.71-0.84)
Asian or Asian British-Bangladeshi 1.05 (0.92-1.2)
Asian or Asian British-Other/mixed/unspecified 0.91 (0.83-1)
Black or Black British - Caribbean 0.67 (0.59-0.75)
Black or Black British-African 0.82 (0.76-0.88)
Black or Black British-Nigerian 0.3 (0.2-0.45)
Black or Black British-Somali 0.46 (0.37-0.57)
Black or Black British - Other/mixed/unspecified 0.63 (0.54-0.73)
Other Ethnic Groups-Chinese/Vietnamese 0.92 (0.72-1.16)
Other Ethnic Groups-Other 0.55 (0.51-0.6)
Not known 0.35 (0.33-0.36)
Gender Male 1.00 (baseline)
Female 1.03 (1-1.06)
Unknown 0.06 (0.03-0.14)
Deprivation Quintile 1 1.00 (baseline)
Quintile 2 0.86 (0.82-0.9)
Quintile 3 0.81 (0.77-0.85)
Quintile 4 0.8 (0.76-0.84)
Quintile 5 0.8 (0.76-0.84)
PCT 1 1.00 (baseline)
2 1.13 (1.05-1.21)
3 0.9 (0.85-0.97)
4 1.37 (1.29-1.45)
5 1.58 (1.47-1.7)
6 1.38 (1.3-1.47)
7 1.16 (1.09-1.23)
8 0.57 (0.54-0.61)
9 1.08 (1.02-1.14)
Year of birth 2005-2006 1.00 (baseline)
2006-2007 1.08 (1.03-1.13)
2007-2008 1.11 (1.06-1.16)
2008-2009 1.4 (1.34-1.47)
2009-2010 1.43 (1.37-1.5)
Number of observations = 181,719 (2% of records did not have a deprivation score assigned)
Overall model significance: LR chi2(34) =  5770, p<0.001
Log likelihood = -66743      Pseudo R2 = 0.041
Hosmer-Lemeshow fit test with 10 groups: chi2(8) = 91.0,  p<0.001
Appendix 3b: 
Multivariable logistic regression model results for vaccination coverage at second birthday
Factor Sub-group OR (95% CI)
Ethnicity White-British 1.00 (baseline)
White-Polish 0.25 (0.21-0.3)
White-Irish 0.58 (0.46-0.73)
White-Other/mixed/unspecified 0.56 (0.52-0.59)
Mixed 0.79 (0.73-0.87)
Asian or Asian British-Indian 0.79 (0.72-0.87)
Asian or Asian British-Pakistani 0.75 (0.68-0.82)
Asian or Asian British-Bangladeshi 1.18 (1.01-1.39)
Asian or Asian British-Other/mixed/unspecified 0.79 (0.71-0.87)
Black or Black British - Caribbean 0.74 (0.64-0.85)
Black or Black British-African 0.75 (0.69-0.81)
Black or Black British-Nigerian 0.24 (0.15-0.36)
Black or Black British-Somali 0.42 (0.33-0.52)
Black or Black British - Other/mixed/unspecified 0.66 (0.56-0.77)
Other Ethnic Groups-Chinese/Vietnamese 0.71 (0.55-0.91)
Other Ethnic Groups-Other 0.43 (0.39-0.46)
Not known 0.25 (0.24-0.26)
Gender Male 1.00 (baseline)
Female 1.05 (1.02-1.08)
Unknown 0.03 (0.01-0.07)
Deprivation Quintile 1 1.00 (baseline)
Quintile 2 0.86 (0.82-0.91)
Quintile 3 0.82 (0.78-0.86)
Quintile 4 0.82 (0.78-0.86)
Quintile 5 0.85 (0.81-0.89)
PCT 1 1.00 (baseline)
2 0.91 (0.85-0.98)
3 0.85 (0.79-0.91)
4 1.35 (1.27-1.44)
5 1.75 (1.62-1.89)
6 1.33 (1.24-1.41)
7 1.05 (0.99-1.12)
8 0.46 (0.44-0.49)
9 1.15 (1.08-1.23)
Year of birth 2005-2006 1.00 (baseline)
2004-2005 0.69 (0.66-0.72)
2006-2007 1.08 (1.03-1.14)
2007-2008 1.13 (1.07-1.18)
2008-2009 1.49 (1.42-1.56)
Number of observations = 176,739 (2% of records did not have a deprivation score assigned)
Overall model significance: LR chi2(34) =  8953, p<0.001
Log likelihood = -61931      Pseudo R2 = 0.0674
Hosmer-Lemeshow fit test with 10 groups: chi2(8) = 105.3,  p<0.001
Appendix 3c: 
Multivariable logistic regression model results for vaccination coverage at fifth birthday
Factor Sub-group OR (95% CI)
Ethnicity White-British 1.00 (baseline)
White-Polish 0.34 (0.28-0.41)
White-Irish 0.67 (0.58-0.78)
White-Other/mixed/unspecified 0.77 (0.73-0.8)
Mixed 0.81 (0.76-0.87)
Asian or Asian British-Indian 1.13 (1.06-1.21)
Asian or Asian British-Pakistani 0.94 (0.89-1)
Asian or Asian British-Bangladeshi 1.11 (1.01-1.22)
Asian or Asian British-Other/mixed/unspecified 0.89 (0.83-0.95)
Black or Black British - Caribbean 0.8 (0.73-0.87)
Black or Black British-African 0.74 (0.7-0.78)
Black or Black British-Nigerian 0.66 (0.44-1)
Black or Black British-Somali 0.56 (0.49-0.64)
Black or Black British - Other/mixed/unspecified 0.76 (0.69-0.84)
Other Ethnic Groups-Chinese/Vietnamese 0.74 (0.62-0.89)
Other Ethnic Groups-Other 0.65 (0.61-0.69)
Not known 0.4 (0.38-0.41)
Gender Male 1.00 (baseline)
Female 1.03 (1.01-1.05)
Unknown 0.14 (0.08-0.24)
DeprivationQuintile 1 1.00 (baseline)
Quintile 2 0.9 (0.87-0.93)
Quintile 3 0.87 (0.84-0.9)
Quintile 4 0.86 (0.83-0.89)
Quintile 5 0.89 (0.86-0.93)
PCT 1 1.00 (baseline)
2 1.15 (1.09-1.21)
3 0.59 (0.56-0.62)
4 1.14 (1.09-1.19)
5 1.62 (1.54-1.71)
6 1.16 (1.11-1.22)
7 1.14 (1.09-1.19)
8 0.78 (0.75-0.82)
9 1.01 (0.96-1.06)
Year of birth2005-2006 1.00 (baseline)
2001-2002 0.53 (0.51-0.54)
2002-2003 0.55 (0.54-0.57)
2003-2004 0.61 (0.59-0.63)
2004-2005 0.78 (0.76-0.81)
Number of observations = 161,356 (2% of records did not have a deprivation score assigned)
Overall model significance: LR chi2(34) =  12216, p<0.001
Log likelihood = -102070      Pseudo R2 = 0.0565
Hosmer-Lemeshow fit test with 10 groups: chi2(8) = 151.6,  p<0.001
